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S U M M A R Y
This thesis describes the antigenic and biological 
analysis of 31 yellow fever (YF) vaccine viruses from 
three different vaccine strains (17D-204, 17DD and the 
French Neurotropic Vaccine [FNV]) using panels of 
monoclonal antibodies (McAbs).
The antigenic specificity and biological function 
of the epitopes recognised by the McAbs were 
identified. Two YF-type specific and one flavivirus 
group reactive McAbs were identified while the remainder 
were partial flavivirus group reactive.
Four panels of McAbs were used together with 
polyclonal anti-sera to antigenically analyse the 
envelope (E) protein epitopes on YF viruses using 
haemagglutination inhibition assays (HAI) and plaque 
reduction neutralisation tests (PRNT’s). Heterogeneity 
in the biological function of the E-protein epitopes was 
demonstrated. Using the technique of cluster analysis a 
dendrogram was produced which divided all YF viruses 
into three groups.
McAb neutralisation escape variants were produced 
to examine the function of particular epitopes in 
detail. One 17D-204 sub-strain specific epitope was 
found to affect the neurovirulence of YF 17D-204 vaccine
virus for mice.
The new 17D YF vaccine virus manufactured in the 
Union of Soviet and Socialist Republics (USSR) was 
examined in detail. The vaccine was indistinguishable 
from other 17D vaccines with the majority of McAbs. 
However, pathogenicity studies showed that the vaccine 
contained virions which killed mice with a reduced 
average survival time compared to other 17D vaccines.
Three FNV vaccine viruses were studied in HAI 
assays, PRNT's and pathogenicity tests. In HAI assays 
they were indistinguishable, while PRNT’s and 
pathogenicity studies were able to distinguish between 
them.
The 17DD sub-strain vaccine viruses and their 
wild-type parent strain Asibi were found to be 
temperature sensitive when grown in the mosquito C6-36 
cell line and not the human SW13 cell line. No evidence 
was found to associate this phenotype with epitopes on 
the E-protein.
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CHAPTER 1
LITERATURE REVIEW
1. YELLOW FEVER VIRUS
I. Historical Considerations of the Virus
In all of the ancient medical literature there is 
no single word written about the disease yellow fever
(YF), by that or any other name. Since epidemic YF is a
dramatic disease due to the quickness that acutely
infected people die and the symptoms of the disease
(e.g "black vomit"), it seems unlikely that it could 
have escaped the attention of even very early medical 
writers.
It was not until the 17th century, that YF was
described as a disease entity and the term 'yellow
fever' was first employed by Hughes in 1750 (Warren,
1951).
A) The Vector
Until the 19th century, the disease was widely 
thought to be caused by airborne miasmas. Although Nott, 
in 1848 (Warren, 1951) suggested the mosquito as a
possible agent for the dissemination of both YF and
malaria and Beauperthuy in Venezuela made a similar 
suggestion in 1854. However, the first serious proponent 
of mosquito transmission was Dr. Carlos J. Finlay 
(Warren, 1951; Amster, 1987) who presented evidence that
YF was spread by a specific mosquito, Stegomyia fasciata 
now known as Aedes aegypti. Finlay’s theory was accepted 
by Lazear who carried out transmission experiments with 
infected mosquitoes on human volunteers. These were 
successful and further experiments were then repeated in 
1902 by Reed and Carroll (Warren, 1951) of the Yellow 
Fever Commission who demonstrated transmission of YF to 
volounteers by mosquitoes (A. aegypti) which had been 
previously fed on clinically ill patients proving vector 
transmission. They also demonstrated by direct human- 
human passage that the aetiologic agent was present in 
the blood of infected patients, and defined the period 
of extrinsic incubation in the mosquito, showing that a 
filterable agent was responsible for the disease. 
Although Reed’s observations were confirmed by many 
other workers, the filterable agent could not be 
isolated, propagated, established or characterized.
Until the 1930s YF was considered essentially an 
urban disease transmitted only by A. aegypti. This 
concept was strengthened by two observations. First, 
Marchoux and Simond (1906 a, b) failed to transmit YF to 
five different mosquitoes; A. scapularis, A. 
taeniorhynchus, Culex quinguefasciatas, Psorophora 
ciliata, and P. posticata and second, the dramatic 
disappearance of YF from all known centres of infection 
on the American continent due to the application of
anti-mosquito measures against A. aegypti. However, an 
early report by Franco et (1911) suggested YF was
acquired in the forest by mosquitoes other than A. 
aegypti. Bauer (1928), and Philip (1929, 1930) in West 
Africa and Davis and Shannon (1929, 1931) in South
America showed that other species of mosquitoes could 
transmit YF virus from animal to animal. The concept of 
jungle YF was only clearly defined by an outbreak of YF 
in Brazil in 1932, in the absence of A. aegypti, (Soper 
et al., 1933). Shannon et (1938) reported the
isolation of YF virus from the Haemagogus species and 
the role of this genus in virus transmission to humans 
working in the forest was subsquently established 
(Bugher et al., 1944). Haddow et al. (1948) in East 
Africa showed that A. africanus was responsible for 
virus circulation between monkeys in the forest canopy 
and A. simpsoni for transmission from monkeys to humans. 
Cornet et (1979) documented the role of A.
luteocephalus and A. (Diceromyia) furcifer-taylori group 
as principal vectors in the savannah belt of Africa 
and isolated YF virus from male mosquitoes. This showed 
that transovarial transmission as a possible mechanism 
of virus survival. Germain et al. (1979) reported the 
isolation of YF from ticks (amblyomma variegatum) 
collected from cattle in the Central African Republic 
and raises the interesting possibility that ticks have a
role in dry season maintenance or dispersal of the virus 
(Monath, 1984).
B ) The Agent
A number of workers at various times claimed 
to have discovered the agent of YF, although the only 
theory to receive attention in the 19th century was that 
of Sanarelli, a distinguished bacteriologist, who 
claimed that a bacillus (Bacillus icteroides) was the 
causative agent. Although his claim was taken seriously, 
it was disproven by Reed's yellow fever commission 
(Warren, 1951).
History again repeated itself when another eminent 
bacteriologist claimed the agent to be a Leptospira. 
Noguchi (1919) investigating a YF epidemic in Ecuador 
showed that leptospira icteroides produced lesions 
suggestive of YF in guinea pigs (Noguchi, 1925). He had 
prepared a vaccine against this organism, stating this 
gave protection against YF for six months.
However, in 1925, workers at the West African 
Yellow Fever Commission were unable to isolate the 
leptospira from YF. Then in 1927, Stokes ^  (1928),
succeded in isolating the agent by inoculation of blood 
from patients into rhesus monkeys. Then isolating the 
agent and passing to another monkey. Thus, the agent now
known as YF virus, was isolated from the blood of a 
Ghanaian man named Asibi and later served as the parent 
to the 17D vaccine (Theiler and Smith, 1937a,b) . In the 
same year Mathis et (1928) isolated a virus in Dakar
and established the French strain (FW) which became the 
parent to the French neurotropic virus (FNV).
II. Geographical Distribution
A) America
YF was first recognized in the Americas, occurring 
in Yucatan in 1648 (Blake, 1968). Although the exact 
place of origin of YF is uncertain, there is agreement 
using immunological, entomological and historical data, 
indicating that the virus was transported to the 'New 
World' from Africa (Strode, 1951; Blake, 1968) around 
the time of Christopher Columbus by sailing ships 
(Portefield, 1989).
During the 18th (Blake, 1968) and 19th (Duffy, 
1968) centuries YF was one of the most important 
epidemic diseases in America. The disease was 
periodically imported by ships into ports of the 
Carribean, Central America and North America causing 
epidemics from 1693 to 1905. For example, in New Orleans
in 1853, a tenth of the population died of YF (Duffy, 
1966) and again in 1905 443 persons died of YF
(Bendiner, 1988). The virus even spread to Europe where 
during the 1800’s Madrid had 60,000 deaths (Theiler,
1952) and Swansea had 27 deaths (Smith and Gibson, 1986; 
Meers, 1986; Porterfield, 1989).
With the introduction of anti-mosquito 
campaigns, for example, Gorgas from 1901 to 1908 
(Patterson, 1989) and the 17D vaccine in the 20th 
century the incidence of YF epidemics was reduced and in 
the 1940's resulted in the loss of Urban YF outbreaks.
Since the 1940's outbreaks have occurred in South 
America exclusively of Jungle or Sylvan YF, the tree 
living Haemagogus mosquito being the responsible vector. 
There are four major countries in South America where 
outbreaks of Jungle YF occur regularly and account for 
95% of the human cases; Peru, Bolivia, Colombia and 
Brazil, (Monath, 1989). Other countries where outbreaks 
have occured are Paraguay where there were 9 cases 
reported in 1974, Argentina in 1966, Eucador where there 
were 29 cases between 1965 and 1984, 49 cases were
reported in Venezuela between 1965 and 1984, and lastly 
Trinidad and the Guianas. Sometimes the varying 
distribution of human cases and the periodicity of 
outbreaks reflect the actual movement of YF virus. The
most studied of these epizootic waves began in 1947, in 
Eastern Panama (Boshell-Manrique, 1959) and crossed the 
Panama Canal in 1950 reaching Mexico in 1958 but was not 
reported by that Government (Trapido and Galindo, 1956). 
Also, YF virus was isolated from migrant workers (Mendez 
et al., 1984) in the YF outbreak in the Apurimac River
valley of south central Peru in 1977, for the first 
time.
Recently, there have been a number of sporadic 
endemic cases notified in South America in 1986 and 
1987, especially in the countries of Peru, Bolivia and 
Brazil (Weekly Epidemiology Record, 1989a,b). Also, in 
1989, the Brazilian Ministry of Health advised 
travellers to be vaccinated against YF due to the 
occurence of jungle YF in 1988. Lewis, ^  aJ. (1989) 
and Rawlins et (1990), showed there had been
sylvatic yellow fever in Trinidad between 1988 and 1989, 
though no human infection was reported.
B ) Africa
The first documented epidemic of yellow fever in 
Africa was in 1778 (Freestone, 1988), much later than 
those reported in the Carribean or the Americas. 
Serological surveys carried out in practically all parts 
of Africa since 1932 have delineated the boundaries of
the area in which the disease occurs. YF is generally
accepted to be endemic or epidemic in 29 countries
between latitudes 15°N and 10°S (WHO, 1971).
Before the 1940s and mass immunization campaigns 
YF occurred in Africa as either sporadic cases of jungle 
YF mainly in forested areas or urban outbreaks mainly in 
the savanna areas. Typical urban outbreaks occurred in 
Nigeria, 1925 - 1926, Ghana, 1926 - 1927, and also in 
1937, the Gambia, 1934 - 1935 (WHO, 1986). The first 
recognized epidemic in East Africa ocurred in Sudan in 
1940 and was very severe. There being 15,641 cases and 
1627 deaths reported among a population of 230,000.
Subsequent serological surveys estimated that there had
been approximately 40,000 infected people with a death 
rate of 10% (Kirk, 1941).
From 1940 until the 1960s there was a mass 
vaccination programme with the French neurotropic 
vaccine in the french speaking countries, whereby 25 
million people were immunized every 4 years. This 
eradicated YF from these areas (Durieux, 1956). With the 
loss of interest in YF in the 1960s and immunization 
neglected epidemics reappeared. The first in Ethiopia in 
1960 - 1962 when 3000 deaths were notified. However, it 
was estimated that as many as 100,000 cases and 30,000 
deaths occured in this area where the population
numbered one million people (Serie, 1968). Outbreaks 
have also occured in Senegal, 1965, Ethiopia, 1966,
Ghana and Mali in 1969, and Nigeria, 1969 to 1970
numbering an estimated 100,786 cases (Carey et al., 
1972; Monath et ^ . , 1973), Burkino Faso, 1969 and 1983, 
Angola, 1971, Sierra Leone in 1975, Ghana in 1977 - 1979 
and 1983, and the Gambia from 1978 - 1979 where there
was 8400 cases and 1600 deaths estimated (Monath et ,
1980).
More recent epidemics have occurred in Mali in 
1987 whereby 304 cases and 144 deaths were notified 
(Meunier, 1988; Weekly Epidemiological Record, 1989). 
Also, in Nigeria between 1986 and 1987 there was 5012 
cases and 1367 deaths reported in the first urban
outbreak of YF for 40 years (DeCock et ^ . , 1988; DeCock 
and Monath, 1988; Weekly Epidemiological Record, 
1989a,b). However, an estimated total of 7500 deaths are 
thought to have occurred, with over 20 million 
inhabitants at risk (Porterfield, 1989; Nasidi et al., 
1989).
Ill. Clinical description and pathogenesis of the 
disease YF
A) Humans
In humans, YF virus produces a viscerotropic
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disease. YF shares many clinical features with other 
viral hemorrhagic fevers (dengue hemorrhagic fever, 
Crimean-Congo hemorrhagic fever and lassa fever) but it 
is characterised by more severe hepatic involvement than 
the other viruses (Monath, 1987). YF varies in severity 
according to the immune status of the individual, from a 
asymptomatic mild or moderate case to a classic severe 
case. Classical (Kerr, 1951) and recent reviews (Monath, 
1987, Freestone, 1988) provide detailed descriptions of 
the clinical and pathological aspects of YF.
i ) Asymptomatic Infections
Symptoms are limited and begin with a headache, 
fever, nausea and vomiting, though conjunctival 
infection and albuminuria can also occur. However, 
patients usually recover in a few days.
ii) Classic Severe Cases
Clinical descriptions of severe YF, emphasize 
three stages: infection, remission, and intoxication.
The period of infection lasts about three days in which 
the patient suffers abruptly from fever, severe 
headache, generalised malaise and weakness, lumbosacral 
pain, nausea and vomiting. Despite a persistent or 
rising severe fever^the pulse rate may decrease (Faget's
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sign). During this phase virus is present to a high 
titre in the blood and the patient is infectious to the 
bite of mosquitoes. Then a period of remission (a period 
of mitigation of symptoms) follows which may last from a 
few hours up to 24 hours. Then the fever and symptoms 
reappear announcing the period of intoxication. This is 
shown by the return of more frequent vomiting, 
epigastric pain, prostration, dehydration, and the 
appearance of jaundice. The bleeding diathesis appears 
as coffee-grounds haematemesis ("black vomit"), melena, 
metrorrhagia and diffuse oozing from the mucous 
membranes. Virus is usually absent from the blood and 
antibodies appear during this phase. Approximately 50% 
of patients in this phase have a fatal outcome between 
the 7th and 10th day heralded by deepening jaundice, 
hemorrhages, tachycardia, and hypotension,
encephalopathic signs and azotemia. Hypothermia, 
agitated delirium, intractable hiccups, stupor and coma 
are terminal signs.
B ) Monkeys
Humans or nonhuman primates infected by peripheral 
routes show a vicerotropic disease, though if inoculated 
by the intracerebral route show both encephalitic and 
viscerotropic disease. Stokes et al. (1928) were the
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first workers to investigate the susceptibility of 
monkeys to YF, They showed that YF virus can be 
successfully transmitted to the indian Macacus rhesus 
monkey and that the clinical course of the disease and 
the lesions were similar to those found in human YF 
cases. Subsequently workers have studied other monkey 
species. Davis, (1930a,b) was able to demonstrate a 
certain degree of susceptibility of seven (the Cebus 
monkey, the squirrel monkey, the spider monkey, the 
woolly monkey, red howling monkey, true marmosets, and 
the black tamarin) South American monkeys to 
viscerotropic YF virus, while Lloyd and Penna (1933) 
studied the susceptibility of the same South American 
monkeys to the neurotropic mouse-brain-adapted YF virus. 
Bugher (1951), reviews the work carried out by many 
workers on the susceptibility of different monkey 
species from those of Africa and South America. Several 
workers showed that West African monkeys (except for the 
North African macacus and chimpanzee) were refractory for 
YF even though the virus replicated in the monkeys, 
suggesting signs of susceptibility to the virus. None of 
the West African monkeys showed any outward signs of 
illness. However there was a range of susceptibility of 
the Galago species to YF. The G. demidovii demidovii 
where no outward reaction was seen to inoculation of YF 
virus, to that of G. crassicaudatus lasiotis were they
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died following YF inoculation. All species of 
cercopithecid and colobid monkeys have been shown to be 
viremic hosts circulating YF virus for many days. While 
infection of African monkeys infrequently leads to 
death, many of the South American monkeys died when 
inoculated with YF.
Monath et aJ. (1981) studied the course of
YF virus following inoculation of the rhesus monkey and 
showed that symptoms of fever and lethargy appeared 14 
to 25 hours before death. In the last six hours 
acidosis, hyper-kalemia, hypotension, hyperthermia, and 
coma developed. Viraemia was first detected on the 2nd 
day post-infection and progressively increased in titre 
until the fifth day when there was a slight fall. No 
anti-YF virus antibodies developed and post-mortem 
samples showed there was total destruction of the 
hepatic structure due to acute necrosis of hepatocytes 
and Kupffer cells, and Councilman bodies were present. 
Post-mortem samples of the kidney showed varying degrees 
of degeneration of tubular epithelia cells and samples 
from the spleen and lymph nodes showed acute lymphoid 
necrosis.
Histopathological changes in the myocardium have 
been found in experimentally infected monkeys (Lloyd, 
1931) adversely affecting the myocardial performance. 
This probably contributes to the rare phenomenon of late
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death in humans at the end of convalescence or even 
weeks after complete recovery from the acute illness.
C) Mice
In 1930, Theiler demonstrated that white adult 
mice are susceptible to YF virus when inoculated 
intracerebrally and, in most cases, are resistant to 
intraperitoneal inoculation. These findings were soon 
confirmed by other workers and led to these animals 
being extensively used for YF studies. Theiler (1930), 
also showed that the passage of YF virus through mice 
leads to a loss of virulence for monkeys, although a 
progressive shortening of the average survival time 
(AST) is seen in mice (Theiler, 1951). On the other 
hand, newborn mice up to the age of two weeks old were 
shown to be susceptible to intraperitoneal as well as 
intracerebral inoculation of wild-type YF viruses and 
the symptoms were the same as those seen in adult mice 
(Theiler, 1930).
Recently, workers have demonstrated that when 
adult mice are inoculated intracerebrally with the 17D 
vaccine they have a similar average time as the parent 
wild-type Asibi strain and the viruses cause a 
neurotropic disease in mice (Fitzgeorge and Bradish, 
1980a,b; Barrett and Gould, 1986a; Gibson et al., 1990).
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D ) Guinea Pigs
Sellards (1930) and Sawyer and Frobisher (1932) 
(Theiler, 1951) showed that after intraperitoneal 
inoculation of YF virus, Guinea pigs develop a viraemia 
and antibodies to YF virus. Guinea pigs show no signs of 
illness, unless they are inoculated intracerebrally with 
the wild-type Asibi strain of YF virus in which case 
encephalitis develops (Theiler, 1933) and the animals 
died after an incubation period of 5 to 14 days.
E ) Rabbits
Whitman (1935) and other workers (Theiler, 1951) 
tested the susceptibility of the rabbit to a number of 
wild-type strains of YF virus. Following inoculation by 
either the intraperitoneal or intracerebral route it was 
found that the virus was at no time present in the 
spleen, liver, kidney, or bone marrow. Whitman, (1935) 
showed the animals readily developed antibodies in 
response to an immunizing inoculum of virus. Moreover, 
after a rest period of 6 weeks, they responded to a 
second injection by producing high titres of serum 
antibody.
F) Hedgehogs
Findlay and Clarke, (1934) showed that both the 
European hedgehog (Erinaceus europaeus) and the Sudanese
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hedgehog (E. pruneri) are both extremely susceptible to 
YF virus. When E. europaeus was inoculated with the 
Asibi strain it died between 4 to 7 days post infection. 
Post-mortem examination showed it had macroscopic and 
microscopic lesions similar to those seen in the rhesus 
monkey. Thus, other than humans and monkeys, hedgehogs 
represent the only other host in which YF virus causes 
viscerotropic disease. Following the initial studies of 
Findlay and Clarke little work has been done on YF 
infection of hedgehogs, presumably because of the 
difficulty of both obtaining and working with this 
animal.
G) Mosquitoes
In South America the haemagogus tree-hole living 
mosquitoes are of primary importance as vectors in the 
sylvatic cycle of YF virus spreading the virus among the 
monkey population. The haemagogus breed in tree-holes 
and during midday they feed in the forest canopy, though 
they are known to bite and infect humans with the YF 
virus in forest clearings and even inside houses near 
the forest (known as Jungle YF). However, in Africa 
there are two principal species involved in sylvatic 
infection (mosquito to monkey to mosquito transmission). 
These are the Aedes africanus which is responsible for 
year-round transmission of YF virus in the equatorial
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African forests and Aedes simpsonii, now known as A. 
bromeliae, which links the forest cycle with humans. The 
principal mosquito vector in urban YF outbreaks in 
Africa is the 'domesticated’ Aedes Aegypti. However, in 
Africa significant outbreaks have occurred in the 
absence of A. Aegypti and have involved A. africanus and 
A. simpsonii
V ) Yellow fever vaccines
A) Vaccine development
Highly effective vaccines against YF have been 
available for over 50 years and along with smallpox and 
rabies vaccines, are among the very first vaccines to be 
developed against human disease. Two live attenuated 
vaccines were independently developed and are named the 
French neurotropic vaccine (FNV) and the 17D vaccines.
i ) French Neurotropic Vaccine virus
Attempts to produce a live vaccine strain of 
YF virus suitable for human vaccination were made at the 
Institut Pasteur, in Dakar, Senegal. The wild-type 
parent virus (termed the French viscerotropic virus 
[ F W ] ) to the vaccine was isolated from a Syrian patient 
named Françoise Mayali in 1927 and was attenuated by 
intracerebral passage in adult mice (Mathis et al..
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1928). This attenuated virus was called the French 
neurotropic vaccine (FNV). The virus (FNV) had lost the 
ability to cause visceral YF in monkeys after 
extraneural inoculaton but had increased neurotropic 
virulence for both monkeys and mice. The first 
attenuated variant was identified at passage 128 and the 
first vaccine was used at passage 237. Later vaccines 
were used at the 260^^ passage. The derivation of the 
FNV vaccines is shown in FIGURE 1.1. The FNV vaccine was 
used extensively in french speaking countries of Africa 
between 1939 and 1980 where more than 80 million people 
were successfully immunized by scarification. The last 
vaccination took place in Malawi in 1980. Although this 
vaccine was more stable to heat than the 17D vaccine, 
reactions have been reported by Peltier (1947) and 
Macnamara, 1953, who reported the cases which evolved 
from the mass vaccination in Nigeria in the epidemic of 
1951 - 1952 where 42,000 persons were vaccinated. There 
were 83 cases of encephalitis of which 32 died. The 
incidence in children was between 0.3 to 0.4% having a 
fatality rate of abut 40%. This led to the vaccine 
being discontinued in Nigeria and led to its prohibition 
of use in children below the age of 14 years old by the 
W.H.O. As a result the vaccine lost popularity and was 
discontinued in 1980.
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FIGURE 1.1 DERIVATION OF THE FNV VACCINE STRAINS
(ADAPTED FROM BARRETT, 1987)
F W  (MAYALI) 
(Mathis et al., 1927)
ORIGINAL FNV (pl28)
FIRST VACCINE (p237)
LATER VACCINES (p260)
FNV-FC F N V - I P IF N V - N T
N.B. ALL FNV VACCINES WERE DISCONTINUED IN 1980 
DUE TO REPORTED CASES OF ENCEPHALITIS
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ii) 17D vaccine virus
The wild-type strain, from which the the 17D 
vaccine was derived, is called Asibi, after a patient in 
Ghana from whose blood the virus was isolated. The 
isolation was achieved by monkey to monkey passage. The 
attenuation process was undertaken by Theiler ^  al. 
(1937 a,b) who noticed that passage of this virus in 
mice reduced its virulence for monkeys following 
peripheral inoculation. These workers passaged the 18^  ^
mouse embryonic tissue culture virus, into whole chick 
embryo for fifty times. Thereafter, this medium was 
modified to whole chick embryo tissues from which head 
and spinal cord had been removed. By the 176^^ passage, 
these workers noticed that this strain, designated 17D 
had lost its ability of producing fatal encephalitis 
when injected intracerebrally into rhesus monkeys. It 
was also considerably less neurotropic for mice than the 
114^^ passage. It is noteworthy that other isolates at 
the same passage (17E etc.) were not sufficiently 
attenuated nor could Theiler ever repeat the attenuation 
process (Theiler and Smith, 1937 a, b; Theiler, 1951).
The virus was shown to produce a safe and 
effective vaccine after the 204^^ passage. The latest 
17D vaccines are derived from two distinct 17D sub­
strains: 17D-204 and 17DD which are both independently
maintained passage series from the original 17D. The
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17D-204 sub-strain is derived from the 204^^ passage of 
Asibi virus and is now at the 233^ *^  - 239^^ passage. The 
17DD sub-strains are derived from 17D at passage 195 and 
subsequent passages were performed in chick embryo 
tissue or embryonated chick eggs to produce the 17DD 
vaccines which are now at passage 286 - 288. The
derivation of 17D vaccines are shown in FIGURE 1.2.
Preliminary tests of 17D vaccine were performed in 
YF-immune subjects and then subsequently in non-immune 
volunteers (Theiler and Smith, 1937a). From 1937 to 1938 
the 17D vaccine produced in chick embryos was first used 
in vaccine trials in Brazil where some 59,000 people 
where vaccinated (Barrett, 1987). This vaccine was used 
increasingly in Latin America and then throughout the 
world. This lead to multiple passages of the 17D vaccine 
virus being maintained in different laboratories and 
vaccine lots were produced as needed from the current 
passage level of the virus available at the particular 
laboratory.
By 1943, however, significant problems with the 
17D vaccine were encountered. The first, was that 
certain high level passsaged cultures of 17DD vaccine 
(300 - 350 passages from Asibi) failed to immuninize.
However, returning to an earlier passage of virus for 
vaccine manufacture overcame this problem (Theiler, 
1951). Another vaccine batch in Brazil showed increased
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FIGURE 1.2 DERIVATION OF YELLOW FEVER 17D VACCINES'
ASIBI
(THEILER ET AL., 1927, GHANA)r
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neurovirulence for children, where 0.36% of vaccinees 
showed symptoms of central nervous system disturbances. 
The degree of encephalitis depended on the vaccine 
substrains examined (Fox et ^ . , 1942). The third
problem was the occurrence of serum hepatitis in 
vaccinees in England and Brazil and American military 
personnel (Strode, 1951). This was shown to be due to 
human serum being incorporated into the vaccine to aid 
its stability. The problem was overcome by omitting the 
serum and increasing the concentration of egg protein. 
The development from 1945 onwards of a seed lot/batch 
system has been adopted to control the passage level and 
production of vaccine (Barrett, 1987). Since then 1000 
million doses of vaccine have been distributed. While no 
case of viscerotropic disease has been observed, there 
have been fifteen cases of encephalitis reported 
worldwide and occurred in infants seven months or 
younger in age (Anonymous, 1966). However one case of 
lethal encephalitis has been repoted in a child 39 
months old who recieved the same 17D-204 USA vaccine 
batch 6145, as her parents. At the autopsy after her 
death, a virus was isolated from the brain and shown to 
be serologically YF virus (Anonymous, 1966).
All vaccines manufactured today are YF 17D 
vaccines and both 17D-204 and 17DD sub-strains are used. 
The vaccine is currently manufactured in eleven
24
countries with the approval of the WHO Two countries 
have recently discontinued production (Holland and 
Colombia) while two other countries have just started 
production (Nigeria and USSR) (WHO, 1981; WHO, 1988). 
The WHO controls the production of YF vaccine, setting 
the preparation techniques and control tests for 
neurotropism and storage stability, as well as heat 
stability tests. The vaccine is still produced in 
embryonated chick eggs using the the same basic
procedures laid down in 1945. However, contamination of 
the YF vaccine with the avian leukosis virus (ALV) was 
shown (Waters, 1972) and has led the WHO to develop an 
ALV-free vaccine seed strain in West Germany. This was 
from a 17D-204 sub-strain of the virus at passage 236 
and now this vaccine is presently at passage 239. This 
ALV-free vaccine strain is only produced by a few 
manufacturers (Australia, West Germany, USSR). The 
manufacturers have been reluctant to use this new seed 
as it causes more histological lesions in the brains of 
monkeys following the WHO safety test than the 
established vaccines (A.D.T. Barrett, pesonal
communication). Currently, the 17DD substrain is only 
manufactured in Brazil. It is of interest that Brazil 
has the highest annual output of vaccine (12 million out 
of a total of 20 million doses produced annually,
Barrett, 1987) but is still not ALV-free.
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The monkey today is used by vaccine manufacturers 
to test the neurovirulence of new vaccine virus batches 
as recommended by the WHO (WHO Technical Report Series,
1981). The monkeys should be Macca Mulatta (Macacus 
rhesus) species or be of equal sensitivity. The monkey 
is inoculated with not less than 5000 mouse LD^q and not 
more than 50,000 mouse in a 250ul volume. The virus
injected in the frontal lobe under anaesthetic and the 
monkeys are observed for 30 days by personnel familiar 
with encephalitis in primates. The vaccine virus must 
not cause severe signs of encephalitis (paralysis, 
inability to stand, or death) in not more than 10% of 
the monkeys.
Thermostability of the vaccine is a problem due to 
exposure at high ambient temperatures in Africa and 
South America. Research has been undertaken on 
stabilising the vaccine to heat. It has been reported 
that lactose, sorbitol, histidine and alanine 
considerably improve heat stability of lyophilised 
preparations (Barme & Bronnert, 1984) and it was shown 
in field conditions to be very stable (Georges et al., 
1985) with no loss of efficacy after five months storage 
at +10°C.
Live attenuated vaccines like YF vaccine virus 
should not be administered to subjects with an impaired 
immunological system (i.e. lymphoma, leukemia and AIDS)
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or patients receiving immune suppressant drugs. 
Vaccination in pregnant women should be delayed till 
after birth due to the theoretical possibility of foetal 
damage. Infants under 6 months of age appear more 
susceptible to adverse reactions and should not be 
vaccinated. As YF vaccine is produced in chick embryos 
and contains chick protein vaccination is 
contraindicated in a patient with a history of allergy 
to chick or egg protein.
Once vaccine has been administered, IgM antibodies 
appear, and decline after 17 days. IgG antibodies appear 
between days 10 and 17 and remain high. More than 99% of 
vaccinees seroconvert and immunity seems to last for a 
long-time (from 30 - 35 years, [Poland ^  , 1981]).
Even though immunity appears long term, WHO vaccination 
certificates are only valid for ten years when re­
vaccination is required.
Only two countries routinely vaccinate all 
children, these are Venezuela and Trinidad (A.D.T. 
Barrett, personal communication).
B ) Research on yellow fever vaccines
i ) Mosquito Transmission
17D virus has been found in the blood of vaccinees 
and this led to worries in the late 1930’s that the 17D
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vaccine could be repeatedly passaged in mosquitoes and 
be converted back to its original virulent form. Whitman 
(1939) studied this and showed that A. aeqypti 
mosquitoes which fed on vaccinees did not become 
infected. Since, other workers (Duebel et ^ . , 1981;
Miller et ^ . , 1986) have shown both the 17D and FNV
vaccines are unable to disseminate to the head tissues 
of the mosquito, while wild-type virus disseminates and 
is transmitted (Duebel et ^ . , 1981; Miller and Adkins,
1988). Although the reason for non-dissemination is 
unknown (Barrett, 1987) it is important that it does not 
occur as there were early fears that mosquito passage 
may result in the reversion or selection of virulent 
viruses.
ii) Passage of YF virus in different tissue types
Since the early studies of Theiler and Smith (1937 
b) who showed the passage of YF virus in different 
tissues could modify the virulence of the virus, other 
workers have tried to modify the 17D vaccine. ’ - : Fox
and Laemmert (1947) studied the infection of developing 
chick embryos with 17D virus and Tannock et (1980)
studied the 17D vaccine prepared from decapitated 
embryos showing that the virus had less thermal 
stablility than vaccines prepared from whole embryos. 
Meers (1957, 1959) studied the affects of passaging 17D
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through mouse brain and showed it became more 
neurovirulent on each consecutive passage.
More recently workers have passaged the 17D virus 
in the human tumour KB cell line and reported the virus 
had lost its neurovirulent character in that it would 
not kill adult mice when challenged intracerebrally and 
also protected monkeys on challenge with wild-type Asibi 
virus (Hallauer, 1959; Schindler & Hallauer 1963). At 
the same time other workers have shown the passage of 
Asibi virus in Hela cells results in the loss of 
virulence for monkeys following intracerebral or 
intraperitoneal inoculation (Hardy, 1963; Hearn et al., 
1968). Workers have now produced the 17D vaccine in 
tissue culture for vaccination of humans (A.D.T. 
Barrett, personal communication).
Two yellow fever vaccines 17D-204 UK and 17D-204 
USA were reported to be able to grow in human monocytes 
and the macrophage like cell line U937 (Liprandi & 
Walder, 1983; Schlesinger & Brandriss, 1981 a,b).
Schlesinger and Brandriss in 1983 showed that thirteen 
IgG McAbs mediated antibody-dependent enhancement (ADE) 
of YF virus in the mouse P388D^ cell line, and ' showed 
that the Fc receptor on these cells was important for 
ADE to occur, ADE has been shown to occur vivo by 
Barrett and Gould, (1986 b) who showed that McAbs would 
cause A FNV and Asibi to be enhanced vivo. Recently
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Gould and co-workers (Gould et , 1987; Gould and
Buckley, 1989) have examined the vivo antibody
enhancement of neurovirulence in detail in wild-type and 
vaccine strains of YF virus. They reported enhancement 
of neurovirulence even when the McAb was given 3 days 
post-infection and stated that enhancement was due to 
the interaction in the brain between virus and antibody 
without the increase in virus titres.
iii) Virulence of YF vaccines
Comparison of the pathogenicity of the FNV with 
the 17D vaccines by Theiler and Smith (1937a,b) showed 
that although both FNV and 17D have lost the ability to 
cause viscerotropic disease, FNV was more neurotropic 
than 17D. Following intraspinally or intracerebrally 
inoculation of FNV, monkeys died of encephalitis, while 
the 17D vaccine caused a mild encephalitis which was 
only occasionally fatal. However, following extraneural 
inoculation the FNV vaccine caused a febrile reaction in 
50% of monkeys and 30% had a lethal encephalitis whereas
the 17D vaccine is not fatal.
Due to the expense and scarcity of monkeys, most 
workers now use the mouse model to investigate the
biology of YF virus, Fitzgeorge & Bradish (1980a) and
Gibson et (1990) have shown that the FNV virus kills
adult mice much quicker than the 17D vaccines as well as
30
its parent F W  wild-type virus when inoculated 
intracerebrally. In comparison, mice infected with the 
17D vaccine and its wild-type parent virus Asibi have 
similar average survival times (AST’s) (Fitzgeorge & 
Bradish, 1980a; Barrett and Gould, 1986 a; Gibson et 
al., 1990). It has been shown that intraperitoneal
inoculation of YF virus into young mice will either be 
fatal or not depending on the age and virus used. Wild- 
type F W  virus will kill 8-10 day old mice and Asibi 
will kill a similar age group (10-12 day old), whereas 
17D will only kill mice upto 5 days old but the FNV 
vaccine kills mice upto 21 days old (Fitzgeorge & 
Bradish, 1980a). Deubel ^  (1986) reported similar
results following inoculation of mice which were eight 
days old; while mice infected with the 17D vaccine and 
F W  had long AST’s (8-10 days), Asibi and the FNV 
vaccine had shorter AST’s (5 - 6 days). Two recent
studies (Barrett & Gould, 1986a; Gibson et ^ . , 1990)
have distinguished the FNV, two out of three 17DD 
vaccines and the wild-type Asibi from the 17D-204 
vaccines by intranasal inoculation of mice, showing that 
the latter were not virulent. Not surprisingly, passage 
of the FNV in mice has resulted in the virus becoming 
highly neurotropic in both monkeys and mice compared to 
its parent and other vaccine strains.
The discovery of 17D-204 variants differing in
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virulence by Liprandi, (1981), was an important 
biological finding, and has been followed up by Gould et 
al., (1989) who isolated variants of the 17D-204 vaccine 
virus having the wild-type epitope present recognised by 
McAb 117 and showed it to be more virulent than other 
plaque variants without the epitope recognised by McAb
117 in weanling mice.
iV. Molecular analysis of YF vaccine viruses
Rice et (1985) published the entire sequence
for the YF17D-204 USA vaccine from the American Type 
Culture Collection. The genome was found to consist of 
10,852 nucleotides and to be a single long open reading 
frame of 10,233 nucleotides with non-coding regions of
118 and 511 nucleotides at the 5’ and 3' regions 
respectively. The structural proteins, C (capsid), M 
(membarane), and E (envelope) were discovered to be 
coded by the 5’ end of the genome, while the last three 
quarters of the genome coded for the non-structual 
proteins. By partial N-terminal amino acid sequencing a 
total of ten polypeptides have now been shown to be 
coded for by the YF virus genome in the order as shown 
by FIGURE 1.3. The functions and molecular weights of 
these ten polypeptides is listed in TABLE 1.1.
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FIGURE 1.3 vYF GENOME ORGANISATION AND PROTEINS ENCODED
(ADAPTED FROM RICE ET AL., 1985)
YF17D GENOME 
(10,862nt)
118nt 10,233nt 511nt
CAP STRUCTURAL NONSTRUCTURAL
ns2afC| prM NSI ns2b NS3 ns4a ns4b NS5
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TABLE 1.1 FUNCTIONS OF YF VIRUS PROTEINS
APPROXIMATE
PROTEIN MOLECULAR WEIGHT GLYCOSYLATED FUNCTION
STRUCTURAL
prM
M
13.000 - 16,000
19.000 - 23,000
8,000 - 8,500
no Nucleocapsid
protein
yes precursor to
M
no virion envelope 
protein
51,000 - 60,000 both forms major virion
envelope
NONSTRUCTURAL
NSl 44,000 - 49,000 yes
ns2a 16,000 - 21,000 no
ns2b 12,000 - 15,000 no
NS3 67,000 - 76,000 no
ns4a 24,000 - 32,000 no
ns4b 10,000 - 11,000 no
NS5 91,000 - 98,000 no
(ADAPTED FROM RICE ET AL., 1986)
protein
soluble 
complement- 
fixing antigen
unknown
protease
&
helicase
unknown
replicase 
component ?
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At the same time as Rice et (1985) published the
entire YF vaccine gene sequence, French workers (Grange 
et al., 1985) published 565 nucleotides of the 3 ’-end of 
the genome of the YF17D-204 vaccine manufactured in 
France and later the 5'-end of the French vaccine was 
published (Despres et al., 1987). The French workers
(Dupuy et ^ . , 1989) compared the two sequences and
showed very few changes in sequence between the two 
vaccine strains. There was a total of nine nucleotide 
changes, giving three amino acid changes over the whole 
genome. Therefore, there is a high degree of homology 
between the two vaccines.
The wild-type parent to 17D, strain Asibi was 
sequenced by Hahn et (1987) and compared to the
YF17D-204 USA vaccine. Although the two YF viruses 
differ by more than 240 passages in different cell 
substrates the two RNAs only differed at 68 nucleotide 
positions. These differences resulted in 32 amino acid 
differences across the whole genome. The overall 
nucleotide divergence was 0.63%, corresponding to a
0.94% amino acid divergence. The envelope protein had a 
relatively high rate of amino acid change (2.4%) of 12 
amino acid substitutions (TABLE 1.2). As the amino acid 
substitutions in the E-protein between the the two 
viruses are not conservative, Hahn ^  (1987) stated
that some of the changes could represent the differences
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table 1.2 NUCLEOTIDE AND AMINO ACID CHANGES BETWEEN
THE ENVELOPE PROTEIN OF THE WILD-TYPE ASIBI 
AND THE YF17D-204 USA VACCINE VIRUS STRAINS
NUCLEOTIDE
NUMBER
1127
1140
1482
1491
1572
1750
1819
1870
1887
1946
1965
2112
2142
2219
2356
NUCLEOTIDE 
CHANGES 
ASIBI 171
G
C
C
C
A
C
C
G
C
C
A
C
C
G
C
AMINO ACID 
CHANGES
-204 ASIBI 17D-204
A GLYCINE ARGININE
U ALANINE VALINE
U ALANINE VALINE
U THREONINE ISOLEUCINE
C LYSINE THREONINE
U NO CODING CHANGES
U 1 NO CODING CHANGES
A METHIONINE ISOLEUCINE
U SERINE PHENYLALANINE
U PROLINE SERINE
G LYSINE ARGININE
G THREONINE ARGININE
A PROLINE HISTIDINE
A ALANINE THREONINE
U
( A D A P T E D  FROM H A H N  E T  , 1987)
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in virulence between both viruses. To date these have 
not been determined. However, recently Rice et al. 
(1989) have developed an "infectious clone"of the 17D- 
204 USA virus. Analysis of this clone should help in the 
understanding of the mechanism of attenuation of the 17D 
virus.
2. CHARACTERISTICS OF THE VIRUS
I. Taxonomic classification
A) Arboviruses
The term arbovirus (arthropod-borne) may be 
defined as those animal viruses which multiply in blood- 
feeding arthropods and are transmitted by bite to 
vertebrate hosts in which it also multiplies, producing 
a sufficient viraemia to infect another arthropod 
feeding on that vertebrate host. The arthropod known as 
the vector is usually a mosquito, tick, sandfly or midge 
and the principal hosts known as the reservoir are 
mammals and birds. Arboviruses can escape from the 
maintained biological cycle by vertical transmission of 
the virus from the arthropod to its offspring.
Several of the most important species were 
identified in the 1930’s including those of eastern and 
western equine, tick borne and St. Louis encephalitis, though YF
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and dengue were shown to be transmitted much earlier 
(Downs, 1989). The Rockefeller Foundation in the 1950’s 
initiated a worldwide program directed towards 
determining the number of Arboviruses. Casals in 1957 
listed 47, then again in 1958 (Casals, 1958) the list 
was enlarged to 72. By 1962 the list had already doubled 
to 161 (Berge, 1975) and as of 1973 the list had reached 
273 (Theiler and Downs, 1973). Though the 1978 edition 
of The International Catalogue of Arboviruses lists 388 
viruses, the 1985 edition lists 504 registered viruses 
of which 32 are designated as probably not arthropod- 
borne viruses. (Karabatsos, 1985).
Casals (1957) grouped arboviruses together with 
the use of serological methods principally, complement 
fixation and haemagglutination inhibition assays. The 
first newly recognised viruses were sorted into 
serological groups A, B, and C. These groups were later 
designated as the Family Togaviridae containing the 
alphaviruses (group A) and flaviviruses (group B) 
(Porterfield et ^ . , 1978; Porterfield, 1980) and the
Family Bunyavirdae containing group C (Porterfield et 
1975/76).
B ) Togaviridae
As the term ’arbovirus’ was only valid in a 
biological sense and had no revelance to the
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replication/structure/chemistry of viruses, the 
Arbovirus Study group was appointed in 1967 to advise 
the International Committee on Taxonomy of Viruses 
(ICTV) on the choice of names. Following the use 
of 'togavirus’ as a 'jargon name' (from the Latin: Toga- 
a Roman mantle or cloak) for the group A and B 
arboviruses, the family name Togaviridae was approved 
(Porterfield, 1978). The family Togaviridae was first 
comprised of only two genera: the Alphavirus (for group
A) and the flavivirus (for group B). Later two more 
genera,' Rubivirus and Pestivirus, were approved (Fenner, 
1975).
C) Flaviviridae
Until 1984, the flaviviruses were always regarded 
as a genus within the Togaviridae (White and Fenner, 
1986). But in 1984, the ICTV approved the recommendation 
of the ICTV Togavirus Study Group to transfer the 
flaviviruses from the Togaviridae into a distinct 
family, the Flaviviridae (Westaway et ^ . , 1985). The
prefix of the family name is derived from flavus 
(yellow) and refers to to the type species, YF virus. 
The recommendation resulted from several fundamental 
differences with regard to flavivirus structure, 
replication strategy, and gene sequence. The flaviviruses 
have two envelope proteins while alphaviruses have
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C The flaviviruses differ in size, the genes
for the structural proteins are located at the 5' end in 
a very long open reading frame and the viruses do not 
possess a poly (A) tail at the 3' end (Rice et al., 
1985). In contrast the genes for the structural proteins 
for the alphaviruses are located near the 3' end of the 
genome and the RNA genome is polyadenylated at the 3' 
terminus and have a subgenomic RNA.
On the basis of cross-neutralisation tests using 
polyclonal, hyperimmune anti-sera De Madrid and 
Porterfield (1974) classified 42 group B arboviruses 
(flaviviruses). They were able to confirm the existence 
of 7 antigenic complexes or antigenic subgroups, with 
six of the viruses being antigenically distinct. In 
1989, Calisher et analysed sixty-six flaviviruses in 
cross-neutralisation tests in cell culture and grouped 
the viruses into eight complexes with 17 other viruses 
still remaining antigenically distinct. This included 
the type virus YF. The viruses were also grouped by the 
principal vector responsible for transmitting the 
disease. The antigenic groups were:
TICK: Tick-borne encephalitis
Tyuleniy
MOSQUITO: Japanese encephalitis
Ntaya 
Uganda S 
Dengue
NO VECTOR: Rio Bravo
Modoc
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The complete list of members of the Flaviviridae is 
shown in TABLE 1.3
II. Flavivirus Morphology and Structure
A) Virion
Morphologically, in negatively stained
preparations, virions of the flaviviridae appear as a 
uniformly icosahedral particle of 45 nm in diameter. 
This consists of an isometric, densely stained 
ribonucleoprotein core, between 30 to 35 nm in diameter 
and which is surrounded by a lipid envelope 
approximately 7-10 nm thick containing spikes or 
clublike projections (Murphy, 1980).
The virion consists of three proteins, E and M 
associated with the envelope and C associated with the 
core particle (Westaway, 1987). The chemical composition 
of one of the flaviviruses was 6% RNA, 66% protein, 9% 
carbohydrate and 17% lipid (Trent and Naeve, 1980).
B) RNA
RNA extracted from purified virions is infectious, 
single stranded, and of positive polarity that can 
immediately serve as messenger RNA (mRNA) upon uncoating 
in the host-cell. The genomic RNA extracted from 
infected cells is a 38-45S RNA and collectively known as
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TABLE 1.3. MEMBERS OF THE FLAVIVIRIDAE
ASSIGNED TO ANTIGENIC COMPLEXES
(Modified from Calisher et al., 1989)
ANTIGENIC COMPLEX VIRUSES
Tickborne
encephalitis
Rio Bravo
Japanese
encephalitis
Tyuleniy
Ntaya
Uganda S
Dengue
Modoc
(RSSE, Central European encephalitis), 
Omsk haemorrhagic fever, LI, Kyasanur 
Forest disease, (Langat, Phnom Penh 
bat, Carey Island), Negishi, Powassan, 
Karshi, Royal Farm.
Rio Bravo, Entebbe bat, Dakar bat, 
Bukalasa bat, Saboya, Apoi
JE, MVE, Kokobera, Alfuy, Stratford, 
SLE, Usutu, WN, Kunjin, Koutango
Tyuleniy, Saumarez Reef, Meaban
Ntaya, (Tembusu, Yokose), (Israel 
turkey meningoencephalitis, Bagaza)
Uganda S, Banzi, Bouboui, Edge Hill
DEN-1, DEN-2, DEN-3, DEN-4
Modoc, Cowbone Ridge, Jutiapa, Sal 
Vieja, San Perlita
Viruses that could not be assigned to an antigenic 
complex are listed below:
Area, Bussuquara, Cacipacore, Gadgets Gully, Ilheus, 
Jugra, Kadam, Montana Myotis leukoencephalitis, Tamana 
bat, Naranjal, Rocio, Sepik, Wesselsbron, Sokuluk, 
Spondweni, yellow fever, and Zika
*: Viruses in parentheses are more closely related to
each other than to other members of the antigenic 
complex
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44S RNA (Westaway, 1980) has a type 1 cap structure: 
m^GpppAmpNp at the 5'-end and no poly (A) at the 3 '-end 
(Trent and Naeve, 1980; Rice et al., 1985). The base 
value of YF virus RNA is 27.3% A, 23.0% U, 28.4% G and 
21.3% C (Rice et al., 1985).
Ill. Flavivirus Replication
A) Uptake of Virus
To initiate the entry process, the flavivirus 
exhibiting selective ligands on their surface must 
attach to corresponding receptors on target cells. These 
specific cell surface receptors for flavivirus binding
to host cells have not been characterized at the
molecular level. Gollins and Portefield (1985) studying 
the mode of entry of West Nile virus into the
macrophage-like cell line P388D1 concluded the virus
entered by receptor-mediated endocytosis. Other workers 
have confirmed this using other flaviviruses: Ishak et 
al., (1988) using YF virus grown in Vero cells and Ng 
and Lau (1988), who used Vero cells infected with
Kunjin. However, Hase et , (1989) demonstrated
the SA^  ^strain of Japanese encephalitis virus and
the PR159 strain of Dengue-2 virus entered 06-36 cells
by direct penetration.
Due to the diverse cell tropism and pathogenicity
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shown among the flaviviruses, it is likely that 
individual flaviviruses have evolved diverse entry 
modes. The entry mode probably depending on their 
characteristic life cycle under different conditions of 
growth and therefore further research in this area is 
required.
B ) Translation
Westaway (1980) has presented evidence that the 
translation strategy of flaviviruses involves the use of 
multiple iniation sites for the translocation of 
proteins from the virion length mRNA. However, the 
nucleotide sequence data for many flaviviruses indicates 
that the viral RNA is translated as a single long open 
reading frame. This produces a polyprotein structure 
which under goes extensive proteolytic processing 
(Chambers ^  a3^ ., 1990).
C) Replication
The replication of flaviviruses is thought to take 
place in the cytoplasm of cells with the general 
agreement amomg investigators (Hase et , 1989) that
replication takes place in the perinuclear region. The 
replication scheme for flaviviruses has been proposed by 
Westaway (1987) on the basis of accumulated data. 
Briefly, RNA replication involves the initiation and
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completion of complementary minus-strands which are then 
used as templates for production of genome length plus 
stranded molecules. The plus stranded molecules can be 
used for translation of additional structural and non- 
structural polypeptides, for minus strand synthesis or 
for encapsidation (Chambers and Rice, 1987, Hase et al.,
1989).
D ) Virion Assembly and release
Electron microscopy studies usually show the 
flaviviruses in cytoplasmic vacuoles of infected cells 
around the membranes of the endoplasmic reticulum (ER) 
and golgi apparatus. Hase et (1989) have reported
nucleocapsids of Dengue-2 forming in the cytosol and 
moving to the cell membrane for viral envelope 
acquisition, while JE virus was shown to form in the 
rough endoplasmic reticulum as whole virions. The 
membranes of the ER undergo a characteristic 
proliferation forming dense microtubular membranous 
aggregates (Chambers and Rice, 1987). The virions exit 
from the cells by many suggested mechanisms. These 
include release of many virions from vesicles either by 
cell lysis or reverse phagocytosis. Also by budding 
internally from sites of membrane junction with plasma 
membranes (Westaway, 1980).
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3. THE PRODUCTION AND USE OF MONOCLONAL ANTIBODIES
IN VIROLOGY
A) History
Prior to the discovery of Kohler and Milstein 
(1975) of the production and isolation of single cells 
which secrete antibody having a discrete specificity for 
a single epitope, polyclonal antibodies were used for 
serological studies. Polyclonal antibodies are still 
used to the present day and have played an important 
biological role in defining important serological 
groupings in virology using the techniques of 
haemagglutination inhibition, complement fixation and 
neutralisation. However, polyclonal sera reacts to more 
than one specific epitope and each preparation may 
contain antibodies with different specificities.
Kohler and Milstein (1975) used the hypothesis of 
Burnet (1957) who stated each mammalian B lymphocyte had 
the capacity to secrete a single specific antibody 
reacting to a single epitope. Though B lymphocytes have 
a short life span when cultivated vitro, they can be 
fused with myeloma cells to produce a hybridoma cell 
line. These hybridoma cells have the immortality of the 
myeloma cell and the antibody secretion property of the 
B lymphocyte. The hybridoma cells can then be cloned out 
in a selective medium to produce hybridomas producing a
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monoclonal antibody (McAb) of a single specificity. In 
virology two of the more important biological functions 
defined using McAbs are those of neutralisation and 
Haemagglutination inhibition.
B ) Haemagglutination and Haemagglutination
Inhibition assays
The phenomenon of haemagglutination (HA) was first 
described by Hirst (1941) when removing previously 
Influenza A infected allantoic fluid from chick embyos. 
He noticed the red blood cells (RBCs) had agglutinated. 
He then demonstrated that he could inhibit this RBC 
agglutination (haemagglutination) by using serum from a 
proven case of Influenza A. This RBC agglutination was 
shown to be due to the virus and was termed 
haemagglutination. The inhibition of RBC agglutination 
is called Haemagglutination Inhibition (HAI). Since its 
discovery HAI has been used in virology for a number of 
purposes including serological techniques to 
systematically group all arboviruses together. In 1947, 
Hallauer reported that he had obtained a 
haemagglutinating antigen from YF virus. From 1951 to 
1953 Sabin and colleagues demonstrated haemagglutination 
in a number of flaviviruses except for YF virus. In 1953 
Casals and Brown showed haemagglutination of both 
viscerotropic and neurotropic strains of YF virus and
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that it was in group B of HAI reactions. Their source of 
antigen was the brains of newborn mice infected with the 
virus and the serum used was from a proven YF virus 
infected monkey. In 1957, Porterfield described a 
technique of HA and HAI using goose RBCs and reported 
these cells were more sensitive than chick RBCs to low 
titre virus.
C) Neutralisation Tests
It has been known for a number of years that 
antibodies induced as a result of viral infection can 
neutralise virions. However, the mechanism of 
neutralisation is still not fully understood and is the 
subject of debate. A number of workers have reviewed the 
mechanisms of neutralisation (Lafferty, 1963 a,b,c; 
Mandel, 1976; Della-Porta and Westaway, 1977 b; Dimmock, 
1984; lorio, 1988)
An antibody which neutralises viral infectivity 
may affect the virion at a number of points in the 
replication cycle and studies using different viruses 
have shown a number of different mechanisms of 
neutralisation. Also, the number of molecules of 
antibody required to neutralise a virus has been 
debated.
Some McAbs bind to the virus and their 
neutralisation activity prevents the virus binding to
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the cell (Massey, 1981). The belief that McAb bound to 
the virus always prevents the virus from binding to the 
cells has had to be altered for some viruses. In 
particular it has been shown that some McAbs which 
neutralise virus do not prevent it from binding to the 
cell surface. Taylor and Dimmock (1985), described IgM 
McAb which neutralised 99% of virus infectivity but only 
prevented 50% of virus attaching to BHK cells. In 1985 
Gollins and Porterfield showed a new mechanism for the 
neutralisation of the flavivirus West Nile virus. They 
reported antibody could neutralise by inhibiting the 
intra-endosomal acid catalysed fusion step.
4. ANTIGENIC AND MOLECULAR ANALYSIS OF THE FLAVIVIRUS
ENVELOPE PROTEIN
The E-protein is approximately 500 amino acids in 
length, depending on the flavivirus studied. For most 
viruses it is glycosylated (asparagine-linked N- 
glycosylation site) with the notable exception of 
strains of Kunjin (Wright, 1982) and West Nile (Wengler, 
1985). Biologically the E-protein encodes the functions 
of neutralisation, haemagglutination, haemolysis, 
passive protection, and antibody dependent
enhancement. To date no one has reported an antibody
with complement fixation activity with this protein. Antigenically a
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number of epitopes have been defined: sub-strain,
strain, type, sub-group (or complex), super complex and 
flavivirus group common. At present relatively few of 
the 68 flaviviruses have been examined in detail. The 
properties of the E-protein of the viruses studied to 
date are discussed below with particular reference to 
those studies using McAbs.
I. Antigenic Analysis
A) Analysis of the YF virus E-protein
YF virus, is the prototype species of the family 
Flaviviridae. Five groups have prepared McAbs against 
this virus. In 1983, Schlesinger et prepared McAbs
using the YF17D-204 USA vaccine strain as
the immunogen. In 1985 Gould et prepared McAbs
against the YF17D-204 UK vaccine strain, while Barrett 
et al. (1989) used the YF17D-204 WHO ALV-free secondary
seed and 17DD Brazil vaccine strains as the immunizing 
viruses to produce two sets of McAbs. Geske et al. 
(1983) only stated McAbs were prepared against
"pathogenic" and "attenuated" strains of YF virus. A 
Russian group, Novokhatski et (1987) produced a McAb
(Yel-2) using the Dakar strain of YF virus as the
immunizing virus. In indirect immunofluorescence tests 
it did not react with dengue-2, dengue-4 and Russian
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spring summer encephalitis (RSSE) viruses. Two of these 
groups have reported McAbs that react with the E-protein 
and these have been used in competitive antibody binding 
assays (CBAs) to map the spatial positions of epitopes 
on the surface of the envelope glycoprotein. Schlesinger 
et al. (1984 b) used sixteen McAbs that reacted with 
YF17D-204 USA to map and define eight domains by the 
techniques of CBAs, Neutralisation tests (N), 
haemagglutination inhibition assays (HAI), and four 
sites by different serological group-reactions. They 
were able to show three YF type specific McAbs which 
constituted one antigenic site, another neutralization 
site spatially different from the first, was recognized 
by the McAb 8A3 which is YF17D-204 strain specific. The 
nine McAbs which neutralized Asibi virus and not YF17D- 
204 USA defined six antigenic sites, of which one was 
associated with neutralization of YF17D-204 viruses.
On the other hand, Cammack and Gould (1986) who 
analysed topographically the epitope relationships on 
the E-protein using eleven McAbs identified five 
topographically distinct antigenic domains on the YF17D- 
204 U.K. virus. Three were defined by one McAb each and 
were a YF17D-204 strain specific McAb (864), a YF 
vaccine specific McAb (411), and a YF-type specific McAb 
(825). One domain was found to consist of at least five 
overlapping epitopes and is thought to represent a
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flavivirus group common antigenic site. They also 
compared epitope maps between the YF17D-204 UK vaccine 
and wild-type Asibi viruses. This revealed considerable 
functional differences but only one structural 
difference which was the epitope recognized by McAb 427. 
This was located in different structural configurations 
on each virus.
Thus, not only were domains found on YF17D-204 
U.K. and absent on Asibi (i.e. strain and vaccine-
specific epitopes) but also a difference in the 
structural configuration of an epitope was detected.
B ) Analysis of the TBE complex E-protein
The so-called TBE complex of the Flaviviridae 
family consists of TBE, LANGAT, NEGISHI, OMSK
HAEMORRHAGIC FEVER, KYASANUR FOREST DISEASE, POWASSAN, 
RSSE and LOURING ILL (LI) viruses (De Madrid & 
Portefield, 1974; Calisher, 1989) all of which are 
closely related and fairly difficult to differentiate 
serologically. TBE could be further divided in to 
Western (Central European) subtype and Far Eastern
subtype based on antibody absorption experiments and
confirmed by competitive RIA and peptide mapping using 
limited proteolysis of the structural glycoprotein 
(Heinz & Kunz, 1981 b). Heinz and Kunz (1981 b) stated 
the observed serological heterogeneity reflects the
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potential for sequence or conformational changes within 
immunogenic regions of the viral glycoprotein. Changes 
which would not impair primary protein functions in cell 
infection.
Using McAbs produced against Central European TBE 
virus, Heinz et ^ . , (1983 b) established a model for
the antigenic structure of the TBE E-protein and showed 
the distribution of conserved and variable epitopes. 
Their clever strategy of selecting McAbs specific for 
different antigenic sites on the structural E-protein 
was achieved by isolating a panel of eight McAbs against 
the E-protein of the Neudorfl strain of TBE and 
subsequently applying the various tests of HAI, N, CBA, 
passive mouse protection and variant analysis. These 
tests analysed the spatial relationships between the 
different McAbs and showed they consisted of eight 
distinguishable epitopes on the native conformation of 
the E-protein . Of the two McAbs that defined a group- 
reactive antigenic site, McAb 6E2 defines a determinant 
which is altered on two viruses from another sub-group
i.e. West Nile and Murray Valley Encephalitis viruses. 
The type-specific determinant was defined by McAb 1G2 
and the subtype-specific determinants by McAbs 1C4 (Cl) 
and 4D9 (A3) which allowed the discrimination between 
Western and Far Eastern subtypes of TBE virus. These two 
McAbs react with an epitope that is altered on the Far
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Eastern subtype but which is present identically on LI 
virus. McAbs 1B3, 5D6, and 2E7 however reacted
exclusively with TBE and LI viruses, thus defining a TBE 
complex specific determinant involved in HAI.
When the epitopes were topologically mapped, five 
independent non-overlapping antigenic sites were 
revealed that clustered into two complex antigenic 
domains. These domains were heterogeneous with respect 
to serological specificity as well as biological 
function. The effect of McAb mediated N or HAI depended 
on the exact location of each epitope in the 3-D 
structure of the E-protein. This was due to HAI reactive 
McAbs defining group, complex, and subtype specific 
epitopes. This agreed with previous studies by Clarke 
(1960) who used polyclonal antibody to demonstrate broad 
cross-reactive HI reactions with members of the TBE 
complex. In later papers Heinz (1986) changed the names 
of his McAbs to correspond with the domains which were 
named domains A, B and C.
Also, in 1983, a Russian group produced McAbs 
against another virus in the TBE complex (Novak et al.). 
This was the Skalica strain of TBE virus which was 
isolated from the bank vole. Three IgM McAbs S-8, S-15
and S-16 elicited HAI activity exclusively with the 
Skalica strain.
In 1984 Stephenson et , prepared a panel of 16
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McAbs using the Austrian isolate of Central European TBE 
virus (Neudorfl) as the immugen. Of these 16 McAbs, 9 
reacted with the 58K polypeptide which was thought to be 
the major envelope protein while the other 7 McAbs 
reacted with a 51K polypeptide (which was thought to be 
NSl). They reported that none of their McAbs would 
neutralise the parent virus. However, clones Til, T13, 
T18, and T33/2 would neutralise the parent virus if
neutralisation was "assisted" with rabbit antibody 
raised against total mouse immunoglobulins. There was no 
correlation between HAI and "assisted" neutralisation as 
clones T6, T9, T18, T33/2 and T35/1 had HAI activity 
suggesting these two activities reside on different 
parts of the E-protein. However, McAbs T18 and T33/2 
recognised epitopes having both biological activities 
and corresponded to results obtained by Heinz et al. 
(1983).
The McAbs were then used in an ELISA assay to
compare the antigenic relationships of (1) between TBE 
viruses, (2) between isolates of wider geographical 
origin and (3) to compare them against a Scotish isolate 
of LI virus.
When they compared three Austrian TBE virus
isolates antigenically in the elisa assay a wide range 
of titres were observed and four broad groups of
epitopes could be distinguished:
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Group 1, (T12, T16, T17) represented epitopes which were 
conserved in all three isolates and were present on the 
51K polypeptide; Group 2 (T18, T33/2, T33/3) represented 
epitopes which were conserved on Neudorfl (CTEN) and St. 
Polten (CTES) but have changed on Hochosterwitz (CTEH) 
virus; Group 3 (T6, T7, T15, T33/1, T35/1) were epitopes 
which were conserved on CTEN and CTEH viruses, but had 
altered on CTES virus. The McAbs in Group 4 (T4, T9,
Til, T13, T35/3) represented epitopes that had changed
antigenically the most and mainly resided on the 58K 
polypeptide.
When TBE virus isolates from Czechoslovakia 
(Hypr), Russia (Sophin), and Turkey (TTE) were compared 
with CTEN virus there was a considerable amount of 
antigenic variation between these isolates. However the 
McAbs T16, T17 and possibly T33/1 reacted with all four
viruses. Conversely, the epitope represented by clone 
T12, while remaining constant in the Austrian isolates 
appeared to vary considerably in this second group of 
viruses with the notable exception of Hypr.
The epitope represented by McAb T12 was also 
conserved on LI virus, thus grouping LI virus among the 
other western subtype isolates. McAb T17, on the other 
hand, represented an epitope which was heavily conserved 
in all isolates.
The epitopes recognized by McAbs in groups 2 and 3
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were moderately conserved in the Austrian isolates 
(CTEN, CTES, CTEH) and were present on either the 58K or 
51K polypeptide.
Phillpotts et (1985) reported antibody-
dependent enhancement with the above McAbs. Thirteen of 
the fourteen McAbs used only enhanced the replication of 
TBE virus (CTEN) and not a strain of West Nile virus 
(Egypt 101). These McAbs were T6, T9, Til, T12, T13,
T15, T16, T17, T18, T33/1, T33/2, T33/3, T33/5. Later,
in 1987, he used these McAbs in passive protection tests 
and reported that only one McAb, T9 which was able to 
neutralise the virus protected mice against viral 
challenge (Phillpotts et s^., 1987).
Another virus in the TBE complex that has been 
studied in detail is Negishi virus (Furata et al., 
1984). The Japanese group has analysed antigenically 
Negishi virus by producing 12 McAbs, using sucrose 
acetone extracted Negishi virus as the immunizing 
antigen.
The McAbs were characterized by HAI and N tests 
using five flaviviruses isolated in the Pan-Pacific 
region (Langat, 3-Arch, JE, Apoi and Negishi viruses). 
The 12 McAbs were classified into eight groups after the 
many N and HAI tests had been combined:
Group 1 McAbs (B9 and H6) reacted only with Negishi 
virus in HAI and N tests.
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Group 2 (F3) and Group 3 (DIO and F4) McAbs reacted with 
TBE virus complex being positive for Negishi and 
Langat viruses in HAI tests. F3 also reacted with 
Negishi virus in N tests.
Group 4 (A5) McAb was positive in HAI tests with Negishi 
and Langat viruses, but only neutralised JE virus 
and none of the TBE viruses.
Group 5 (A2) was positive in HAI tests with
Negishi, Langat, JE, and Apoi viruses while it had 
positive N activity with JE virus and no activity 
with homologous Negishi virus.
Group 6 (C5) had high HAI activity with all four
flaviviruses and positive N activity with JE 
virus.
Group 7 (All, B1 and Fll) had high HAI activity with all 
four flaviviruses and N activity with JE and Apoi 
viruses.
Group 8 (B2) had no HAI activity but showed N activity 
only with the homologous Negishi virus.
These workers suggested that the reaction pattern 
of the McAbs showed that Negishi virus was most closely 
related to Langat virus followed by 3-Arch, JE, then 
Apoi viruses respectively.
Later, the same group of workers (Motohide et al., 
1988) used ten of these McAbs to study Negishi virus in 
the biological reactions of HAI and several types of
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neutralisation tests. The McAbs were classified into 
three groups and seven types according to the reaction 
pattern obtained. They also reported a mixture of 4 
McAbs enhanced neutralisation in a kinetic assay.
C ) Analysis of the JE subgroup E-protein
On the basis of serological tests, especially N 
tests, flaviviruses were subdivided into subgroups or 
complexes (Chamberlain, 1980; Porterfield, 1980). One of 
these subgoups was known as the West Nile (WN) group and 
contained viruses such as Murray Valley Encephalitis 
(MVE), St. Louis Encephalitis (SLE), Japanese 
Encephalitis (JE), and WN. On further examination of
this group of viruses by Calisher et (1989) the
group was renamed the Japanese encephalitis antigenic 
complex. The E-protein epitopes of many of these 
viruses have been analysed in detail; JE virus (Kimura- 
Kuroda & Yasui, 1983, 1986; Cecilia et ^ . , 1988;
Kobayashi ^  ^ . , 1984, 1985), SLE virus (Roehrig et
al., 1983; Mathews & Roehrig, 1984), WN virus (Peiris et 
al., 1982; Besselaar & Blackburn, 1988) and MVE virus
(Hawkes et ^ . , 1988; Hall ^  ^ . , 1988). These studies
have shown that the majority of E-protein epitopes can
be divided mainly into virus specific, subgroup-
reactive, and flavivirus cross reactive sites.
Early studies with WN virus suggested the
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existence of two main antigenic groups (Hamman et al.,
1965). These are strains from Africa, Europe, the USSR, 
and the middle East which formed the Paleartic antigenic 
group which are serologically distinct from strains 
isolated in India (Gaidamovich, 1973; Hamman et al.,
1966)
Peiris et (1982) were the first to produce
McAbs against WN virus. They used the Egypt 101 strain 
of WN virus as the immunizing strain and produced three 
McAbs all directed against determinants on the E- 
protein. The McAb F7/3 bound to the group-specific 
determinant and had good HAI activity but had poor N 
activity. Another McAb, F/lOl, which recognised a 
subgroup specific determinant, also had poor N activity 
and no HAI actvity. The last McAb, F6/16A had good N 
activity which was limited to the homologous virus as it 
only recognized a strain specific determinant. It is 
interesting that the Smithburn strain of WN virus was 
not recognised, as both strains (Smithburn and ElOl) are 
indistinguishable by classical polyclonal tests (Hammam 
et al., 1965 ).
In 1988 Besselar & Blackburn produced eleven 
anti-E protein reactive McAbs using a WN virus isolate 
from South Africa as the immunogen could be divided into 
four groups on the basis of cross-reactivity with 
various flaviviruses by indirect immunofluorescence ;
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Group 1, WN-type specific; Group 2, WN complex-reactive; 
Group 3, Partially flavivirus group-reactive; Group 4, 
Broadly flavivirus group-reactive. One of the two McAbs 
in group 4 (6E8) defined a flavivirus cross-reactive HAI 
site present on YF, Dengue 2, Kunjin, and Wesselsbron 
viruses. The other flavivirus cross-reactive epitope was 
recognized by McAb 2A4 which unlike McAb 6E8, did not 
exhibit any biological activity in N and HAI tests. 
While they did not carry out competitive binding 
studies, they grouped the WN anti E-McAbs on the basis 
of functional activity and immunological cross­
reactivity to tentatively define a minimum of six 
epitopes.
Seven groups of workers have produced McAbs to 
analyse the antigenic structure of JE virus (Boquan ^  
al., 1983; Gould et ^ . , 1983; Kedarnath et al.,
1986; Kimura-Kuroda & Yasui, 1983, 1986; Kobayashi et
al., 1984, 1985; Cecilia et , 1988; Mason et al.,
1987; Srivastava, et ^ . , 1988).
The morphological, chemical, and biological 
characteristics of JE virus were first investigated by 
Kitano et (1974) who showed that the surface
glycoprotein (E-protein) projecting from the surface 
induced neutralizing antibodies and also had
haemagglutination activity. In 1983 a group of Chinese 
workers (Boquan et ) produced three McAbs using the
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SA-14 strain as the antigen. McAb "32" showed HAI 
activity against JE, Kunjin and WN viruses. The second 
McAb "51" had N activity and in indirect 
immunofluorescence tests (IIP) only reacted with JE 
virus. It neutralised the avirulent 2-8 strain, 2 to 4 
fold more than its parent SA-14 strain. The last McAb 
produced "43", showed N and IIP activity only against 
the JE SA-14 and 2-8 strains, but not against other JE 
strains (e.g. the JE JAK-2 strain).
In 1983, Gould ^  ^ . , produced a single IgM McAb 
using the Nakayama strain of JE virus. They reported 
that the McAb reacted with the NS3 (NV4) protein on 
western blots and it reacted in IIP tests with a number 
of flaviviruses.
Also in 1983, Kimura-Kuroda and Yasui produced ten 
McAbs against the E-protein of JE virus strain JaGAr-01. 
They characterized the McAbs by HAI, N, and ELISA and 
divided them into four types.
Group 1 (McAbs 110, 111, 301, 23) was flavivirus-cross
reactive with HAI reactivity but no N activity. Group 2 
(McAb 109) was subgroup specific having HAI but no N 
activity. Group 3 (McAb 112) was JE virus strain 
specific having N but no HAI activity. Group 4 (McAbs 
203, 302, 303) and Group 5 (McAb 204) had no HAI
activity but neutralised JE and WN viruses but not 
dengue-2 virus. They then also performed CBAs which
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demonstrated the existence of atleast five distinct 
antigenic sites on the E-protein. Their results also 
separated non-HAI and N McAbs into groups 4 and 5 
respectively and also showed that the group 1 site was 
distinct from any other site , but the sites of groups 2 
and 3 seemed to be located together.
In 1986 the same workers produced other McAbs
against the JE virus strain Nakayama-yoken. With a
larger panel of 17 McAbs they were able to divide the
McAbs into eight groups using CBAs and analysed these 
groups for their cross-reactivity with several other 
flaviviruses. The results indicated that JE virus
belonged to the WN subgroup and was antigenically 
closely related to viruses in this group. It was more
closely related to MVE virus, than it was to WN virus
and was least closely related to SLE virus. The results 
of the N tests indicated McAb 503 from group 8 
recognised determinants on a critical N site that was JE 
virus specific and had the highest N activity among the 
N McAbs. All the McAbs from group 7 showed high N
against JE and MVE viruses and one (McAb 402) also 
cross-neutralised WN virus. From these results they 
proposed that there is a variable region (recognised by 
McAbs in groups 3, 7, 8) on the E-protein which is
important for infection of JE virus.
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Using the JE virus strain Nakayama-RFVL as the 
immunizing strain, Kobayashi et (1984) produced 26
McAbs and tested them for HAI activity with six 
flaviviruses: JE, MVE, Egypt 101 strain of WN, SLE, 
RSSE, and dengue-1. They showed that the McAbs fell into 
four groups : 14 JE species specific , 6 reactive with
JE and MVE viruses, 3 specific to the JE-MVE-WN-SLE 
subgroup and 3 McAbs were flavivirus group common in 
reactivity. They examined and compared twenty seven 
strains of JE virus using McAbs 1 to 14. McAbs 13 and 14 
were typical species specific while McAb 13 showed 
almost the same HAI titre against 26 JE virus strains. 
Also, McAb 5 and 6 were Nakayama strain specific McAbs. 
From these studies they were able to show atleast three 
antigenically distinct strains of JE virus existing in 
Japan over a period of more than 40 years. In 1985, 
Kobayashi ^  , used the same panel of McAbs in
competitive binding assays. They suggested the existence 
of at least five HAI sites on JE virus and that JE 
species-specific and flavivirus group reactive HAI sites 
were topologically distinct.
In 1986 Kedarnath et ^ . , produced a panel of 
sixteen McAbs against an Indian strain (733913) of JE 
virus that exhibited either antigenic specificity or 
cross-reactivity in some or all of the tests e.g. HAI
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and N, The same group (Cecilia et a^., 1988) then used
these McAbs to map the antigenic sites on the E-protein 
of JE virus and assigned biological functions to the 
mapped domains. Firstly two separate clusters of 
epitopes were revealed. Secondly, on the basis of 
reactivity in HAI, N, CBAs, and passive protection 
assays with McAbs , five functional domains (A, B, C, D, 
and E) were delineated. The HAI reactive flavivirus 
cross-reactive domain A was distinct and comprised five 
epitopes represented by McAbs Hx-1 to Hx-5. The HAI 
reactive JE specific domain B consisted of four epitopes 
Hs-1 to Hs-4 and was in continuum with the other 
domains. The non HAI reactive JE virus specific domain C 
contained two overlapping epitopes reactive with NHs-1 
and NHs-2 McAbs. The non HAI reactive flavivirus cross­
reactive domain D was represented by three non­
overlapping McAbs NHx-1 to NHx-3. The last domain E 
contained two non-HAI cross-reactive and auto-reactive 
epitopes represented by McAbs NHA-1 to NHA-2 which were 
overlapping and were also juxtaposed to the Nhx-1 McAb 
reactive site.
Cecilia et (1988) concluded from their
results:
(a) Two distinct antigenic domains were associated 
with HAI.
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(b) HAI and N vivo and dji vitro were dissociated 
functions.
(c) Antibody-Dependent Plaque Enhancement (ADPE) 
activity was associated only with domain A.
(d) All McAbs reacting with epitopes in B domain had 
HAI,N and protective activity but failed to show 
ADPE.
They suggested that domain B would be the most 
suitable for development of synthetic or genetically 
engineered vaccines due to its biological function.
Srivastava et (1988) examined 42 monoclonal
antibodies prepared against JE virus (strain JaOArS982) 
grown in C6-36 cells and classified 17 McAbs into five 
antigenic groups: strain specific, JE virus specific,
sub-group specific reacting with MVE, WN, SLE, and JE 
viruses. The other two groups were subgroup and dengue 
specific as well as flavivirus specific.
Mason et (1987) produced ten McAbs against the
Nakayama strain of JE virus. Nine of these McAbs were 
specific for the envelope glycoprotein. McAbs 1, 2, 3,
4, 6, 8 and 9 were type specific with McAbs 1, 4, 6, and 
8 having high N activity ; while the other two McAbs 
were cross-reactive (5 and 7).
Roehrig et (1983) produced 21 McAbs specific
for the E-protein of SLE virus strain MSl-7. They
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determined serological reactivities using indirect 
immunofluorescence assays and were one of the first 
groups to demonstrate that the E-protein of a flavivirus 
is divided into atleast four determinants, the type (E-
1), subcomplex (E-2), supercomplex (E-3), and flavivirus 
group (E-4) reactive determinants. Using HAI and N 
assays they divided the groups into eight epitopes:
El® (McAb 3B4C-7) type specific and no biological 
activity.
El^ (McAb 1B2C-5) type specific with only HAI 
activity.
El^ (McAb 6B5A-2) type specific with N and HAI 
reactivity.
El^ (McAb 4A4C-4) type specific with N activity only.
E2 (McAb 1B5D-1) subcomplex with only HAI activity.
E3 (McAb 2B5B-3) supercomplex with only HAI activity.
E4® (McAb 2B6B-2) group epitope with no HAI or N
activity.
E4^ (McAb 6B5C-1) group epitope with high HAI and N 
activiy.
Using these McAbs in a CBA assay showed that the 
E-protein was divided into atleast six binding groups 
and that the epitopes are arranged as an overlapping 
continum.
Roehrig’s group (Hawkes et ^ . , 1988) have also
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produced 10 McAbs against the Original strain of MVE 
virus. The McAbs were tested in an ELISA and 
demonstrated specificities ranging from MVE type 
specific to flavivirus group reactive. Eight epitopes 
were identified in neutralization tests and HAI assays. 
Some of the epitopes were identical to those found with 
their SLE virus McAbs and were assigned identical 
nomenclature. Three of the epitopes E-1® (McAb 4B6A-2), 
E-l^ (McAb 4B6C-2), and E-1^ (McAb 4B5A-2) were type 
specific for MVE virus. One epitope E-5 (McAb 4B3B-6) 
was shared by MVE and JE viruses. Another epitope E-6 
(McAb 4B5B-10) was shared by MVE, JE and Alfuy viruses. 
Two epitopes E-4® (McAb 4A5D-7) and E-4^ (McAb 4A1B-9) 
were flavivirus group reactive. The remaining epitope 
was identified by the SLE virus McAb 2B5B-3. Of these 
epitopes E-l°, E-3, E-4^ showed both N and HAI activity. 
E-1^ and E-5 elicited MVE N antibodies, while E-6 showed 
HAI reactivity.
Their results collaborate the close antigenic 
relationship between viruses of the JE/SLE/MVE/WN 
serocomplex. Only the equivalent of the E-1^ epitope of 
SLE virus was not identified. Presumably, this was due 
to either absence of the epitope or their failure to 
isolate the appropiate McAb.
Also in 1988, Hall et ^ . , produced two type- 
specific McAbs against the French (3/51) strain of MVE
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virus. One McAb (M-Bll) reacted with the PrM protein and 
the other (M-E6) reacted with both the E and NSl 
proteins in immunoblots. The McAbs failed to react in 
HAI assays with all viral antigens tested and did not 
neutralize the French 3/51 strain of MVE virus.
D) Analysis of the dengue virus complex E-protein
The dengue (DEN) viruses form a complex of four 
closely related antigenic types (types 1 to 4). Each of 
the four virus types can be transmitted by infected 
mosquito vectors. Three groups of workers have raised
McAbs against one or more of the four DEN groups in the 
last ten years.
One of the first to produce McAbs against DEN
virus was Dittmar et (1980) who produced 46 McAb
hybridomas against DEN-3 virus. These 46 McAbs showed 
flourescence when added to DEN-3 infected cells in IIF 
tests. From this number of hybridomas they picked four
to study: numbers 31, 36, 20 and 27. They showed McAb 31
was DEN-3 virus specific when assayed by HAI assays and 
McAb 20 was highly cross-reactive. From their data it 
was not possible to accurately determine which viral 
protein the McAbs were directed against. But as all were 
involved in HAI, they postulated clone 31 was directed 
against a type-specific determinant on the E-protein.
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Then Gentry et al. (1982) produced 22 McAbs against the 
New Guinea C strain of DEN-2, which they characterised 
by HAI, N, IIP tests and complement fixation tests (CF). 
They showed five different McAbs to be type-specific for 
DEN-2. One of them (McAb 3H5) recognized a type-specific 
determinant that exhibited high N, but had low HAI 
activity. While the other four McAbs (1C7, 1C12, 2H3,
3H1) were type-specific with high HAI but having no N 
activity with the homologous virus. The other seventeen 
McAbs were all broadly cross-reactive McAbs. In the same 
year, the same group (Henchal et ^ . , 1982) produced
McAbs against the four DEN virus serotypes and
identified four categories of reactions by 
immunofluorescence.
(i) Flavivirus group reactive
(ii) Dengue complex specific
(iii) Dengue subcomplex specific (e.g. DEN-1 & DEN-3)
(iv) Dengue serotype specific.
This was the first time that McAbs had been
produced for all of these unique antigenic determinants.
The majority of their McAbs were flavivirus group 
reactive e.g. 1B8, IBIO, ICIO, 4G2, 2C4 (DEN-2 New
Guinea C strain), 1B6, (DEN-3 strain H87), 4B10, 1D7,
(DEN-4 H241 strain) which generally reacted with all 
flaviviruses tested using IIP tests. Several other McAbs 
reacted solely with DEN virus serotypes. One group was 
DEN subcomplex specific only recognizing DEN-1 and 3
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viruses (McAb 13E7 [DEN-1 strain Hawaian] and McAb 2F3 
[DEN-3 strain H87]). A second group of McAbs were DEN 
complex specific, these were McAb 9D12 (DEN-1 Hawaian 
strain) and McAb 2H2 (DEN-4 H241 strain). The last nine 
McAbs they tested were type-specific by IIF tests, McAbs 
15F3, 5C11 (DEN-1), 5D4 (DEN-3) also by N activity McAb 
3H5 (DEN-2) or by HAI activity 3H1, 2H3, 1C7, 1C12 (DEN-
2), IHIO (DEN-4).
They proposed that the second epitope (subcomplex 
specific) and common to DEN-1 and DEN-3 must also exist 
within the variable region of the E-Protein, as well as 
the complex specific epitope because McAbs 9D12 and 2H2 
were totally unreactive with other flaviviruses.
Henchal et (1985) then used some of these
McAbs in CBAs and analysed the epitopes of the antigenic
determinants on the surface of the DEN-2 virus E-
protein. They showed that four groups of antigenic 
determinants 3H5, 4E5, 2H3 were type, 9D12, 13B7 were 
subcomplex, 1B7 flavivirus subgroup and 4G2 was
flavivirus group specific, and identified atleast seven 
epitopes which could be grouped into atleast three 
different linkage groups. The presence of epitopes with 
different serological reactivities in the same linkage 
group was similar to the findings of Roehrig et ,
(1983) and supports their conclusion that epitopes on 
the E-Protein of DEN virions maybe arranged as a
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continuum of reactivities in overlapping domains.
Morens et al. (1987) produced nineteen McAbs 
against dengue type 4 (DEN-4) virus strain 4328-S. These 
McAbs were first characterized serologically in ELISA, 
N, and HAI assays. Twelve McAbs were flavivirus group- 
reactive (UH-2B2, UH-2B4, UH-2C3, UH-3D1, UH-3D3, UH-
5B3, UH-6B3-4, UH-5C1, UH-7D6, UH-8A1, UH-8C2, and UH-
8D5-1) and seven were DEN-4 serotype reactive (UH-3C5- 
Bl, UH-5C3, UH-6C3, UH-6D3, UH-2A1, UH-8A4, and UH-8A6). 
The last three McAbs reacted only in ELISA tests and 
were assumed to be directed against non-envelope 
determinants. The McAbs produced were then studied in 
antibody-dependent enhancement (ADE) experiments. They 
showed that McAbs raised against DEN-4 could inhance 
infection of DEN-2 viruses. The McAbs were serotype- 
reactive in HAI and N activity. Therefore they 
postulated some DEN-2 virus strains must have DEN-4 
virus like epitopes.
II. Molecular analysis of flaviviruses
The use of McAbs to define serological 
relationships and to ascribe functional activities to 
the individual epitopes has been extensively used for 
the analysis of flaviviruses. In addition, McAbs are 
excellent tools to probe the structural properties of 
individual antigenic determinants. Accordingly, they
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have increased the knowledge of the antigenic structure 
of proteins in general. However, to date, this potential 
has not been exploited to a great extent, and detailed 
data relating to the structural properties of epitopes 
in relation to their RNA sequence and peptide fragments 
is still fairly limited though still being extended.
A detailed study of the TBE virus E-protein has 
been made by Heinz et (1983). They showed that
domain A, which contains the flavivirus group-reactive 
epitope Al, was sensitive to conformational change at 
different pH levels. This also corresponds to similar 
findings of Henchal et al. (1983) who showed that a 
flavivirus group-reactive epitope on DEN-2 virus was 
also sensitive to pH changes. Also Kimura & Ohyama 
(1988) studied the association between pH-dependent 
conformational changes when the virus fused to the cell 
membrane.
In contrast, Heinz et (1983) showed domain B
is resistant to acid pH and even guanidine-HCl urea and 
also SDS treatment, though it is destroyed by 
carboxymethylation. This suggests a role for disulphide 
bridges in the structure of the E-protein.
Winkler et (1984) reported evidence for a
strongly stabilised core and suggested evidence of the 
involvement of disulphide bridges. Subsequently the 
nucleotide sequence of the first flavivirus genome, YF
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virus, was published in 1985 (Rice et a^., 1985).
Wengler and co-workers (Wengler et ^ . , 1985) analysed
the sequence of the E-protein of WN virus and then in
1987 proposed a model for the E-protein (Nowak & Wengler
1987). They showed the E-Protein of the YF and WN
viruses contain twelve cysteine residues which are in 
conserved positions among both viruses and form six 
disulphide bridges; cysl-cys2, cys3-cys8, cys4-cys6, 
cys5-cys7, cys9-cyslO, cysll-cyslO.
Investigating proteolytic cleavage, Heinz et al. 
(1983) have shown that different antigenic domains
correspond to different structural entities. Mandl 
et al. (1989 a) continued this work and have
sequenced the proteolytic fragments and have correlated 
the sequences to the defined epitopes and antigenic 
domains recognized by their McAbs. They proposed a 
model for the TBE virus E-protein (FIGURE 1.4) which 
reveals features of folding of the polypeptide chain 
including the generation of discontinuous protein 
domains. Recently Heinz and co-workers have pepared a 
new panel of McAbs against TBE virus (strain Neudoerfl, 
Guirakhoo et ^ . , 1989) and extended the limited epitope 
map of Heinz et (1983) by 11 distinct epitopes.
Roehrig et (1989) using computer analysis modified
the E-protein structure proposed by Nowak and Wengler
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FIGURE 1.4 ..STRUCTURE OF THE TBE VIRUS E-PROTEIN 
(TAKEN FROM HEINZ ET , 1990)
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1) A, B, C: correspond to different antigenic protein
domains recognised by McAbs
2) Disulphide bridges are marked by connecting 
solid lines (from Nowak and Wengler, 1987)
3) Thin lines indicate variable sequences
4) Thick lines indicate hyoervariable sequences
5) Diamonds indicate potential N-glycosylation sites for 
TBE and other flaviviruses
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(1987) and prepared synthetic peptides from the deduced 
amino acid sequence which were recognised by polyclonal 
antiviral (MVE virus) antibodies. Using antipeptide 
antisera in CBA's they showed spatial overlap of the R1 
and R2 domains.
Other workers using other flaviviruses have 
studied the proteolytic cleavage events in flavivirus 
maturation. Wengler and co-workers (Wengler et al., 
1987; Wengler & Wengler, 1989, Nowak, et al., 1989) have 
used WN virus to study these events, while Biedrzycka et 
al. (1987) have used DEN-2 virus. New Guinea C strain
and have determined the amino acid sequences surrounding 
the likely proteolytic cleavage sites used in the 
formation of the E-protein and three non-structural 
proteins. Markoff (1989), produced mutants of DEN-4 
virus by site-directed mutagenesis, and have observed 
that the cleavage at the capsid-prM and prM-E sites is 
effected entirely by signal peptidases.
Two groups of workers have studied the maturation 
of YF virus. A French group (Ruiz-Linares et 1989)
and an American group (Chambers et ^ . , 1989, 1990) have 
both analysed the role and site of action of cellular 
proteases to produce both the structural and non- 
structural proteins (FIGURE 1.5).
Mason et (1987) used McAbs (previously
described above) to examine the expression of the E-
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FIGURE 1.5 THE STUCTURE OF THE YF VIRUS GENOME AND 
PROTEOLYTIC PROCESSING OF THE YF POLYPROTEIN 
(ADAPTED FROM CHAMBERS ET AL., 1990)
YF17D GENOME 
(10,862nt)
llSnt 10,233nt 512nt
5'CAP- STRUCTURAL NONSTRUCTURAL
virion
assembly
prManchC
' 0
NS2B
NS4A
NS2ANSl
NS4B
NS3NS1-2A NS4A-4B NS5
□ 0Ml virionrelease ?
CLEAVAGE EVENTS:
♦ signalase (rapid, in lumen of intracellular membranes)
I Dibasic (rapid, in cytoplasm)
* Dibasic (delayed in cytoplasm)
4^  Dibasic (delayed, in lumen of intracellular membranes)
V Novel (delayed, in lumen of intracellular membranes)
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protein of JE virus in E. coli. The clone J7-ls, which 
only contained 135 of the 500 amino acids of the E-
Protein, still retained immunoreactivity with each of
the nine McAbs. The workers detected two immunogenic 
regions in the E-protein which they presumed are exposed 
on the surface of the virion. Only one domain is
recognized by all nine anti-E McAbs, between amino acids 
280 to 414 of the E-protein. This segment ends 83
residues from the C-terminus of the protein.
Ill Sequence Analysis
A number of groups have sequenced the entire or 
parts of the genome of a limited number of flaviviruses 
with many strains also being sequenced. TABLE 1.4 lists 
the flaviviruses which the entire genomes have been 
sequenced. Two groups of workers have sequenced the 
E-protein of the YF17D-204 vaccine strain (Rice ^  al., 
1985; Despres et ^ . , 1987) while Hahn et (1987)
have sequenced the Asibi virus. Lobigs et al., (1987)
have localized and sequenced a neutralisation YF type- 
specific determinant on the E-Protein of YF virus at 
amino acid positions 71 or 72.
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TABLE 1.4 FLAVIVIRUSES SEQUENCED
Virus/strain Author
DEN-2 Jamaica 
DEN-2 SI
DEN-2 New Guinea C 
DEN-4 Caribbean814669 
JE JaOArS982 
JE Beijing—1 
JE SA-14 
JE SA-14-14-2 
Kunj in MRM61C 
TBE Neudoerfl 
TBE Sofjin 
WN Nigeria 
YF 17D-204 USA 
YF 17D-204 France 
YF Asibi
Deubel et al., 1988 
Hahn et al., 1988 
Irie §t al., 1989 
Mackow et al., 1987 
Sumiyoshi et , 1987 
Hashimoto et , 1988 
Nitayaphan et , 1990
Coia et al., 1988 
Mandl et , 1989 b 
Pletnev ^  , 1990
Castle ^  , 1986
Rice et al., 1985 
Dupuy et al., 1989 
Hahn et , 1987
DEN-3 H87 Osatomi and Sumiyoshi, 1990
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5. AIMS OF THESIS
Previous studies (Liprandi, 1981; Buckley and 
Gould, 1985 and Barrett and Gould, 1986a) have shown 
that YF vaccine viruses from different manufacturers are 
antigenically and biologically distinct. The aim of this 
thesis was to examine and compare in detail all the YF 
vaccine viruses produced by manufacturers in different 
countries using different conditions of manufacture and 
different seed viruses. In particular, the studies would 
concentrate on the E-protein of the viruses. Therefore, 
panels of McAbs were generated and the epitopes of the 
E-protein of different strains and sub-strains of YF 
vaccine viruses examined using these McAbs in the 
biological assays of HAI and PRNT.
Also, the pathogenicity of the YF vaccine viruses 
will be compared using the mouse and monkey as models to 
test the neurovirulence of different strains of YF 
virus.
Finally, a comparison will be undertaken of the 
properties of YF vaccine viruses when passaged in 
vertebrate and invertebrate cell lines. Each cell 
passaged virus will be tested for temperature 
sensitivity as well as differences in biological 
function in PRNT's and HAI assays.
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CHAPTER 2
MATERIALS AND METHODS
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1: CELL CULTURES AND VIRUSES
I. Cell Cultures
A) Propagation and maintenance of cell lines
All cell lines (TABLE 2.1) were maintained on 
Eagle’s minimal essential medium [EMEM] (Eagle, 1959), 
with the addition of L-glutamine (2mM), penicillin G 
(100 units/ ml) (Sigma chemical company Limited, Poole, 
Dorset), streptomycin sulphate (0.1 mg/ml), sodium 
bicarbonate (0.075% final concentration) (Sigma chemical 
company Limited). The media contained 2% (v/v)
(maintenance media) or 10% (v/v) (growth media) newborn 
calf serum (NBCS, mycoplasma and virus free. Flow 
Laboratories, Irvine, Scotland) for SW13, LLCMK-2, CV-1 
cell lines. VERO, BHK-21, C6-36 and CEF cells were
maintained on 2% (v/v) (maintenance media) or 10% (v/v) 
(growth media) foetal calf serum (FCS, mycoplasma and 
virus tested. Flow Laboratories). Cell culture media 
were obtained from Flow or Gibco Laboratories.
All the cell lines ( except for C6-36 cells) were 
trypsinized when the cell monolayer was confluent, using 
5 mis of a versene (0.05% [w/v] EDTA, lOOmM Sodium
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hydroxide, 0.0025% [w/v] Phenol red/PBS solution) /
trypsin (1:250, 2.5% in Hanks Balanced salt solution
[Hanks, 1949], Flow Laboratories) PBS solution (Oxoid 
Limited, Basingstoke). The C6-36 cell line was 
subcultured by manually tapping the tissue culture flask 
and splitting the contents in a 1:5 dilution.
B ) Storage of cells
Cells were frozen in cell medium containing 20% 
FBS (Flow Laboratories) and 7.5% Dimethyl Sulphoxide 
(Sigma Chemical Company). The cryotubes (Nunc) were 
wrapped in cotton wool in a foam box to ensure the 
temperature decreased slowly and then placed at -70°C 
for 24 hours before being transferred to liquid nitrogen 
for long-term storage.
II. Viruses
A) Wild-Type YF Viruses
The wild-type YF viruses used in this study are 
shown in TABLE 2.2. All viruses were obtained as freeze 
dried preparations which were rehydrated with 1ml of 
distilled water and aliquoted into lOOul amounts and
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stored at -70°C in cryotubes (Nunc/Gibco, Uxbridge) as 
virus seed stocks.
Wild-type YF viruses were grown by infecting a 
confluent 25cmf tissue culture flask (Nunc/Gibco) of 
SW13 cells with approximately 0.01 PFU/cell. After 72 
hours or when CPE was observed in 90% of the cells, the 
tissue culture media was clarified by centrifugation in 
plastic universals (Sterilin, Feltham, Middx.) for 5 
minutes at 2000rpm in a MSE bench-top centrifuge. The 
supernatant was then dispensed into 1ml aliquots and 
frozen at -70°C in cryotubes.
Wild-type YF viruses were also propagated in a 
confluent tissue culture flask of C636 cells using a 
similar M.O.I as before. After five days the media was 
clarified by centrifugation and the supernatant stored 
at -70°C.
B ) YF Vaccine Viruses
All YF vaccine viruses were obtained from 
individual manufacturers ( TABLE 2.3) as freeze dried 
preparations which were stored at -20°C until required. 
YF vaccine viruses were propagated by taking a freeze- 
dried ampoule of commercial vaccine thawed out at 37°c 
and then rehydrated with 1ml of sterilised distilled 
water.
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Then lOOul of virus was used to infect a confluent 25cm^ 
tissue culture flask of SW13 cells. This virus 
preparation was then used as the seed stock to infect 
other confluent cell lines when that particular cell 
line derived virus was required in an experiment.
C ) Other Flaviviruses
Other flaviviruses listed in TABLE 2.4 were used 
to make spot slides for the use in indirect 
immunofluorescence studies. They were propagated and 
frozen as described above for YF virus.
D ) Virus Plaque Assay
All virus titrations were performed in LLCMK-2 or 
Vero cell monolayers prepared in six welled tissue 
culture plates (Nunc or Gibco). Ten-fold dilutions of 
virus were made in PBS and lOOul of each dilution was 
inoculated onto a monolayer of an appropiate well which 
was previously washed once with PBS. Following 
incubation for 30 minutes at room temperature (RT), the 
wells were overlaid with 6mls of a mixture of 2% (w/v)
agar (Sigma chemical company Limited) and double 
strength Eagle's minimal essential medium containing 4%
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foetal bovine serum (Flow Laboratories) and 4% DEAE- 
Dextran (Sigma chemical company Limited). After 6 days 
incubation at 37°C in a CO^ ( 5% in atmosphere ) 
incubator, 2mls of a second 'overlay ' containing 0.008% 
neutral red (BDH Chemicals, Eastleigh, Hampshire) was 
added to each well. After 24 hours incubation at 37°C in 
the dark, plaques were visualised via the use of a light 
box (Genetic Research Instruments).
E ) Virus TCIDg^ Assay
All the virus assays were performed on SW13 cell
monolayers prepared in 24 well tissue culture plates
(Nunc or Gibco). The monolayers were washed once with 
PBS and then ten-fold dilutions of the relevant virus 
were made in PBS and lOOul of each dilution was 
inoculated onto the monalyers of an appropiate well
across the row of five wells, as one remains as a
control plate. This procedure was repeated with the 
same virus dilutions across the plate with the other 
three rows of six wells. Following 30 minutes incubation 
at RT the cell monolayers were overlaid with 2mls of 
virus maintenance media and placed in a CO^ incubator 
for up to four days. After four days incubation the 
virus media was poured off and the cell monolayer was 
stained with 0.2% crystal violet. The tissue cell
90
destruction was noted and used to work out the TCID^^ 
for the particular virus using the equation below:
TCIDgQ = M - A (S - 0.5)
M = Dilution containing the highest
concentration of virus
A= LOG q^ dilution factor
S = Sum of proportion of positive 
cultures
0.5 = Constant
III Haemagglutinin Titrations and Haemagglutination 
Inhibition Assays
A) Haemagglutination Titrations
Haemagglutination assays were carried out 
according to that of Clarke and Casals (1958). and as
modified for use in microtitre plates by Sever et al.
(1964).
The diluent Borate Saline Bovine Albumin (BABS),
(50mM boric acid, 120mM sodium chloride, pH 9.0 with
sodium hydroxide, containing 0.4% [w/v] bovine serum 
albumin) was first added (50ul/well, except for the 
first row) to the plates (96 conical well plates, 
[NUNC or GIBCO]).
The viral haemaglutinin was produced by
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propagating the appropiate virus for up to 5 days in 
tissue culture flasks containing confluent monolayers of 
C636 cells. The clarified virus supernatent was then 
assayed for HA activity, whereby 50ul of virus was added 
to the first well of each row of the plate and diluted 
two-fold across the row of the microtitre plate.
Gander erythrocytes (Tissue Culture Services, 
Slough) suspended in dextrose-gelatin-veronal buffer 
(0.058% [w/v] veronal (barbitone), 0.038% [w/v] sodium
barbitone, 0.06% gelatin, 0.14mM calcium chloride,
0.49mM magnesium chloride, 1.45 M sodium chloride, 55.6 
mM D-glucose, pH 7.4), were standardised so that a 1:40 
dilution of the cell suspension had an optical density 
of 0.45 at 490nm. The cells were then diluted 1:240 with 
the 'red cell' pH diluent, a buffer made up of monobasic 
(150 mM sodium chloride, 200 mM monobasic sodium 
phosphate) and dibasic (150mM sodium chloride, 200mM 
dibasic sodium phosphate) sodium phosphate solutions 
mixed in predetermined proportions to produce the 
desired final pH after 50ul was added to the plates 
containing an equal volume of BABS, pH 9.0.
The plate was incubated at room temperature for 
upto 90 minutes and then read to give the optimum pH for 
the highest HA titre of the virus showing complete 
agglutination.
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B) Haemagglutination Inhibition Assays
These assays were carried out after the HA titre 
was noted on day five using the same sort of 96 welled 
plate as in (A) above. BABS diluent was added (25ul) to 
each well (except the first row) and the monoclonal 
antibody (1:10 dilution) was serially diluted in two 
fold dilutions (begining with 50ul in the first well and 
then carrying over 25ul each time). Eight HA units of 
the YF virus in 25ul of BABS was added to each well and 
then the plate was incubated for two hours at room 
temperature. Then a 50ul aliquot of gander erythrocytes 
(diluted 1:240 in the appropiate ’red cell’ pH diluent) 
was added to each well. After 60 minutes incubation the 
HI antibody titre was read as the highest dilution to 
show complete inhibition of haemagglutintion.
The results of HAI assays can be converted into 
Log^Q values (Appendix) and used to produce a dendrogram 
by using a computer programme called Clustan Analysis as 
described by Fitch and Margoliash (1967) and Rico-Hesse 
et al. (1987).
2: MONOCLONAL ANTIBODIES
I. Production of ascitic fluid from hybridomas
An ampoule containing the desired hybridoma was 
obtained from liquid nitrogen, thawed out rapidly at
93
37°C and centrifuged at 2000 RPM for five minutes. The 
supernatant containing dimethyl sulphoxide was poured 
off and the cells were resuspended in Leibovitz L15 
medium (FLOW) supplemented with 10% FCS and 0.2% 
hypoxanthine thymidine (HT)(SIGMA) in a 25cmf tissue 
culture flask.
When the flask was confluent, the hybridoma cells 
were transferred to a 80cm^ and then to a 175cmf by 
simple aggitation of the flask. The contents of a 
confluent 175cm? was then centrifuged at 2000 RPM for 5 
minutes and the supernatant was poured off. The cell 
pellet was then washed in PBS, centrifuged as before and 
then resuspended in 300ul of PBS. The cell suspension 
was then inoculated intraperitoneally into a previously 
(4-7 days earlier) ’pristaned' (intraperioneal injection 
of 0.5ml of 2, 6, 10, 14-tetra methyl pentedecane
[Sigma]) female Balb C mouse (six weeks old, OLAC, UK ). 
This procedure was repeated twice and the mouse examined 
daily for the swelling of the peritoneal cavity due to 
the build up of ascitc fluid. Two to four weeks after 
the third innoculation the fluid was 'drained’ by the 
insertion of a wide bore hypodermic needle (19G, Luer, 
Reading, Berkshire) into the peritoneal cavity. This 
allowed the ascitic fluid to run off into a sterile 30ml 
plastic universal (NUNC) which was centrifuged at 2000 
RPM for 5 minutes, then the ascitic fluid was pippetted
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off and stored at -20°C. This procedure was repeated on 
consecutive occasions whereby ascitic fluid from each 
’draining' was pooled until no more ascitic fluid was 
produced. Then the ascetic fluid for that particular 
hybridoma was frozen at -70°c in 1ml aliquots until 
required.
II. Properties of McABs Obtained from other laboratories
McAbs were kindly provided as freeze dried ascitic 
fluids by E.A. Gould, J.T. Roehrig, M.K. Gentry and 
J.J. Schlesinger and stored at -20°C until required. 
McAbs were prepared for use by thawing out at 37oC and 
then rehydrating with the required amount of distilled 
water. The properties of the McAbs obtained and used are 
listed in TABLE 2.5.
III. Properties Of McAbS Produced in the Laboratory 
McAbs already produced against YF17DD BRAZIL
vaccine virus (H McAbs) by Sil et ^ . , (manuscript in 
preparation) and YF FNV IP vaccine virus (F McAbs) 
prepared by A. Jennings were used in this study and 
their properties are shown in TABLE 2.6.
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TABLE 2,6 PROPERTIES OF THE F AND H McAbs SERIES
McAb Specificity HAI PRNT
YF
Immunogen
FIO Partial Group + +
F14 Group + +
F16 I I NT +
F17 Partial Group + +
F19 I I - +
F20 I I + +
F21 I I NT +
F23 I I + -
F25 Group + -
F27 I I NT -
F28 YF & Wesselsbron + -
F33 Partial Group + —
H3 YF-Type + +
H5 YF-Vaccine + +
H6 YF17D Vaccine + +
H8 Partial Group + -
HIO 17DD sub-strain + +
Hll Partial Group + -
H14 YF-Vaccine + Asibi + —
H16 Group + -
H17 Partial Group + —
H20 I I + —
H21 I I + -
H22 I I + -
H23 I I + -
H24 I I + NT
H25 Group + +
H27 Partial Group + —
H29 I I + NT
H30 Group + —
H31 I I + +
H32 I I + -
H33 YF-Type + +
FNV-IP
17DD BRAZIL
NT: Not Tested
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IV. Determination of the Protein Content of Ascitic 
Fluids.
McAb ascitic fluid was diluted 1:1000 mixed with 
the protein sensitive reagent (diluted 1:5, BioRad 
protein assay mixture) and after 15 minutes incubation 
at room temperature vortexed using a whirlimixer. The 
absorbance of this mixture was then read with the use of 
a spectrophotometer at a fixed wavelenght of 595 nm and 
the result compared graphically to the curve of the 
standard protein provided.
V. Isotyping of McAbs
The McAbs were isotyped with the use of a mouse 
monoclonal antibody isotyping kit (Amersham). The kit 
provides the reagents for determining the class, sub­
class, and light chain type of mouse monoclonal 
antibodies.
A 1:500 dilution of each ascites fluid under test 
is prepared in PBS and 5 mis of this is added to a 
container containing a sample stick, then incubated for 
15 mins at RT. These typing sticks are nitrocellulose 
membranes having segments each containing peroxidase 
labelled goat antimouse antibodies specific for each 
Isotype class. A final segment of the stick is a
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positive control which contains mouse antibody.
After incubation the fluid was decanted off and 
the stick was washed twice with 5mls of a 20mM Tris- 
buffered Saline (137mM sodium chloride)-Tween (0.1% V/V 
Tween 20) (TBS-T). After decanting off the last wash, 
5mls of a 0.2% (diluted in TBS-T) solution of the 
supplied peroxidase labelled antimouse antibody was 
added and incubated for 15 mins. Then the sticks where 
washed twice with TBS-T and then 5mls of a substrate (4- 
chloro-l-naphthol [one tablet] in lOmls methanol added
to 30% v/v solution of hydrogen peroxide in TBS-T) and
incubated with agitation for fifteen minutes. The
substrate was decanted and after the sticks were washed 
with three changes of distilled water H20 the results 
were read.
VI. Preparation of multispot immunofluorescence slides
25 cm^ tissue culture flask(s) (NUNC) containing a 
monolayer of Vero cells was inocculated with the chosen 
virus(es) as descibed in Part 1 (II). The tissue culture 
flask was incubated at 37°C in a CO^ incubator for 48
hours. Before any CPE was observed, the Vero cells were 
trypsinised, centrifuged at 1000 RPM and resuspended in 
3 mis of virus growth media. Then 25ul aliquots of the 
cell suspension containing approximately 10^ cells were
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pippetted on to each spot of the twelve spot Poly 
Tetra-Flouro-Ethylene (PTFE) coated slide(s) (Hendley 
Essex) which were then incubated at 37°C for 4-12 hours. 
The spot slide(s) were then washed once in PBS, then 
once in ice-cold acetone and then finally fixed by 
placing in fresh ice cold acetone forlS minutes. The 
spot slides were then stored at -20°C prior to use.
VII. Indirect Immunofluorescence Tests
For immunofluorescence the spot slides were thawed 
out at room temperature and then incubated for 30 
minutes at 37oC with 25ul of each McAb (diluted 1:50) 
required to be tested. The positive control was a
(Htà)
flavivirus group reactive McAb^and the negative control 
was PBS.
The spot slides were washed twice for 15 minutes 
with PBS, air-dried and 25ul of 1:40 dilution of goat 
anti-mouse polyvalent immunoglobulin conjugated to 
fluorescein isothiocyanate (SIGMA) was added to each 
spot and the slides were incubated at 37°C for 30 
minutes. The spot slides were then again washed twice 
with PBS for 15 minutes and then once in distilled 
water. After finally being air-dried, mounting media 
(10% saline in glycerol) (Sigma chemical company 
limited) was added and the slides were examined under
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ultraviolet light with the aid of a Leitz dialux 20 
epifluorescent microscope for fluorescence. Results of 
immunofluorescence tests were confirmed by two 
individuals reading slides independently.
VIII. Plaque Reduction Neutralisation Tests (PRNTs)
A) Serum neutralisation Indices
These were performed in 6 well tissue culture 
plates (NUNC), using the plaque assay technique as 
described in 1. II D (above) except that the virus 
dilutions were incubated overnight at 4°C with a 1:20 
dilution of McAb prior to infecting a confluent cell 
monolayer of Vero cells, as described by Buckley and 
Gould (1985) and modified by Barrett et (1989) who
used 1% noble agar and 0.015% DEAE in the overlay 
medium. The assays were stained on the sixth day with 
neutral red and the results were read on the seventh day 
as neutralization titres expressed as the LOG^g 
reduction in virus titre.
B) The 100 PFU Test
This was also performed in six well dishes as 
described above except that the virus was diluted to a 
concentration of 100 pfu in lOOul of PBS and incubated
101
with lOOul of McAb, diluted 1:20 in PBS for 24 hours at 
4°C. This mixture was then added to a confluent Vero 
cell monolayer, incubated at room temperature for 30 
minutes and then overlaid with overlay medium. The 
results were recorded after seven days and expressed as 
either full neutralisation (90% or more) where the McAb 
neutralised all the virus or negative neutralisation 
where the virus was either partially or not neutralised 
by the McAb. If a McAb fully neutralized 100 pfu of a 
particular virus, this assay was repeated using the PRNT 
technique to gain the serum neutralization index (SNI), 
stated as the log^g reduction in virus titre.
3: PRODUCTION OF MONOCLONAL ANTIBODY
NEUTRALISATION ESCAPE VARIANTS
I. Plaque Purification Of Single Neutralisation
Escape Variant Virions from Plaque Reduction 
Neutralisation Tests.
A) Preparation of Neutralisation Escape Variants
(McAb^)
If a particular McAb neutralised one of the virus 
strains approximately 4000 fold or more in a SNI PRNT, 
individual plaque isolates that had escaped
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neutralisation were cloned by plaque purification as 
described by Wiktor and Kowprowski (1980). This method 
involved the use of a small glass pasteur pippette to 
suck up an individual plaque isolate in a plug of 
agar, which was then frozen in 1ml of virus growth 
medium at -70°C. The antibody escape variant was then
thawed at 37°C and lOOul was used to inoculate confluent 
monolayers of SW13 cells. After 30 minutes incubaton at 
room temperature virus maintenance media was added. The 
virus infected cells were incubated at 37°C for up to 
seven days or until 90% CPE occured to prepare a seed 
stock. The virus was then clarified by centrifugation 
and frozen in 1ml aliquots at -70°C until required.
B ) Confirmation of McAb Neutralisation Escape Variant
The putative McAb neutralisation escape
variant (McAb*) was first re-identified by repeating the 
antibody treatment protocol to observe that this 
individual plaque isolate still escaped neutralisation 
for the second time. Secondly, spot slides of virus 
infected Vero cells of this seed stock were used in
indirect immunofluorescence tests. This was to check 
whether the epitope for that particular McAb used to
produce the neutralisation escape variant was present or 
absent on that virus. If the variant re-escaped
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neutralization and the epitope for that particular McAb 
was absent, the virus was deemed to be a true 
neutralization escape variant.
II. Producing Neutralisation Escape Variants by a
Immunoprécipitation Technique
The virus required in the experiment was diluted 
to give 1x10^ PFU in 250ul of PBS and was mixed with
1.25ul, 12.5ul, or 25ul of pre-spLun (2 minutes at
13000 RPM in a bench-top microfuge) ascites fluid of 
relevant McAb. After this mixture was incubated for 45 
minutes at RT, 25ul of Goat anti-mouse immunoglobulin G 
(SIGMA) was added, then the mixture was incubated at 
37°C for 30 minutes and then 25ul of 10% (w/v) Protein A 
(SIGMA) was added. After 45 minutes incubation at RT the 
mixture was microfuged at 13000 RPM for 5 minutes and 
the pellet was discarded. Then 20 ul of the supernatant 
(S/N) was diluted in a serial ten fold dilution and 
plated out on six well plates (Nunc) for each 
McAb/virus reaction at each dilution as described before 
for virus plaque assays. While the rest of the reaction 
mixture was frozen at -70°C until required in further 
experiments. Production of escape variants were assumed 
if the virus/McAb plaque assays gave a 4000 fold 
reduction in virus titre.
104
III. Producing Neutralisation Escape Variants in Tissue
Culture.
The appropiate McAb (6ul) was added to 120ul of 
the desired virus and incubated for 45 minutes at RT 
before being inoculated onto a confluent layer of SW13 
cells. This mixture was then incubated on the cell sheet 
for 30 minutes and after virus growth medium was added 
they were placed in a CO^ incubator and checked every 
day for signs of CPE. The virus was harvested on the 
production of 90% CPE or after six days growth whichever 
the earlier. This procedure was repeated twice more and 
then each virus passage was tested for its ability to 
escape neutralisation with the relevant McAb. If the 
virus population escaped neutralisation and the epitope 
for that particular McAb was absent in IIP studies it 
was de&med to be a neutralisation escape resistant 
variant.
IV. Producing variant virus using an Elisa Plate Method
The specific monoclonal antibody ascitic fluid(s) 
is first clarified by centrifugation at 1300 RPM for 2 
minutes and then diluted 1:20 in coating buffer pH 9.6 
(15mM Na^COg /35mM NaHCO^) (Wreghitt and Morgan-Capner, 
1990). Then lOOul of the diluted McAb is added to a well
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of a flat bottomed ELISA plate and incubated 0/N at 4°C. 
The remaining solution in the well of the plate is then 
pippetted off and lOOul of virus containing 1x10* PFU is 
added to each well. After the plate is incubated for 2 
hours at RT, most of the virus is pipetted into 
cryotubes and frozen at -70°C. The remaining 20ul of 
virus is serially diluted in PBS and plagued on six well 
tissue culture plates. If there is a 4000 or more fold
reduction in virus infectivity the virus samples are
assumed to be antigenic variants and individual plaque
purifications were made. These were then grown up and
studied in indirect immunofluorescence tests to see if 
the epitope for that particular McAb is present or 
absent. If absent the virus samples are assumed to be 
true variants.
4: VIRAL PATHOGENESIS STUDIES
I. Mouse Pathogenesis Studies
A) Adult Mice
In pathogenesis studies, female mice 4-5 weeks old 
and weighing 20-25 grms (Strain TO, OLAC, U.K.), were 
used. Light ether anaethetised mice were inoculated from 
either a freshly thawed, whirlimixed ampoule of virus or
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a diluted, whilimixed preparation of virus. Mice were 
inoculated with either 20ul of virus by the 
intracerebral route or 20ul of virus by the intranasal* 
route. The mice were then monitored daily for up to 37 
days and mouse illness or death per day was recorded. 
The average survival time (AST) plus or minus the 
standard error of the mean (SEM) was calculated for each 
experiment where by :
AST = No. of deaths / day + SEM = <Tn-l 
Total No. of mice JrT"
B) Newborn mice
Newborn mice no-more than 48 hours old were 
inoculated by the intraperitoneal route with a 50ul 
volume of virus containing 200 pfu. Mice were monitored 
for up to 15 days and mouse death was recorded daily. 
The average survival time (AST) plus or minus the 
standard error of the mean (SEM) was calculated for each 
experiment as above.
II. Monkey Pathogenesis Tests
Cynmologus monkeys were inoculated with 1x10^ pfu 
in a volume of 500ul by the intracerebral route. Monkeys 
were examined for signs of encephalitis for up to 30 
days.
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5: TEMPERATURE SENSITIVE STUDIES WITH YF VIRUSES
I. Growth of The Virus
Virus was propagated in either SW13 or C636 cells 
for three or five days respectively, then clarified by 
centrifugation and frozen in 1ml aliquots at -70°C until 
required for use.
II. The Virus Assay
Plaque assays were performed as described 
previously except that LLCMK-2 or Vero cells were used 
and the assays were incubated at 37°C or 39.5°C. The 
efficiency of plating of the virus which compares the 
ability of the virus to plaque at both the two 
temperatures was caculated by using the equation below:
E.O.P. = pfu/ml at 39.5 C 
pfu/ml at 37.0°C
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6 : Radio-immuno-precipitation of virus polypeptides
One 5cm petri dish containing a confluent
monolayer of Vero cells was infected with the YF17D- 
204 UK vaccine virus using an MCI of 5, another which 
lOOul of PBS had been added was used as a the mock 
infected control dish. The two petri dishes were
incubated for 30 minutes at room temperature and then
FC5 Mmwiaaaaog
prior to incubating in a CO^ incubator  ^ medium was 
added to the petri dishes. At 48 hours post infection 
the virus medium was removed and 1ml of PBS was added to 
the plate which was incubated at 37°C for two hours to 
starve the cells of methionine. Then after 50 hours post 
infection the PBS was removed and SOOul of PBS
containing 25uCi ^^ S was added and incubated at 37°C for 
4 hours. Then the label was removed from the petri
dishes and the cells were then removed from the petri
dishes in a volume of 500ul to 1.5ml microfuge tubes. 
The cells were pelleted by centrifugation at 13,000 rpm 
for 3 seconds. The S/N was removed and a lOOul of 
detergent was added (PBS containing 1% NP40, 1%
deoxycholate and 2% Triton X-100), prior to to whirly- 
mixing. After incubation at 37°C for 30 minutes the
samples were frozen at -20°C.
On thawing the sample, 20ul of the radiolabelled
S/N was added to 2ul of clarified McAb with the addition
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of 80ul of detergent, mixed and incubated at 37°C for 
one hour. Then lOOul of excess protein A was added and 
the sample was again incubated at 37°C for 1 hour. Then 
the complex was pelleted by centrifugation at 13,000 rpm 
for 2 minutes, the S/N was removed and the pellet was 
washed with 200ul detergent. After centrifugation for 2 
minutes, the S/N was discarded and the pellet was
resuspended in 50ul of detergent and after addition of
20ul of cracking buffer (10% SDS, 2*5% 2-mercaptoethanol 
and 25% glycerol in lOmM Tris pH 7.2. Coloured with 
small amount of bromophenol blue)and boiled for 3 minutes.
The samples were then seperated on a 10 30%
linear gradient polyacrylamide gel. After staining with 
coomassie blue (Ig in lOOmls methanol, lOOmls 
distilled water, 36 mis glacial acetic acid) and
destaining (7% glacial acetic acid, 50% methanol, and 
43% distilled water) the gel was dried and put up for 
autoradiography.
110
RESULTS
CHAPTER 3
DERIVATION OF McAbs
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I. Introduction
The flavivirus E-protein has been shown to be
important for the induction of protective 
immunity, including neutralization antibodies. The E-
protein also encodes the biological properties of 
haemagglutination (Della-Porta & Westaway, 1977; Heinz 
et al., 1981; Kitano et , 1974; Quereshi & Trent,
1973) and haemolysis (Cammack & Gould, 1985).
To examine the E-protein of YF virus in detail 
panels of McAbs prepared against3ifferent wild-type
and vaccine strains of YF virus and recognising 
different epitopes are required.
Therefore, this chapter describes the derivation 
and properties of three series of McAbs which are used 
in later studies in this thesis. Series A was prepared 
by Ms. A. Pryde, series B by A.R. Medlen and series G by 
Ms. G. Lewis in collaboration with the author. 
Basically, hybridoma cell lines already established and
secreting McAb were cultivated to produce ascites in
mice as described in the Methods section. Two series of 
hybridoma cell lines (series B and G) involved 17DD 
Brazil as the immunogen and the other (series A) used 
YF17D-204 WHO as the immunogen. These three panels of 
McAb containing ascitic fluids were used to examine the 
17D-204 WHO and 17DD Brazil vaccine virus strains in IIF
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tests, PRNTs and HAI assays to investigate the antigenic 
and biological properties of the epitopes recognised by 
the McAbs.
II. Results
A) Cloning and selection of ’G ’ hybridoma colonies
secreting McAb
Hybridoma colonies showing vigorous cell growth 
were selected for cloning by serial two-fold dilution of 
the cells and clones obtained at the end point were 
screened by IIF for the presence of antibodies to 
YF17DD Brazil. The positive single clones were expanded 
and recloned and those still positive by IIF tests 
were grown up for inoculation into pristane treated 
mice.
B ) Production of McAb containing ascitic fluids from 
the A, B and G series of hybridoma cell lines
Hybridoma cells from the A, B and G series 
were inoculated into pristane treated mice as described 
in the Methods section. Ascitic fluids were produced 
from each hybridoma cell line, clarified by 
centrifugation, aliquoted and stored at -70°C until
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required. In total three A (A3, A4, A6), six B (B19, 
B26, B37, B39, B44 and B45) and seven G (G6, G14, G16, 
G23, G46, G49 and G65) McAb containing ascitic fluids 
were collected for use in future experiments.
C) Antigenic reactivities of ascites fluid in Indirect 
Immunofluorescence tests
i) The A, B and G series of ascites fluid
A selection of viruses from different flavivirus 
sero-groups as described by Calisher et (1989) were
used in indirect immunofluorscenee tests (IIF).
The majority of the McAbs (A3, A4, A6, B19, B26,
B37, B44, B45, G6, G14, G16, G49, G65) were found to be
partially flavivirus group reactive, only McAbs B39 and 
G23 were YF type specific and McAb G46 reacted with all 
flaviviruses tested (TABLE 3.1).
McAbs G6, G14 and G16 did not react with all
the wild-type strains of YF virus studied. McAb G6 did 
not react with Asibi, McAb G14 did not react with Dak 
1279, and McAb G16 did not react with Asibi and B4.1.
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TABLE 3.1 RESULTS OF INDIRECT IMMUNOFLUORESCENCE
Viruses^
STUDIES WITH THE A, B AND G SERIES OF 
ASCITES FLUID
McAbs
A A A B B B B B B G G G G G G G
1 2 3 3 4 4 1 1 2 4 4 6
3 4 6 9 6 7 9 4 5 6 4 6 3 6 9 5
17D-204 + + + + + + + + + + + + + + + +
17DD + + + + + + + + + + + + + + + +
FNV IP + + + + + + + + + + + + + + + +
ASIBI + + + + + + + + + - + - + + + +
B4.1 + + + + + + + + + + + - + + + +
FVV + + + + + + + + + + + + + + + +
Y5 + + + + + + + + + + + N + + + +
DAK 1279 + + + + + + + + + + - N + + + +
LGT TP21 
JE 5-3 
WN-INDIA 
DEN-2 NGC
+ +  +  - +  -
+  +  —  —  —  +
—  +  —  —  —  +
+ + + 
+ - N 
+ — N 
+ + N
+ + +
+  - +
+  +  -
+  -  -
+ :
N:
$.
POSITIVE REACTION 
NEGATIVE REACTION 
NOT TESTED
ABBREVIATIONS FOR FLAVIVIRUSES ARE THOSE DESCRIBED 
IN THE METHODS CHAPTER
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D ) Serum Neutralisation Indices (SNI) of McAbs from 
the A, B, and G series against their respective 
virus strains
Plaque reduction neutralisation tests (PRNTs) were 
performed using the technique described in the Methods 
section to test the ability of each of the McAbs to 
neutralise the YF17D-204 WHO and the YF17DD Brazil 
vaccine viruses. Using virus grown in the SW13 cell 
line, four (McAbs A6, B37, B39, B44) of the sixteen
McAbs neutralized the YF17D-204 WHO vaccine strain whil 
only two (McAbs G15 and G46) neutralised the YF17DD 
Brazil vaccine strain (TABLE 3.2). It was noted that 
none of the B series of McAbs neutralised 17DD Brazil 
(the immunogen for this series of McAbs) and only three 
of them (B37, B39, B44) neutralised YF17D-204 WHO, with
McAb B39 neutralising this vaccine virus to a high titre 
( 4 LOG^g units ).
E ) HAI activity of McAbs from the A, B and G series 
against their respective virus strains
McAbs from the A, B and G series were used in HAI 
assays as described in the Method section to determine 
if they elicited HAI activity against the two YF vaccine 
strains 17D-204 WHO and 17DD Brazil. Interestingly,
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TABLE 3.2 SERUM NEUTRALISATION INDICES (SNI) OF McAbs 
FROM THE A, B and G SERIES
McAb YF Vaccine Viruses
17D-204 WHO 17DD Brazil
A3 — —
A4 — —
A6 2.0*
B19 -
B26 — —
B37 1.5
B39 4.4
B44 1.0
B45
G6 “ —
G14 — —
G16 - 1.0
G23
G46 - 1.0
G49 — —
G55
SNI’s ARE EXPRESSED AS THE LOG^q REDUCTION IN 
VIRUS TITRE
SNI <0.5
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McAbs A3, A4, A6 did not elicit HAI activity with YF17D- 
204 WHO (the immunogen for these McAbs), similarly McAbs 
B19, B39, 06, 014, 023, 046, 049 did not elicit HAI
against their immunogen; YF17DD Brazil. However, the 
majority of these McAbs did elicit HAI from the other 
virus, for example McAb 06 had a HAI titre of 320 
against the 17D-204 WHO vaccine virus and McAb A3 had a 
titre of 80 against the YF17DD Brazil vaccine virus 
(TABLE 3.3). McAbs A6, B37 and B45, reacted to low titre 
with only YF17DD Brazil while McAbs B26, B44, and 065
elicited HAI against both YF vaccine virus strains 
tested. In contrast, McAbs A4, B19 and 049 elicted no
HAI activity against either vaccine virus studied.
F) Isotype Characterisation of the A, B and O series
Using an isotyping system supplied by Amersham 
pic, the A, B and O series of McAbs were isotyped using 
the methodology described in chapter 2. While all the A 
and B series of McAbs were of an IgOl subtype, the 0 
series of McAbs are nearly all of the Ig02a isotype 
except for McAb 065 which had an Ig02b isotype.
O) RIP of virus Polypeptides
The A and B series of McAbs have already been used
in an radio-immuno-precipitation protocol and run on
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TABLE 3.3 HAI ACTIVITY OF McAbs FROM THE A, B and G
SERIES
McAb YF Vaccine Viruses
17D-204 WHO 17DD Brazil
A3 - 80
A4 -
A6 20
B19
B26 40 40
B37 - 20
B39 40
B44 20 80
B45 - 20
G6 320
G14 40
016 NT NT
023 80
046 40 —
049
065 40 160
: HAI TITRE EXPRESSED AS THE RECIPROCAL OF 
THE DILUTION INHIBITING HAEMAOOLUTINATION
HAI TITRE LESS THAN 20
NT; NOT TESTED
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polyacrylamide gels. They were all shown to recognise 
the E-protein of YF virus (A.D.T. Barrett, personal 
communication) and McAb A6 recognised a conformational 
epitope (M. Bouloy, personal communication). One of the 
G series of McAbs, G23 was used in a radio-immuno- 
precipitation reaction as described in Chapter 2. The 
final reaction was run on a PAGE gel, stained, destained 
and set up for autoradiograhy. FIGURE 3.1 shows that 
McAb G23 precipitates the E (p54) protein of YF virus 
from infected cells.
Ill. Discssion
This Chapter descibes the characterisation of 16 
McAbs produced in the Author's laboratory using two 
different YF vaccine virus strains as immunogens (17D- 
204 W.H.O. and 17DD Brazil). The properties of the McAbs 
are summarised in TABLE 3.4. The McAbs were tested for 
reactivity in IIF tests with three of the eight 
representative antigenic subgroups of the genus 
Flavivirus. Those subgroups were the JE/WN, TBE, and 
dengue complex groups and also the three vaccine strains 
of YF virus (17D-204, 17DD, and FNV IP) and five wild-
type strains from Africa and South America were used. 
Preliminary analysis in IIF tests using McAbs from the A 
and B series (Barrett et al., 1989) showed that most
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FIGURE 3.1 AUTORADIOGRAPH OF PAGE GEL OF SEPERATED
VIRUS POLYPEPTIDES
Track A: non immunoprecipitated virus infected cell lysates
Track B: E-protein from virus infected cell lysates 
immunoprecipitated with McAb G23
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McAbs were YF type specific except for McAbs A6, B19,
B26, and B44 which were partial group reactive. However, 
using different viruses from the flavivirus serogroups 
showed that the majority of McAbs were partially
flavivirus group reactive except for McAb B39 which
remained YF-type specific.
In the IIF tests with the three series of McAbs, 
A, B and G, three antigenic specificities were 
identified. These were; flavivirus group common,
flavivirus partial group reactive and YF-type specific.
Previously, Schlesinger et (1983) identified
antibodies showing YF17D-204 sub-strain, YF-type and
flavivirus group specificities. Gould et (1985)
identified five antigenic specificities on the E-protein 
of a YF vaccine virus. These were; 17D-204 sub-strain 
specific, vaccine (17D-204, 17DD, and FNV) specific, YF- 
type specific, partial group specific and flavivirus 
group reactive. Thus none of the McAbs had the YF sub­
strain or vaccine specificity described by the previous 
workers.
The 16 McAbs were also used in PRNTs and HAI
assays with both virus immunogens and showed a range
of patterns of reactivities. Similar reactivities have 
been reported by Schlesinger ^  al. (1983) and Gould et 
al. (1985). It was noted that most of the McAbs would
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TABLE 3.4 SUMMARY OF PROPERTIES OF THE A, B AND G
McAb
A3
A4
A5
B19
B26
B37
B39
B44
B45
G5
G14
G16
G23
G46
G49
G65
McAb SERIES USING ONLY THE 17D-204 WHO
AND 17DD BRAZIL VACCINE VIRUSES TO
Isotype
IgGl
NT
IgG2a
IgG2b
IgG2a
STUDY THE McAbs
Specificity 
Partial Group
YF-Type 
Partial Group
YF-Type 
Group 
Partial Group
YF
HAI PRNT Immunogen
+
+
+
+
+
NT
+
+
17D-204 WHO
17DD BRAZIL
NT
POSITIVE REACTION 
NEGATIVE REACTION 
NOT TESTED
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not neutralise the virus immunogens (TABLE 3.2) and most 
of the Mcabs had little or no HAI activity with the 
homologous virus (TABLE 3.3). All McAbs produced are of 
the IgG isotype either IgGl, IgG2a or IgG2b similar to 
those McAbs produced by Schlesinger et (1983) and
isotyped by Monath et (1984).
Although the McAbs descibed in this Chapter were 
only studied with the two parent strains in 
biological assays (HAI and PRNT's) it still gives an 
indication of differences n the biological function of 
the E-protein epitopes that they recognise. This
indicates that care should be taken in the
interpretation of the biological function of the same 
epitope on different viruses. The protein content of the 
McAb containing ascitic fluids were determined as 
described in Chapter 2 and found to be similar (3- 
5mg/ml) (data not shown). Thus, the difference in 
biological function could not be attributable to the 
variation in concentration of McAbs. The heterogeneous 
response of viruses being either neutralised or fully 
resistant to neutralisation has been reported previously 
by Buckley & Gould (1985). They stated that a 'critical 
area' on the virus is required. This 'critical area was
first referred to by Della-Porta and Westaway (1977 b).
In the next Chapter the response of McAbs in biological 
assays (PRNT's and HAI assays) against a variety of
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strains of YF vaccine viruses is examined,
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CHAPTER 4
ANTIGENIC ANALYSIS OF EPITOPES ON YELLOW 
FEVER VIRUSES BY HAI ASSAYS AND PRNT's
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I. Introduction
In the previous Chapter differences in the 
abilities of epitopes of the E-protein of YF vaccine 
viruses to elicit HAI and neutralisation activities with 
McAbs were observed. In this chapter, a large panel of 
McAbs (A, B and G series described in the last chapter 
and two other McAb series prepared in the authors 
laboratory [the F series of McAbs prepared by A. 
Jennings and the H series of McAbs prepared by B.K. 
Sil]) were used to analyse 31 YF vaccine viruses in HAI 
assays and PRNTs and compared with three wild-type YF 
viruses.
In addition, polyclonal anti-sera were also used 
in both HAI assays and PRNT's to compare their 
properties of eliciting HAI and neutralising activity 
with the McAbs used in this Chapter.
II. Results
A) Study of the Nigerian and USSR vaccine by IIF, HAI
and PRNT
The two new YF 17D vaccines were studied using 
YF-type (McAb H3), YF vaccine specific (McAbs H5, 411), 
17D strain (McAb H6), 17DD (McAb HIO) and 17D-204 (McAb 
864) sub-strain specific McAbs in IIF, HAI and PRNT's.
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As seen in TABLE 4.1, both vaccine strains have epitopes 
recognised by all McAbs with the exception of McAb HIO 
in IIF studies. There is a similar reactivity in HAI 
studies except McAb H3 does not elicit HAI with the
Nigerian vaccine and H6 does not elicit HAI with the
USSR vaccine strain. In PRNT's, neither of the vaccines 
were neutralised by any of the McAbs used.
From this data, one is able to assume that both
viruses are derived from the 17D-204 sub-strain of YF 
vaccine viruses.
B ) Analysis of viruses by HAI assays using the A, B,
G and H series of McAbs
i) 17D-204 Vaccine strains
As seen in TABLE 4.2, 32 McAbs were used to screen 
17, 17D-204 vaccine viruses and also 4 plaque purified
preparations from the vaccines manufactured in France, 
South Africa and the UK. The vaccines came from twelve 
different manufacturers as described in the Methods 
Section. Overall, the vaccines display a heterogeneous 
HAI response dependent upon the virus and McAb
combination being analysed. Examining particular viruses 
in detail, for example comparison of two Australian
vaccine batches in HAI assays, one having the avian
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TABLE 4.1
A)
REACTIVITY OF THE USSR AND NIGERIAN 
VACCINES IN IIF TESTS, HAI ASSAYS 
AND PRNT's
IIF TESTS
VIRUSES McAbs
H3 H5 H6 HIO 411 864
USSR + + + + +
NIGERIA + + + + +
B) HAI ASSAYS
VIRUSES McAbs
H3 H5 H6 HIO 411 864
USSR + + - + NT
NIGERIA + + NT NT
C) PRNT's 
VIRUSES
USSR
NIGERIA
McAbs
H3 H5 H6 HIO 411 864
- - - — NT NT
— — — — NT NT
+: POSITIVE REACTION 
NEGATIVE REACTION 
NT: NOT TESTED
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TABLE 4.2 ANALYSIS OF YF17D-204 AND THE TWO NEW 
VACCINE (NIGERIA AND USSR) VIRUSES BY 
HAI ASSAYS USING THE McAb A, B, G AND H 
SERIES
: HAI TITRE EXPRESSED AS THE RECIPROCAL OF THE
DILUTION INHIBITING HAEMAGGLUTINATION
HAI TITRE LESS THAN 20
NT: NOT TESTED
VIRUS ABBREVIATIONS ARE THOSE USED IN THE
METHODS CHAPTER
EXCEPT FOR USA VACCINES WHERE A: P-16065,
B: 6145, C: 2848, D: 4E158
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TABLE 4.2
VIRUSES'
McAbs
AUS
033.
AUS 
1 008
COL
915
DAK
78LF
FR FRpp FRG HOL IND RF
318
SA
894A
A3 20 80 — 320 80 160 160 80 20 40 320
A4 40 - 20 80 80 - - 20 40 40 20
A5 40 160 160 80 — 40 40 40 -
B19 _ 20 20 20
B26 160 80 20 40 20 160 80 — 80 20 320
B37 40 40 160 160 80 40 80 80 160 20 160
B39 80 80 80 - 160 20 160 80 160 — 640
B44 160 80 160 320 160 80 80 160 80 80 640
B45 80 40 40 320 40 160 40 40 40 40 320
G6 20 40 20
G14 NT 640 NT NT NT 40 80 NT NT NT 640
G23 160 40 640 80 160 640 80 320 80 640
G46 - 40 - - 20 — 40
G49 - - - - - - 20 20
G65 640 320 160 320 160 160 160 640 - 80
H5 80 20 320 20 20 40 20 80
H6 40 320 - 160 - 10 80 - 40 80 40
H8 80 640 20 20 80 40 160 40 80 40 40
HIO - - - - 20 - . — 20 40
Hll 20 - 40 320 20 40 - 40 80 40 160
H14 - - - - 20 80 — 40 40
H20 160 - 80 320 - . - - 320 40
H21 NT NT NT NT 320 NT NT 160 NT NT NT
H22 80 NT NT 160 NT 40 NT NT 20 NT
H23 - 40 - 320 - - 160 20 160
H24 - 640 NT NT 20 40 — 20 i. NT
H25 160 20 - - 20 160 80 — 160 — 40
H27 320 - NT NT NT 160 20 80 640 NT
H30 80 160 - 320 - 20 20 20 80 640
H31 40 40 20 160 20 20 160 40 40 320
H32 40 320 80 - 160 - 160 160 40 20
H33 80 160 - 40 20 40 80 40 80 160 20
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TABLE 4.2
McAbs
VIRUSES*
SA SApp UK UKpp UKpp 
10802 +wt -wt A
USA* 
B C
WHO
17D 
NIG USSR
A3 80 160 40 80 80 40 80 20 160 160
A4 20 - . - 40 40 - - 80 - - 80 40
A6 80 40 80 80 20 20 160 — — 320 160
B19 20 _
B26 40 80 - - 20 - - 80 320 40 160 —
B37 160 80 40 80 80 - 20 80 40 — 160 160
B39 160 640 160 80 80 - 20 160 160 40 80 320
B44 160 320 320 640 320 40 40 80 640 20 160 160
B45 160 80 20 160 80 20 20 80 160 — 80 40
G6 40 40 320 20
G14 NT 640 NT NT NT NT NT NT 640 40 NT NT
G23 160 640 40 320 160 20 40 160 320 80 160 80
G46 - - 40 20 20 - - — — 40 ' — —
G49 20 20 20 - - 20 - — — 20 —
G65 80 640 160 160 160 ' — — 80 320 40 640 320
H5 40 40 80 40 _ 40 80 20 40
H6 20 320 - - - - - 40 160 80 40 —
H8 - 640 80 80 80 - - 20 640 320 40 40
HIO - 320 20 20 40 10 - - — 20 _ 20
Hll 20 160 80 640 80 320 - 160 — 80 160 40
H14 80 - 40 40 40 160 20 80 - 80 — 40
H20 - - 160 160 320 160 - 40 - 320 40 320
H21 NT NT 80 160 160 NT NT NT NT 160 NT 640
H22 80 NT NT NT NT 160 40 40 NT NT NT NT
H23 - 640 - - 20 — - - 640 80 _ _
H24 NT - 160 80 40 NT NT - 640 80 — 40
H25 40 40 - 80 160 320 - 160 40 - 640 —
H27 - - 80 160 320 NT NT 320 - 80 640 NT
H30 160 - 40 20 40 - 40 - — 160 — 20
H31 40 20 80 80 40 - 20 - - 80 _ 40
H32 40 20 320 160 80 - - - - 320 — 160
H33 - 20 40 40 40 - - 80 - 80 - 20
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leukosis virus (ALV) as a contaminant (008) and the
other prepared using an ALV-free seed (033-1), showed 
that these viruses show more similarity in reaction with 
the B and G McAbs than to the A and H McAbs. McAbs B26,
B44, G55 react to a high HAI activity with both of the
vaccines while McAbs H6, H8, H20, H24 and H27
differentiate the vaccines by reacting with either one 
or the other vaccine viruses to a different extent (four 
fold or more difference in HAI titres). The plaque 
purified preparations, two from the UK vaccine, one with 
(+wt) and one without (-wt) a YF wild-type specific 
epitope (recognized by McAb 117 [Gould, et ^ . , 1989]), 
one from the French and one from the South African 
vaccine all showed similar HAI titres as their parent 
strains. Although there were differences in HAI titres 
between the McAbs with different viruses, there was 
considerable homogeneity in the response of particular 
McAbs (HAI or no HAI) with certain viruses. For example, 
McAbs B26, B37, B39, B44, B45, G23, G65, H8, H32
inhibited haemagglutination to a high dilution with 70% 
of the viruses studied. In comparison McAbs B19, G46,
G49, showed very little or no HAI activity with any of 
the viruses. Other McAbs (G5, H20, H23) had intermediate 
HAI activity with the viruses studied, having high HAI 
activity with some, and low HAI activity with others. It
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was also noted that McAb HIO, though being 17DD vaccine
specific elicited HAI activity with the 17D-204 SA
plaque purified preparation. Two vaccines from new 
manufacturers (17D Nigeria and 17D USSR) were studied 
with 34 McAbs. McAbs A6, B37, B39, B44, G23, G65,
reacted with high HAI activity with both of the 17D
vaccines, while McAbs A3, B26, Hll, H20, H25 and H32
showed considerable differences in HAI activity between 
both of the vaccine strains. Other Mcabs used either
reacted with low or no HAI titres with both viruses, or 
reacted with one and not , the other with low HAI
activity.
ii) 17DD vaccine viruses
The 17DD vaccines and two plaque purifications 
(one from the 17DD Brazil vaccine, and the other from
17DD Colombia) were studied with 34 McAbs. As seen in
TABLE 4.3, McAbs from the B and H series had high HAI 
activity with the 17DD vaccine viruses but to a lesser 
extent with the two plaque purified preparations. There 
seemed to be more differences between these plaque 
purified preparations and their parent strains than the 
two parent strains to each other. Although McAb HIO is 
17DD specific, it only reacts with the 17DD vaccines
with a low HAI activity.
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TABLE 4.3 ANALYSIS OF THE YF17DD VACCINE VIRUSES BY HAI
McAb
ASSAYS USING THE A, B, G AND H McAb SERIES 
Viruses*
BRAZ BRAZpp COL COLpp DAK
A3 80* — _ 160 80
A4 - - 20 - 20
A6 20 40 40 40 40
B1 _ _ _ 20
B2 40 40 160 320 40
B3 20 160 40 160 20
B3 - 160 40 80 -
B44 80 160 40 160 80
B45 20 80 80 320 -
G5 — 20 40 20
G23 - 20 320 160 -
G45 - - 20 - 20
G49 - - - - -
G65 - 40 160 80 -
H3 160 20 320 40 160
H5 80 160 80 40 160
H6 40 40 40 - 80
H8 160 20 160 40 320
HIO 40 - 40 40 40
Hll 40 160 40 - 80
H14 40 - 40 80 80
H16 160 NT 160 NT 160
H17 160 NT 160 NT 160
H20 320 80 320 160 320
H21 160 NT 160 NT 160
H23 80 - 80 - 80
H24 80 NT 80 - 80
H25 - 20 - 160 -
H27 160 NT 160 160 160
H29 160 NT 160 NT 160
H30 320 - 320 - 160
H31 80 40 80 - 80
H32 640 320 640 160 1280
H33 160 - 160 40 80
; HAI TITRE EXPRESSED AS THE RECIPROCAL OF THE 
DILUTION INHIBITING HAEMAGGLUTINATION
HAI TITRE LESS THAN 20
NT: NOT TESTED
*: VIRUS ABBREVIATIONS ARE THOSE USED IN THE
METHODS CHAPTER
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iii) FNV vaccine viruses
Three different preparations of the French 
neurotropic vaccine virus (FNV) were examined with 30 
McAbs. As shown in TABLE 4.4, there are different groups 
of reactions. The first, where McAbs elicit very low or 
no HAI activity with all three viruses (McAbs B19, G46,
G49, H6 [17D specific], and HIO [17DD specific]). The 
second where McAbs (e.g. B26, B37, B44, B45, Hll, H20
and H31) elicit HAI activity with all three vaccine 
viruses (FNV FC, FNV IP, FNV NT), another where McAbs 
elicit HAI activity with two out of the three FNV’s 
(e.g. McAbs A3, A6, B39, G23, G65, H5, H8, H14, H22,
H25, H30 and H33). The last was McAb H23 which elicited
HAI with only one of the vaccines (FNV IP).
iv) Wild-type YF viruses
Three wild-type viruses were examined using 35 
McAbs (TABLE 4.5). Two of the viruses were from Africa 
(Asibi and FVV) and one was from South America (B4.1). 
Nearly 50% of the McAbs used had high HAI activity with 
all three of the viruses. McAbs H5, H6, and HIO had no
reactivity as they are vaccine, 17D and 17DD specific 
respectively. Other McAbs which had low or no HAI 
activity were B19, G46, G49, H23 and also H25 which is
flavivirus group reactive. McAbs B26 and G65 had 
similar HAI titres with the Asibi and FVV wild-type
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TABLE 4.4 ANALYSIS OF YF FNV VIRUSES BY HAI ASSAYS
USING THE A, B, G AND H McAb SERIES
McAb
A3
YF
FNV FC
Viruses* 
FNV IP
40*
FNV NT 
80
A4 80 - 20
A6 20 80 80
B19 _ 20
B26 80 40 80
B37 80 40 40
B39 160 20 -
B44 320 160 160
B45 40 40 40
G6 _
G23 160 80 -
G46 - - -
G49 20 40 -
G65 640 80 -
H5 20 160 80
H6 - 20 -
H8 40 - 160
HIO - - -
Hll 160 40 80
H14 - 640 40
H20 640 160 320
H22 - 160 320
H23 - 160 -
H24 - NT 80
H25 640 320 -
H27 160 NT 40
H30 - 160 320
H31 40 80 40
H32 - 20 640
H33 80 — 160
HAI TITRE EXPRESSED AS THE RECIPROCAL
DILUTION INHIBITING HAEMAGGLUTINATION
HAI TITRE LESS THAN 20
NT: NOT TESTED
*: VIRUS ABBREVIATIONS ARE THOSE USED IN THE
METHODS CHAPTER
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TABLE 4.5 ANALYSIS OF WILD TYPE VIRUSES BY HAI ASSAYS 
USING THE A, B, G AND H McAb SERIES
McAb YF Viruses*
ASIBI FW* B4.1
A3 - 160 20
A4 40
A6 20 -
B19 - - -
B26 40 80
B37 40
B39 40 80 40
B44 40 160 80
B45 80 20 20
G6 - 80 80
G14 NT 40 80
G23 160
G46 — 40 —
G49 20
G65 80 40
H3 160 160 80
H5 — — —
H6 NT
H8 160 160 160
HlO — — —
Hll 160 80 160
H14 80
H16 320 160 320
H17 320 160 160
H20 160 320 320
H21 160 - 160
H23
H24 80 80 80
H25 - - -
H27 80 40 80
H29 80 160 160
H30 80 160 80
H31 80 80 160
H32 320 320 320
H33 160 80 160
*: HAI TITRE EXPRESSED AS THE RECIPROCAL OF THE
DILUTION INHIBITING HAEMAGGLUTINATION
HAI TITRE LESS THAN 20
NT: NOT TESTED
*: VIRUS ABBREVIATIONS ARE THOSE USED IN THE
METHODS CHAPTER
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strains from Africa but no HAI activity with the 
wild-type strain B4.1 from South America. McAb G6 had 
HAI activity with only the F W  and B4.1 strains of 
wild-type YF virus. McAb G23 only elicited HAI activity 
with Asibi virus, while McAb A3 elicited a high HAI 
titre with FW.
C) HAI assays with polyclonal anti-sera
A number of YF viruses were examined in HAI assays 
using polyclonal mouse anti-sera made against 17D-204 
USA, FNV FC, and Asibi viruses. As seen in TABLE 4.6, 
the polyclonal anti-sera elicit high HAI activity with 
most of the viruses studied. However, there is still a 
heterogeneous HAI response seen with some of the viruses 
(e.g. 17D-204 Colombia, the FNV strains and the 17DD
strains) as seen with the McAbs used previously.
D ) Cluster analysis of the HAI assays with viruses 
against twenty seven of the McAbs used in the study
All the HAI titres for 27 McAbs which reacted with 
each virus were converted into Log^^ values (Appendix). 
Any HAI titres below ten were given a log^^ value of 
1.0, due to the zero point of the HAI assay was taken as 
ten. The values were then typed into the computer
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TABLE 4.6 REACTION OF POLYCLONAL ANTI-SERA
IN HAI ASSAYS WITH YF VIRUSES
VIRUSES
17D-204
RF31B
DAKAR
COLOMBIA
UK
UKpp+wt 
UKpp-wt 
USA 6145
POLYCLONAL ANTI-SERA 
17D-204 USA FNV FC ASIBI
320
80
20
160
640
160
160
160
160
20
320
320
160
640
320
320
40
320
320
160
NT
17D USSR 320 160 160
17DD
Brazilpp
Brazil
20 40
40
80
NT
FNV
FC
IP
NT
40
20
40
NT
NT
NT
WILD-TYPE
ASIBI
FVV
640
640
640
640
NT
NT
NT:
HAI TITRE EXPRESSED AS THE RECIPROCAL OF THE 
DILUTION INHIBITING HAEMAGGLUTINATION
HAI TITRE LESS THAN 20
NOT TESTED
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programme and the cluster analysis was performed on: i) 
all the 34 viruses, ii) all viruses except the plaque 
purifications and iii) all the 17D-204 vaccine virus 
strains were compared to the wild-type Asibi strain.
i) All viruses and plaque purified preparations
FIGURE 4.1, shows the result of the Cluster analysis 
with all the viruses examined in HAI assays with 27 of 
the McAbs which reacted with all the viruses. As can be 
seen there are three main groups, group 1 consists of 
the wild-type viruses and some of the vaccine strains, 
group 2 a large group of 17D-204 vaccine strains and 
group 3 containing only two viruses: the revertant USA 
virus P-16065 and FNV IP. Wild-type strains Asibi, F W  
and B4.1 grouped fairly close together in the cluster 
analysis, although Asibi is separated from F W  and B4.1. 
All three 17DD vaccines are in the same group. Group 1, 
but while the 17DD vaccines produced in Brazil and Dakar 
are closely related to each other and to the vaccines 
RF318 and FNV NT, the 17DD Colombia vaccine is more 
closely related to the wild-type Asibi virus. It was 
noted that the majority of the YF vaccines are grouped 
together into group 2, except for the 17D-204 WHO, 17DD 
Colombia, 17DD Brazil, 17DD Dakar, FNV NT and RF318 
vaccine viruses which are all in group 1, with the
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FIGURE 4.1. CLUSTER ANALYSIS OF ALL 34 VIRUSES WITH 
TWENTY SEVEN McAbs WHICH REACTED WITH 
ALL VIRUSES IN THE STUDY
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17DD COL 
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GROUP 2
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17D20A DK 
UKpp+ 
OKpp- 
17D204 FR 
17D20A FRpp 
17DD COLpp 
17D20A DAK 
17D NIG 
17D20A USA 2848 
17D204 AUS 033-1 
17D204 IND 
FNV FC 
17D204 SA 10802 
17D204 USA 6145
17D204 COL 
17DD BRAZpp
17D 204 FRG 
17D204 AUS 008 
17D204 SApp 
17D204 USA 4E158 
17D204 SA 894A
GROUP 3
P-16065 
FNV IP
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wild type viruses. The 17D-204 UK vaccine and its 
plaque purified viruses were shown previously to react 
similarly with most of the McAbs (TABLE 4.2) and in the 
clustan analysis they are also very close together 
(group 2).
ii) Viruses without the plaque purified preparations
The cluster analysis was recalculated to exclude 
the plaque purified viruses (FIGURE 4.2). Nonetheless, 
the viruses still group into a similar pattern as before 
although some of the viruses have differences in their
detailed relationships within group 2. For example, the 
YF17D-204 Dakar vaccine which was grouped with two 
different plaque purified preparations has now moved 
closer to the FNV-FC vaccine. YF17D-204 Colombia has 
moved away and is now closer to group 3.
iii ) 17D-204 vaccine viruses compared to the Asibi
wild-type strain
FIGURE 4.3, shows a cluster analysis involving the 
17D vaccines and their wild-type parent virus strain 
Asibi with the 27 McAbs. Of the 19, 17D vaccines
examined, the 17D-204 WHO ALV-free seed stock showed
the most similarity to Asibi virus. The other 17D- 
204 vaccines group together showing a similarity of
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FIGURE 4.2. CLUSTER ANALYSIS OF VIRUSES WITHOUT 
PLAQUE PURIFIED VIRUSES WITH THE TWENTY 
SEVEN McAbs WHICH REACTED WITH ALL 
VIRUSES IN THE STUDY
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FIGURE 4.3. CLUSTER ANALYSIS OF 17D204 AND WILD-TYPE
ASIBI VIRUSES WITH THE TWENTY SEVEN McAbs
WHICH REACTED WITH ALL VIRUSES IN THE
STUDY
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reaction with the McAbs used. However, there is still a 
separate group containing vaccines P-16065 and 17D-204 
Colombia which show the least reactivity with the McAbs 
to the other vaccines.
E ) Analysis of viruses using the A, B, F, G and H
McAbs series in PRNT's
Thirty-two YF viruses were studied in PRNT's with 
the A, B and G McAbs derived in chapter 3 and also the 
’F ’ and 'H ’ series of McAbs whose properties are 
described in the Methods section (Chapter 2).
i ) Three YF17D-204 vaccine strains and their plaque
purified virus isolates
Three 17D-204 viruses ( France [Fr], UK and South 
Africa [SA]) were compared in PRNT’s with one plaque 
purified strain from both the Fr and SA vaccines 
and two from the UK vaccine strain, one with a wild-type 
(+wt) and another without a wild-type epitope (-wt) 
(recognised by McAb 117, [Gould et al., 1989]). Of the 
36 McAbs used in PRNT's to survey these YF virus 
strains, only 18 would neutralise one or more of the 
vaccines. McAbs FIG, F19, F25, F27, F28, G6, G16, G46, 
G49, G65, H5, H8, HIO, Hll, H14, H23, H27 and H33 failed
146
to neutralise any of the above viruses. As can be seen 
in TABLE 4.7, there is a heterogeneous neutralisation 
response by the McAbs where each McAb only neutralises 
particular viruses. Only McAb G23, neutralised all the 
strains used, with the exception of the vaccine 
manufactured in France. Also, apart from the French 
plaque purified preparation, McAb B26 neutralises all 
plaque purified strains and none of the parent strains. 
It neutralises the 17D204 UKpp- strain to a high SNI 
value of 3.8. McAbs A3, H3 and H6 only neutralised the 
17D-204 SA vaccine and McAb A6 only neutralised the 
French plaque purified preparation.
McAb G14, neutralised the vaccines from both 
France and the UK as well as the SApp preparation but 
not the SA vaccine. McAbs B44 and B45 neutralised the 
UKpp+wt strain while McAb H25 neutralised both this and 
the 17D-204 SA vaccine. The F Mcabs only neutralised the 
UK vaccine strain, except for McAb F14 which also 
neutralised the UKpp- strain.
ii) Analysis of two 17DD vaccines
Out of the 31 McAbs tested (TABLE 4.8) using the
two YF 17DD vaccines from Brazil and Colombia, only 7
McAbs (F14, F19, G16, G46, H3, HIO, H33) neutralised the
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TABLE 4.7 SURVEY OF A, B, F, G and H SERIES OF McAbs 
WITH THREE YF17D-204 VACCINE STRAINS AND 
THEIR PLAQUE PURIFIED VIRUS ISOLATES IN 
PRNT's
17D-204 VIRUSES
McAb Fr Frpp SA SApp UK UKpp-wt UKpp+wt
A3 — — 1 . 0 — — — —
A6 — 0.7 — — — — —
B19 — — — 0.7 — — —
B26 - - - 1.1 - 3.8 0.9
B3 7 — — — — — — —
B39 — — — — — 1.7 —
B44 — — — — — — 0.8
B45 — — — — — — 1.3
F14 — — — — 2.3 1.4 —
FI 6 — — — — 0.7 — —
F17 — — — — 0.6 — —
F20 — — — — 0.9 — —
F21 - - NT NT 1.0
G14 0.7 - - 0.7 1.0
G23 - 1.8 1.0 1.9 3.2 1.3 2.3
H3 — — 0 . 7 — — — —
H6 — — 2.0 — — — —
H25 - - 1.0 - - - 0.7
*: ANTIBODY TITRES EXPRESSED AS LOG^ q^ REDUCTION IN
VIRUS TITRE
-: NEUTRALISATION TITRE £ 0.5
NT: NOT TESTED
McAbs THAT DID NOT NEUTRALISE ANY OF THE YF17D-204
VIRUSES ABOVE ARE LISTED BELOW:
FIO, F19, F25, F27, F28, G6, G16, G46, G49,
G65, H5, H8, HIO, Hll, H14, H23, H27, H33.
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TABLE 4.8 SURVEY OF A, B, F, G and H SERIES OF McAbs 
WITH TWO YF17DD VACCINE STRAINS IN PRNT's
YF17DD VIRUSES 
COLOMBIA BRAZIL
McAbs
F14 - 1.0*
F19 - 0.8
G16 1.0 1.0
G46 - 1.0
H3 3.0 3.0
HIO - 1.0
H33 - 3.0
*: ANTIBODY TITRES EXPRESSED AS LOG^^ REDUCTION IN
VIRUS TITRE
NEUTRALISATION TITRE £ 0.5 
3  McAbs THAT DID NOT NEUTRALISE ANY OF THE YF17DD
VIRUSES ABOVE ARE LISTED BELOW:
A3, A5, B19, B26, B37, B39, B44, B45, FIO, F16,
F17, F20, F21, F25, F27, F28, G6, G23, G49, G65,
H5, H6, H14, H25,
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Brazil vaccine while only two (G16 and H3) neutralised 
the Colombia vaccine.
F) Examination of YF viruses with McAbs that elicit
neutralisation activity
i) 17D-204 vaccine viruses
As with the HAI results there was a heterogeneous 
response of epitopes eliciting neutralising activity 
(TABLE 4.9). Out of the seventeen viruses examined, only 
seven were neutralised by one or more of the eight McAbs 
used. McAb A6, neutralised the 17D-204 Colombia 
and 17D-204 WHO vaccines to 2 log^^s, while only 
neutralising the revertant USA vaccine P-16065 to nearly 
1 log^ Q. The USA vaccine batch 6145, was only 
neutralised by McAb B26, while the WHO vaccine was only 
neutralised by McAb B39. McAb F14 neutralised the UK and 
WHO vaccine viruses, while McAb G23 neutralised the 
UK, South Africa and Holland vaccine viruses. The 17D- 
204 SA vaccine virus was also neutralised by McAbs H3, 
H6 and H25. None of the eight McAbs which elicit 
neutralising activity, neutralised the vaccines produced 
in either Nigeria and Russia.
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TABLE 4.9 EXAMINATION OF YF VIRUSES WITH McAbs THAT 
ELICIT NEUTRALISING ACTIVITY IN PRNT'S
VIRUSES
17D-204
AUS 033-1
AUS 008
COL 915
DAK 78LF
FR
FRG
HOL
IND
RF312
RF318
SA
UK
USA 6145 
USA P-16065 
USA 4E158 
USA 2848 
WHO
17D
17DD
FNV
NIG
USSR
BRAZ
COL
DAK
FC
IP
NT
WILD-TYPE
ASIBI
FVV
B4.1
A6
2.4
McAbs 
B26 B39 F14
3.3
0.7
2.0
1.0
1.8
G23 H3 H6 H25
2.3
1.8
1.0 0.7
3.2
1.9 1.0
4.3 2.5
1.0
NT
1.5
1.9
1.9
1.8
3.0
3.0
3.0
0.6 2.0
ANTIBODY TITRES 
VIRUS TITRE
1.4
EXPRESSED AS LOG10 REDUCTION IN
NT:
NEUTRALISATION TITRE <0.5 
NOT TESTED
VIRUS ABBREVIATIONS ARE THOSE USED IN THE METHODS
CHAPTER
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ii) 17DD vaccine viruses
Of the eight McAbs used, only McAb H3 previously 
shown to neutralise the 17DD Brazil and Colombia 
vaccines also neutralised the 17DD Dakar vaccine (TABLE 
4.9).
iii) FNV vaccine viruses
All three of the FNV vaccine viruses were 
neutralised by one or more of the eight McAbs used in 
the study. McAb F14, neutralised all the FNV vaccines to 
a SNI value of 1.5 to 1.9. The FNV IP strain was only 
neutralised by McAb F14, while the FNV FC strain was 
also neutralised by McAbs A6 and G23. However, the FNV 
NT strain was neutralised by McAbs A6, F14, H3 and H25.
Thus, the FNV vaccine strains show a heterogeneity of 
epitopes eliciting neutralisation, like that of the 17D- 
204 and 17DD vaccine strains.
iv) Wild-type YF viruses
Of the eight McAbs used, only one McAb neutralised 
only one of the wild-type viruses. This was McAb F14, 
which neutralised FW.
G) Examination of the YF viruses with polyclonal
anti-sera
Since only seven of 17 YF17D-204 vaccines were
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neutralised by the McAbs used, polyclonal anti-sera were 
used in PRNT’s with one virus from each strain of virus 
studied. As seen in TABLE 4.10, all the three 
polyclonal anti-sera raised against Asibi, FNV FC, and 
17D-204 USA viruses neutralised these strains in 
PRNT's.
III. Discussion
In the early phase of YF 17D vaccine development 
and production, a number of different sub-strains of YF 
vaccine were found to be unsatisfactory when studied in 
pathogenicity tests and human trials. The instability of 
YF vaccines were resolved by the establishment of the 
seed/lot system in 1945. However, the difference of sub­
strain origin of the early vaccines continues to be 
reflected in the vaccines manufactured today, both the 
17D-204 and 17DD sub-strains are at different passage 
levels (233 to 239 and 286 - 288 respectively). Although 
these vaccines have proven highly eficacious and safe 
they have not been fully characterised. In particular, 
the two new manufacturers of YF vaccines (USSR and 
Nigeria) refer to their vaccines as '17D'. The results 
in this chapter indicate that both viruses are 17D-204 
sub-strain viruses, although this has only been
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TABLE 4.10 EXAMINATION OF YF VIRUSES WITH
POLYCLONAL ANTI-SERA IN PRNT's
VIRUS POLYCLONAL ANTI-SERA
17D-204 FNV-FC ASIBI 
USA
ASIBI >2.1 >2.1 >2.1
YF17D204 USA 
(4E158)
1.1 1.6 1.4
YF17D204 UK 2.1 >3.4 >3.4
FNV IP 0.5 1.8 1.6
YF 17DD BRAZ 0.8 2.2 1.8
: ANTIBODY TITRES EXPRESSED AS LOG^g REDUCTION IN
VIRUS TITRE
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confirmed for the USSR vaccine (Elbert, personal
communication).
Previously Monath et (1983) genetically
characterised the 17DD vaccines by ribonuclease
oligonucleotide fingerprinting and Gould and co-workers 
(Gould et al., 1985; Buckley & Gould 1985; and Cammack & 
Gould, 1986) have examined some of the vaccines in PRNTs 
and HAI assays. This is the first study to compare all 
the YF vaccines manufactured in every centre
antigenicall in HAI assays and neutralisation tests 
with a large panel of McAbs. Overall, the results 
demonstrate heterogeneity in the E-protein epitopes that 
elicit HAI and neutralisation. Since this work involved 
the use of McAbs it could be argued that the McAbs are 
examining only some epitopes. Thus, the heterogeneous 
HAI results with the McAbs were confirmed by the use of 
polyclonal antibodies (TABLE 4.6)
The biological activities of the McAbs can be 
grouped into four biological reactive groups; those that 
have the property of both neutralisation and HAI, those 
with neutralisation only, those with only HAI activity 
and those with neither of the biological activities. 
This is similar to other workers who have noted that the 
biological properties of HAI and neutralisation in 
flaviviruses were associated with distinct epitopes 
(Kimura & Kuroda, 1983; Cammack and Gould, 1986). Also
155
no evidence of linkage between HAI and neutralisation 
activity was shown. The McAbs used in this study 
confirm the studies of Casals and Brown (1954) who 
stated that HAI shows the greatest serological overlap 
and neutralisation tests the least. Although each McAb 
used may elicit HAI with many YF vaccine and wild-type 
viruses, it will only neutralise specific YF vaccine or 
wild-type viruses with the appropiate 'critical site' or 
'critical area' present (Della-Porta and Westaway, 
1977 b).
The results of the biological activity of 
single epitopes on the E-protein of YF virus in HAI 
assays in this Chapter show that each McAb has a 
heterogeneous response with each YF vaccine virus strain 
used in the study, both qualitatively and quantitively. 
The reactivity of 27 McAbs in HAI assays with all the 
viruses was examined in a cluster analysis. As shown in 
Figures 4.1, 4.2 and 4.3, the combined McAb HAI
reactivities were able to differentiate three major 
groups of viruses. The first contained the wild-type 
viruses and 17DD vaccines, the second contained the 
majority of the vaccine strains and the third contained
only two vaccine strains (FNV IP and the revertant virus
of the YF 17D-204 USA batch 6145, named P-16065).
However, when the 17D-204 vaccines were studied in the 
cluster analysis with only the wild-type Asibi virus,
156
parent to the vaccine strains, the YF17D-204 Colombia 
vaccine, merges into a separate group with the P-16065. 
This shows that these two viruses are more distantly 
related to the remainder of the YF17D-204 vaccines. 
There is no evidence to suggest that the 17D-204 
Colombia vaccine is neurotropic like P-16065. Previously 
Monath et (1983) have used T^  ribonuclease
oligonucleotide mapping to genetically compare YF
vaccine viruses. They found a high degree of homology
')
between the 17D vaccine viruses, with the 17DD derived 
vaccines being more closely related to each other than 
the 17D-204 vaccines. Thus, in this study, antigenic 
analysis of the E-protein of YF vaccines with McAbs has 
revealed very similar degrees of relatedness as the T^  
mapping study. Analysis of the three batches of 17D-204 
USA vaccine and two batches of 17D-204 SA vaccine 
revealed that these batches of vaccine are closely 
related, but not identical. This variation presumably 
reflects differences due to manufacturing the vaccine in 
embryonated chick eggs on different dates.
The biological activity of the epitopes recognised 
by the McAbs described previously in Chapters 2 and 
3 were also examined in PRNT’s (TABLES 4.7, 4.8, 4.9).
Overall, the majority of the McAbs did not neutralise 
the YF viruses. Of the McAbs that did, they only 
neutralised specific YF viruses and not all of the 32 YF
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viruses studied. This heterogeneous response of MoAbs in 
PRNT’s has been described previously by other workers 
(Buckley and Gould, 1985; Barrett ^  al., 1989).
Clearly, there is heterogeneity in the biological 
activity of the E-protein epitopes of vaccine viruses 
from different manufacturers in HAI and PRNT's. Whether 
or not this has any practical considerations in the 
production and efficiency of YF vaccine is not known and 
requires epidemiological studies in human vaccinees.
Finally, two McAbs neutralised particular viruses 
to a high titre. McAb B39, which recognises a YF-type 
specific epitope, neutralised the YF17D-204 WHO vaccine 
and McAb B26, which recognises a partial flavivirus 
group reactive epitope, neutralised the YF17D-204 USA 
vaccine batch 6145. These two McAbs are used in the next 
Chapter to produce McAb neutralisation escape variants 
to examine the epitopes of the YF vaccines in more 
detail.
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CHAPTER 5
PRODUCTION AND ANALYSIS OF YELLOW FEVER
ANTIGENIC VARIANTS
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1. Introduction
In the previous chapter, the results showed that 
envelope protein epitopes of YF vaccine viruses react 
with McAbs to different extents in PRNT’s and HAI 
assays. Therefore, the biological function of these 
epitopes was examined in detail by the generation of 
antigenic variants.
The selection of antigenic variants depends upon 
the virus populations being heterogeneous, including 
virions lacking envelope protein epitopes. Accordingly, 
the specificity of McAbs for particular epitopes allows 
the selection of virions in the population lacking the 
epitope recognised by the McAb. This chapter describes 
four procedures to produce and analyse antigenic 
variants of YF virus using McAbs. The best method of 
producing antigenic variants was by selection of McAb 
neutralisation escape variants (McAb* variants). 
However, as shown in the previous chapter few McAbs 
neutralise YF virus. Thus, three other procedures to 
select and prepare antigenic variants, using McAbs, are 
described and compared to that of the neutralisation 
escape variants. These are immunoprécipitation by the 
addition of goat anti-mouse immunoglobulin to virus-McAb 
complexes, capture of virus using McAb attached to ELISA 
plates and growth of the virus in tissue culture in the
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presence of a McAb.
II. Results
A) Producing____antigenic____variants____by_____the
Immunoprécipitation technique.
The methodology for this procedure is described in 
detail in Chapter 2. Briefly, virus was incubated with a 
McAb, followed by incubation with goat anti-mouse 
immunoglobulin to form virus-antibody complexes. These 
were then precipitated by high speed centrifugation and 
the supernatant was examined for residual infectivity 
and compared to appropiate controls.
Four McAbs, recognising different epitopes on YF 
virus were used in different combinations with six 
different viruses in the imunoprecipitation technique. 
McAb 117 (wild-type specific) which previously showed 
no neutralising activity in PRNTs (Gould ^  ^ . , 1989)
and McAb 6B3B-3 a flavivirus group reactive McAb which 
previously was shown to neutralise wild-type YF virus 
(Roerhig et , 1983; Barrett et al., 1990) were used
to produce antigenic variants against the YF17D-204 UKpp 
with the wild-type epitope (+ve WT). Also McAb 411, a 
non-neutralising vaccine specific McAb (Gould et al., 
1985) was used against four vaccine strains used in the
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study. McAb 864 which recognises the 17D-204 sub-strain 
specific epitope and neutralises virus was used as the 
positive control and PBS was used as the negative 
control (instead of any McAb). Also, a normal standard 
virus plaque assay was carried out to get the standard 
titre of the virus used.
The results, in Table 5.1, show that the control 
neutralising McAb, 864, reduced the virus titre of only 
the YF17D-204 vaccine virus strains that it recognised. 
None of the other McAbs examined reduced the infectivity 
titre of any of the viruses significantly. Thus, the 
procedure was not continued further.
B ) Producing Neutralising Escape Variants in Tissue
Culture.
McAbs 6B3B-3 and 6A3C-4 (Flavivirus group 
reactive) were used in this experiment. McAbs 6B3B-3 and 
6A3C-4 were incubated with the wild-type virus 1899/81 
B4.1 for 45 minutes at room temperature and then this 
mixture was inoculated onto a confluent monolayer of 
SW13 cells and incubated up to seven days or when 90% 
CPE occurred. The above procedure was repeated 
consequtively twice more with the same McAb. Each
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TABLE 5.1 RESULTS OF THE IMMUNOPRECIPITATION TECHNIQUE
McAbs & 
or CONTROL
STANDARD
PLAQUE
ASSAY
17DD
BRAZIL
4.8*
UKpp+
5.3
17D-204
UKpp-
6.3
SApp
4.3
FNV
NT
4.3
WILD
TYPE
B4.1
4.0
PBS + GAM 4.9 5.5 6.0 4.0 4.5 4.2
864 + GAM Nt 1.0 1.9 1.6 Nt Nt
ONLY 864 Nt 1.3 2.0 <0.9 Nt Nt
117 + GAM Nt 5.2 Nt Nt Nt 4.3
ONLY 117 Nt 6.5 Nt Nt Nt 4.4
411 + GAM 4.8 5.4 5.8 4.8 4.2 Nt
ONLY 411 4.9 5.4 5.9 Nt Nt Nt
6B3B-3 + GAM Nt 5.3 Nt 4.0 Nt Nt
ONLY 6B3B-3 Nt Nt Nt Nt Nt <0.9
: TITRES ARE EXPRESSED AS THE LOG^q INFECTIVITY IN
VIRUS TITRE
GAM: GOAT ANTI-MOUSE IMMUNOGLOBULIN
Nt: NOT TESTED
163
passage was titrated to determine the presence of virus. 
The results of these virus titrations by the standard 
plaque assay technique described in the methods section 
showed that virus was not detected. Therefore, this 
method of producing antigenic variants was not continued 
further.
C) Production of variants using the ELISA technique
McAbs 411, H5 (vaccine specific) and H6 (YF17D 
specific) were incubated overnight at 4°C, in a 96 well 
flat-bottomed tissue culture plate. McAb B39 (YF-type 
specific) which neutralises YF17D-204 WHO was included 
as the positive control and McAb P6 (made against 
Coxsackie A9 virus) as the negative control. The virus 
(YF17D-204 WHO) was then added to the plate and 
incubated for 2 hours at room temperature. After this 
period, the remaining virus supernatant from each well 
was titrated for infectivity using the standard virus 
plaque assay technique. As shown in Table 5.2, there was 
no significant reduction in virus titre with any of the 
McAbs used including McAb B39 which neutralises the 
virus. Therefore, this procedure was not continued.
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TABLE 5.2 RESULTS OF THE ELISA TECHNIQUE TO
GENERATE ANTIGENIC VARIANTS TO 
YF17D-204 WHO
McAb/PBS LOG^q LOG^q
INFECTIVITY REDUCTION IN 
INFECTIVITY
PBS 4.3
411 4.2 0.1
H5 4.1 0.2
H6 3.9 0.4
B39 4.0 0.3
P6 4.3
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D ) Production of McAb neutralisation resistant
(McAb^) variants from PRNTs
i) Selection of McAb^ variants
The detailed procedure for the selection of McAb* 
variants is described in the Methods section (chapter
2). Briefly, a McAb was incubated with a virus at room 
temperature for 45 minutes or overnight at 4°C 
(neutralisation titres were the same for both incubation 
regimes [data not shown]) and then titrated in plaque 
assays. The McAb* were selected by picking plaques, 
amplifying in cell culture and then confirming that the 
progeny virus were resistant to neutralisation by the 
same McAb. Only McAbs that neutralised virus titres 1000 
fold or more were selected as the aim of this procedure 
was to select and generate stable antigenic variants. 
Thus, a 1000 fold reduction in infectivity titres
indicate that each plaque pick represents on average 1 
in a 1000. Since the genome of YF virus is 10,862 
nucleotide bases long, a mutation frequency of 1 in a 
1000 is equivalent, on average to 10.8 nucleotide
changes randomly distributed across the entire genome of 
the virus.
McAb* variants were plaque purified from PRNTs, if 
the SNI was above a value of 3. This was done by
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incubating McAb 854 with two plaque purified strains of 
the YF17D-204 UK vaccine, parent A with a wild type 
epitope (+WT) and parent B without a wild type epitope 
(-WT). Since the YF-type specific McAb B39 does not 
neutralise the parent A strain and only neutralises the 
parent B strain to a SNI of 2, it was used to produce 
McAb^ variants from the YF17D-204 WHO secondary seed 
vaccine. Finally, McAb B26 was also used to produce 
McAb^ variants from the parent B strain of the YF17D-204 
UK vaccine and the YF17D-204 USA (6145) vaccine (TABLE 
5.3)
All McAb^ variants were grown up in SW13 cells and 
harvested on the fifth day post-infection or when 90% CPE 
was observed, whichever was the sooner. The McAb* 
variants were then titrated. As can be seen in TABLE 
5.4, only McAb* variants derived from McAbs 864 and B39
gave infectivity titres detectable by plaque assay.
These McAb* variants were then re-identified by escaping 
neutralisation for the second time with the relevant 
McAb used to select the respective McAb* variants (TABLE 
5.5). All McAb* variants showed very little (^ 0.1) or
no neutralisation with its respective McAb (e.g. 864 or
B39 ) and were selected. Three were derived from the 
parent strain A and were designated YF17D 864* Al, A2,
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TABLE 5.3 SNI's of FOUR YF17D-204 VACCINE VIRUS STRAINS 
IN REACTIONS WITH NEUTRALISING McAbs
McAb S
YF
VIRUSES
864 B39 B26
17D-204 UK 1.0*
STRAIN A 3.9 - 0.9
17D-204 UKpp+
STRAIN B 3.6 1.7 2.6
17D-204 UKpp-
17D-204 USA 6145 0.8 - 3.3
17D-204 WHO >4.3 4.4
SNI's ARE EXPRESSED AS THE LOG^q REDUCTION IN VIRUS 
TITRE
DENOTES NEUTRALISATION TITRE <0.6
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TABLE 5.4 TITRE of McAb* VARIANTS PLAQUE
PURIFIED FROM PRNTs
LOGio LOG.o
McAb* VARIANTS CPE INFECTIVITY TCID5,
YF17D 864* Al + 5.0 NT
YF17D 864* A2 + 4.9 NT
YF17D 864* A3 + 4.9 NT
YF17D 864* B1 + 5.3 NT
YF17D 864* B2 + 5.2 NT
YF17D B39* D1 + 3.4 NT
YF17D B39* D2 + 3.6 NT
YF17D204 UKpp- + 5.0 5.2
YF17D B26* El + <0.9 4.0
YF17D B26* E2 + <0.9 2.0
YF17D B26* E3 + <0.9 4.5
YF17D B26* E4 + <0.9 3.0
YF17D-204 USA + 6.0 4.5
YF17D B26* FI + <0.9 2.0
YF17D B26* F2 + <0.9 2.5
+: POSITIVE REACTION 
NT: NOT TESTED
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TABLE 5.5 LOGIO INFECTIVITIES OF DERIVED McAb* VARIANTS 
IN PRNT's WITH THE McAbs WHICH SELECTED THEM
LOG^q infectivity REDUCTION IN
LOG^o INFECTIVITY
YF17D MINUS WITH
McAb* VARIANTS McAb McAb
864* Al 5.1 6.3 -
864* A2 5.3 6.3 -
864* A3 5.5 6.4 -
864* B1 5.5 6.4 -
864* B2 5.3 5.2 0.1
B39* D1 3.8 3.8 -
B39* D2 4.6 4.6
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A3, while two were selected from strain B and were 
designated YF17D 864* B1 and B2 and two, designated 
YF17D B39* D1 and D2 were selected from the YF17D-204 
WHO vaccine. In further studies described below the 
McAb* variants were also passaged in Vero cells for IIF 
studies and epitopes to the relevant McAbs from which 
they were derived from were shown to be absent, thus 
indicating that the McAb* variants lacked the appropiate 
epitope and appeared stale on passage. The B26*
variants which gave no detectable infectivity titre in 
plaque assays were designated B26* El, E2, E3 and E4 for 
those plaque purified from the UKpp -wt epitope or B26* 
FI and F2 from the YF17D-204 USA vaccine batch 6145. 
Although the latter variants contained no virus
detectable by plaque assay, virus was nonetheless
detected in TCID^q assays. For comparison, the results 
obtained with the parent viruses to the B26* variants 
are also shown in TABLE 5.4.
E) Indirect Immunofluorescence Tests on McAb* variants
i ) The YF17D-204 864* variants
A panel of 24 four McAbs recognising different 
epitopes on YF vaccine viruses was used in IIF tests to 
examine and compare the parent strains and the McAb
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864* variants derived from them. As can be seen in TABLE 
5.6 all McAbs, except McAbs 117 and 864, recognize 
epitopes on all the virus variants, parent A and B 
strains and the YF17D-204 UK vaccine. The epitope 
recognised by McAb 864 was present on the YF17D-204 UK 
vaccine and the two plaque purified parent A and B 
strains but not on any of the McAb 864* variants. On the 
other hand, the YF wild-type specific McAb (117) only 
recognised the epitope on the parent A strain and the 
McAb 864* variants made from this parent strain.
ii) The YF17D-204 B39* variants
The same panel of 24 McAbs was used to compare the 
McAb B39* variants with the parent YF17D-204 WHO vaccine 
virus. All McAbs, excluding McAbs 117 and B39, 
recognised epitopes on both the McAb B39* variants and 
their parent YF17D-204 WHO vaccine strain (TABLE 5.7). 
However the epitope recognized by McAb 117 was neither 
present on the two McAb* B39 variants nor their parent 
YF17D-204 WHO virus and the epitope recognised by McAb 
B39 was present on YF17D-204 WHO vaccine virus was 
absent from both the McAb* B39 variants.
iii) The YF17D-204 B26* variants
Although both sets of the McAb* B26 variants gave 
no titre in virus plaque assays, they showed CPE and
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TABLE 5.6 COMPARISON OF INDIRECT IMMUNOFLUORESCENCE 
STUDIES BETWEEN THE YF17D-204 U.K. PARENT 
VIRUSES AND THE DERIVED YF17D 864* VARIANT 
STRAINS
YF17D-204 VIRUSES
McAbs
864
117
411
A3
A4
A6
B19
B26
B37
B39
B44
B45
G23
G65
H3
H5
H6
H14
H25
H33
612
813
825
843
868
UK
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
B
+ +
+
+ +
YF17D 864* VARIANTS 
Al A2 A3 B1 B2
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ 
+ 
+ ■ 
+ 
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+ +
+ +
+ +
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+ +
+ +
+ +
+ +
+: POSITIVE REACTION IN INDIRECT IMMUNOFLUORESCENCE 
NEGATIVE REACTION IN INDIRECT IMMUNOFLUORESCENCE
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TABLE 5.7 COMPARISON OF INDIRECT IMMUNOFLUORESCENCE 
STUDIES WITH THE YF17D-204 WHO PARENT 
VIRUS STRAIN AND THE YF17D B39* VARIANTS
YF17D-204 YF17D B39* VARIANTS 
McAbs WHO D1 D2
B39 + — —
864 + + +
117 - -
411 + + +
A3 + + +
A4 + + +
A6 + + +
B19 + + +
B26 + + +
B37 + + +
B44 + + +
B45 + + +
G23 + + +
H3 + + +
H5 + + +
H6 + + 4-
H14 + + +
H25 + + +
H33 + + +
612 + + +
813 + + +
825 + + +
846 + + +
868 + + +
+: POSITIVE REACTION IN INDIRECT IMMUNOFLUORESCENCE 
NEGATIVE REACTION IN INDIRECT IMMUNOFLUORESCENCE
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gave an infectivity titre in a TCID^q test. Each virus 
was examined in infected Vero cells by IIF tests using a 
flavivirus group reactive McAb (H25), a YF-type specific 
McAb (2E10) and McAb B26 (TABLE 5.8). The results of the 
IIF tests showed the presence of virus antigen in the 
cells and the epitopes recognized by the flavivirus 
group reactive McAb H25 and the YF-type specific McAb 
2E10. However, the epitope recognised by McAb B26 was 
absent in the McAb* variant infected cells but not those 
infected by the parent viruses.
F ) Comparison of the McAb* variants with their parent
virus strains in HAI assays
i) The YF17D-204 864* variants
A panel of McAbs was used to compare the 
neutralisation escape variants with their parent strains 
in their capacity to elicit HAI activity (TABLE 5.9). 
While a number of McAbs tested (A3, A6, B37, B44, B45,
G23, G65, H33) elicited HAI activity to high titre with
the parent strains A and B, they elicited either no 
detectable or low HAI activity with the McAb 864* 
variants. McAb 864, which was used to produce the McAb*
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TABLE
McAbs
5.8 RESULTS OF INDIRECT IMMUNOFLUORESCENCE
STUDIES WITH THE YF17D B26 VARIANTS AND
THEIR PARENT VIRUSES
PARENT
YF17D-204
VIRUSES
B26* VARIANTS
UKpp- USA
6145 El E2 E3 E4 FI F2
H25 + + + + + + + +
2E10 + + + + + + + +
B26 + +
+: POSITIVE REACTION IN INDIRECT IMMUNOFLUORESCENCE
NEGATIVE REACTION IN INDIRECT IMMUNOFLUORESCENCE
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TABLE 5.9 REACTION OF McAbs IN HAEMAGGLUTINATION
INHIBITION ASSAYS (HAIs) WITH PARENT 
VACCINE STRAINS AND DERIVED 864* VARIANTS
YF17D-204
VIRUSES YF17D McAb* VARIANTS
McAbs
UK A B Al A2 A3 B1 B2
864
*
80 640 80 _ _ _ _ _
117 20 80 20 - - - - -
411 40 40 20 - - - - -
A3 40 80 80 20 20 20 20 40
A6 40 80 80 20 20 20 20 40
B19 — _ _
B26 - - 20 - - - - -
B37 40 80 80 - 20 - - 20
B39 160 80 80 — - - - -
B44 320 640 320 - 20 20 20 20
B45 20 160 80 20 20 20 20 20
G23 40 320 160 _ 20 20 20
G46 40 20 20 20 20 20 20 20
G65 160 160 160 - 20 20 20 20
H3
H33 40 80 80
*: HAI TITRE EXPRESSED AS THE RECIPROCAL OF THE DILUTION
INHIBITING HAEMAGGLUTINATION 
HAI TITRE LESS THAN 20
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variants, elicited HAI activity only with the parent 
virus strains A and B but not the McAb* variants. 
However, some McAbs (B19, H3) used in the study had no
detectable HAI activity with either the parent virus 
strains or their McAb* variants. McAb 117 only had high 
HAI activity with the Parent A strain (which possesses a 
wild-type epitope recogised by McAb 117) and not with 
the McAb* variants produced from this parent A strain.
ii) The YF17D-204 B39* variants
The same panel of McAbs was used to compare the 
ability of the 17D-204 WHO parent strain with the B39* 
variants to elicit HAI activity (TABLE 5.10). While a 
number of McAbs tested (864, 411, B26, B39, G23, G46,
G65, and H33) elicited HAI activity with the parent WHO
vaccine strain, they elicited either no or low HAI 
activity with the McAb B39* variants. McAb B39, which 
was used to produce the McAb* variants elicited HAI 
activity only with the parent WHO vaccine virus but not 
the McAb* variants. Some McAbs (117, A3, A6, B19, B37,
and H3) used in the study had low HAI activity or no HAI 
activity with either the parent virus or the B39*
variants. McAb 864, however had high HAI activity with
the parent WHO vaccine but low activity with the B39* 
variants.
178
TABLE 5.10 REACTION OF McAbs IN HAEMAGGLUTINATION
INHIBITION ASSAYS (HAIs) WITH PARENT
VACCINE STRAINS AND DERIVED B39*VARIANTS
McAbs
864
117
411
A3
A6
B19
B26
B37
B39
B44
B45
G23
G46
G65
H3
H33
YF17D-204
WHO
320
20
40
40
40
20
80
40
40
40
YF17D McAb* VARIANTS 
D1 D2
20 20
20 20 
20 20
20 
-  20
20 20 
20 20
HAI TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION 
INHIBITING HAEMAGGLUTINATION
HAI TITRE LESS THAN 20
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iii) The B26* variants
The B26* variants were assayed for a 
haemagglutination (HA) titre as described in Chapter 2. 
The titre for each McAb* variant was found to be very 
low (^8 HAU / 50ul) and so the variants were not studied 
in HAI assays.
G) Comparison of McAb* variants With Their Parent 
Virus Strains in PRNT's with McAbs
i) The YF17D-204 864* Variants
A panel of fourteen envelope (E) protein reactive 
McAbs, of which eight were previously shown to 
neutralise, were used in PRNT's to study and compare the 
parent strains with their McAb* variants (TABLE 5.11).
Two of the McAbs neutralised one or more of the 
McAb 864* variants. The first McAb, B26, neutralised all 
the variants and both the parent A and B strains but not 
the YF17D-204 UK vaccine. McAb G23 neutralised both the 
parent A and B strains, the YF17D-204 U.K. vaccine 
strain and variants 864* A3, 864* Bl, 864* B2, but not
the variants 864* Al and 864* A2. Of the other McAbs 
tested, McAbs B44 and B45, neutralised the parent A 
strain with a neutralisation index of approximately 1
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TABLE 5.11 REACTION OF McAbs IN PRNTs WITH THE 
YF17D-204 U.K. VIRUS STRAINS AND THE
DERIVED McAb 864 VARIANTS
McAbs
YF17D-204 VIRUSES 
UK A B
YF17D 864* VARIANTS 
Al A2 A3 Bl B2
864 1.0 3.9 3.6
117
411
A3
A6
B19
B26
B37
B39
B44
B45
G23
G65
H3
H33
0.9 2.6
1.7
0.8 
— 1.3 —
3.2 2.3 1.3
3.4 2.1 1.2 2.1 1.8
1.0 1.5 0.7
: ANTIBODY TITRES EXPRESSED AS LOG^ ^^  REDUCTION IN VIRUS 
TITRE
DENOTES NEUTRALISATION TITRE < 0.6
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and not any of the McAb* variants from this parent A 
strain. Thus, indicating alteration in the biological 
function of these epitopes in the variants. McAb B39 
neutralised only the parent B strain while McAb 864, 
which previously was shown to neutralise the parent A 
and B strains, also neutralised the YF17D-204 UK vaccine 
strain but did not neutralise any of the variants 
produced from it. McAbs 117, 411, A3, A6, B19, B37, G65, 
H3 and H33 neutralised none of the variant or parent 
viruses.
ii) The YF17D-204 B39* Variants
Of the 15 McAbs used (TABLE 5.12), seven McAbs 
either neutralised the parent YF17D-204 WHO strain or 
the McAb* B39 variants derived from it. McAb 864 was the 
only McAb which neutralised both the parent YF17D-204 
WHO strain and albeit lower, the two B39* variants D1 
and D2. McAb A6 only neutralised the parent YF17D-204 
WHO and McAbs B26 and G23 only neutralised, poorly, the 
B39* variants D1 and D2. McAb B39, which had been shown 
previously to neutralise the parent YF17D-204 WHO 
strain, did not neutralise the variants which were 
produced using this McAb. McAbs 117, 411, A3, B19, B45, 
G65, H3, and H33 neutralised neither the parent YF17D-
204 WHO nor the B39* variant strains D1 and D2.
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TABLE 5.12 REACTION OF McAbs IN PRNTs WITH THE
YF17D-204 WHO VIRUS STRAIN AND THE 
DERIVED McAb B39-* VARIANTS
YF17D-204 VIRUS YF17D B39* VARIANTS
WHO D1 D2
McAbs
B39 4.4
117 - -
411 - - -
864 >4.3 2.0 2.0
A3 -. - -
A6 2.0 - -
B19 -
B26 - 0.6 0.7
B37 1.5 0.9 -
B44 1.0 0.8
B45 - - -
G23 - 0.7 0.7
G65 - - -
H3 - - -
H33 - - -
*: ANTIBODY TITRES EXPRESSED AS LOGIO REDUCTION IN VIRUS 
TITRE.
DENOTES NEUTRALISATION TITRE < 0.5
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H ) Comparison of mouse virulence of the Parent Virus
Strains With the Variants.
i) The YF17D-204 864* variants
a) Adult mice
Female mice 4-5 weeks old and weighing 20-25g 
(Strain TO, Olac, U.K.), were inoculated
intracerebrally with 10,000 pfu of virus and were 
monitored daily for up to 37 days. The majority of mice 
tested with four (Bl, Al, A2, A3) out of the seven 864* 
variants remained healthy showing no signs of sickness 
or death until the end of the study, while mice 
inoculated with the YF17D-204 UK and the parent A 
strain died (TABLE 5.13). One variant, B2, killed (9/9) 
of the mice and therefore was more virulent than the 
parent strain B from it was derived, which only killed 
17.7% (8/45) of the mice. Another variant Bl, derived 
from the same parent strain B, was more attenuated than 
the parent strain B and killed no mice (0/26). The 
variants of strain A were also attenuated; Al killed no 
mice, while A2 and A3 killed 11% (1/9) and 13% (1/8) of 
mice respectively.
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TABLE 5.13 COMPARISON OF THE PATHOGENICITY OF THE
YF 17D-204 PARENT STRAINS WITH THE 
864* VARIANT STRAINS IN ADULT MICE*
YF17D-204
VACCINE
VIRUSES
N. DEAD %
N°. INOCULATED MORTALITY
AVERAGE
SURVIVAL
TIME*
UK
A UKpp+
10/10
17/20
100.0
85.0
10.3 + 0.6 
10.1 + 0.5
864* Al 
864* A2 
864* A3
0/8
1/9
1/8
<U2.5
11.0
12.5
N.A.
N.A.
N.A.
B UKpp- 8/45 17.7 9.5 + 0.5
864* Bl 
864* B2
0/26
9/9
4 3.8 
100.0
N.A.
9.2 + 1.1
N.A.
MICE WERE INOCULATED WITH 10,000 pfu BY THE 
INTRACEREBRAL ROUTE
AVERAGE SURVIVAL TIME IN DAYS + THE STANDARD 
ERROR OF THE MEAN (SEM)
NOT APPLICABLE
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ii) The YF17D-204 B39* variants
a) Adult mice
Mice inoculated intracerebrally with either the 
parent WHO strain and the B39* variants died ( as shown 
in TABLE 5.14).
iii) The YF17D-204 B26* variants
a) Adult mice
Only two (El and E3) of the B26* variants from 
the 17D-204 UKpp- parent B strain were examined due to 
their low infectivity titre. 200 TCID^q of parent B 
strain, B26* El and B26* E3 viruses were each inoculated 
intracerebrally. As seen in TABLE 5.15, the UKpp- 
parent strain killed only 33.3% of the mice with an AST 
of 12.0+1.0 days, while neither of the variants B26* 
El and E3 killed any of the mice.
b ) Newborn mice
The two other variants (B26* E2 and B26* E4) of 
the 17D-204 UKpp- parent B strain and the 17D-204 USA 
parent and its two B26* variants (B26* FI and B26* F2)
were inoculated intraperitoneally with 10 TCID^q of 
virus in a volume of 50ul. As shown in TABLE 5.16, only
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TABLE 5.14 COMPARISON OF THE PATHOGENICITY OF THE
YF17D-204 WHO STRAIN WITH THE
B39 VARIANTS IN ADULT MICE
YF17D-204
VACCINE
VIRUSES
N. DEAD %
nV  inoculated mo rt a l i t y
AVERAGE
SURVIVAL
TIME*
WHO
B39* D1 
B39* D2
8/8
9/9
7/9
100.0
100.0
78.0
11.0 + 0.7 
9.0 + 1.0
10.0 + 0.9
MICE WERE INOCULATED WITH 10,000 pfu BY THE 
INTRACEREBRAL ROUTE.
AVERAGE SURVIVAL TIME IN DAYS + THE STANDARD ERROR 
OF THE MEAN (SEM).
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TABLE 5.15 COMPARISON OF THE PATHOGENICITY OF THE
YF17D-204 UKpp-- PARENT VIRUS STRAIN B
WITH THE B26* ' E' VARIANTS IN ADULT
MICE*
YF17D-204
VACCINE N°. DEAD %
AVERAGE
SURVIVAL
VIRUSES N°. INOCULATED MORTALITY TIME*
B UKpp- 2/5 33.3 12.0 + 1.0
B26* El 0/8* ^12.5 NA
B26* E3 0/8* 41 2.5 NA
MICE WERE INOCULATED WITH 200 TCID50 UNITS IN A
VOLUME OF 20ul BY THE INTRACEREBRAL ROUTE.
AVERAGE SURVIVAL TIME IN DAYS + THE STANDARD ERROR 
OF THE MEAN (SEM).
$. MICE WERE MONITORED FOR 21 DAYS
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TABLE 5.16 COMPARISON OF THE PATHOGENICITY OF THE 
YF17D-204 PARENT STRAINS WITH THE 
B26R* VARIANTS IN NEWBORN MICE*
YF17D-204
VACCINE
VIRUSES
N. DEAD %
N^7 INOCULATED MORTALITY
AVERAGE
SURVIVAL
TIME*
B UKpp- 
B26* E2 
B26* E4
4/6
0/14
0/13
66.6
^7.1
^7.7
12.0 + 0.0 
NA 
NA
USA 6145 
B26* FI 
B26* F2
3/16
1/17
0/11
25.0
5.8
^9.1
16.3 + 1.2 
NA 
NA
MICE WERE INOCULATED WITH 10 TCID^q IN A VOLUME OF 
5Oui BY THE INTRAPERITONEAL ROUTE.
AVERAGE SURVIVAL TIME IN DAYS + THE STANDARD ERROR 
OF THE MEAN (SEM).
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the parent strains 17D-204 USA and 17D-204 UK strain B 
killed 25.0% and 66% respectively of mice with AST’s of
16.3 + 1.2 and 12 + 0.0 days. None of the B26* variants 
killed newborn mice, with the exception of B26* FI which 
killed one mouse (5.8%) on day twelve.
Ill Discussion
The studies described in this chapter have shown 
that the most successful method of producing antigenic 
variants by selection with McAbs was by plaque 
purifiction from PRNTs. It was not found possible to 
prepare antigenic variants with McAbs that do not 
neutralise virus. In the case of the "ELISA" and 
"Immunoprécipitation" techniques this may reflect 
incorrect pH buffers. However, the amount of time 
required for this investigation could not be justified 
by the Author.
Three McAbs produced variants from four different 
virus strains. Of the variants produced, three sets 
gave virus titres when titrated by plaque assay, while 
variants derived from McAb B26 did not. However, 
infectivity titres could be determined by use of TCID^q 
assays. The reason for the lack of plaquing is not 
understood but may relate to the function of the epitope
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recognised by McAb B26 on the surface of the virus. It 
may also be significant that 6 variants derived from two 
parent vaccine viruses all share this property while the 
two parent viruses do not. The B26* variants were 
examined by indirect immunofluoresence using flavivirus 
group (H25) and YF type (2E10) specific McAbs, in 
addition to the partial group reactive McAb, B26, from 
which they had escaped neutralisation. As seen in TABLE 
5.8, viral antigen was detected in the cells which 
possessed the epitopes for both McAbs H25 and 2E10, 
while the epitope for B26 was not present. This would 
indicate replication within the cells be, it complete or 
abortive. The B26* variants were also examined in 
pathogenicity studies (TABLES 5.15 and 5.16), and 
except for B26* FI none of the variants killed mice. 
Therefore, it would appear that the B26* variants are 
attenuated, however further studies are required to see 
if the B26* variants replicated in the mouse, be it 
complete or abortive. This could be achieved by 
extracting virus from the brains of mice or challenging 
mice pre-inoculated with the variants with a virulent YF 
vaccine virus to see if the mice have acquired 
protective immunity.
McAb* variants derived using McAbs B39 and 864 
were examined in IIF, HAI and PRNTs with a panel of
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McAbs. In IIFs all McAb* variants were found to lack the 
appropiate epitope. All McAb^ variants showed very 
little (<0.1) or no neutralisation and little or no HAl 
activity with their respective McAbs indicating that the 
variants had also lost the biological activity 
associated with the epitope recognised by their 
respective McAb. The McAb* variants did not regain the 
epitope upon atleast three passages in cell culture, 
indicating that the variants were probably stable and 
lacked the epitope recognised by the selecting McAb.
The differences in serum neutralisation indices 
(SNl) and HAl titres between the parent strains and 
McAb^ variants can not simply be explained on the basis 
of the lack of epitopes on the relevant virus strains. 
IIF tests showed that all McAbs, except McAbs B39, 864
and 117, recognize epitopes present on all the McAb* 
variants, the YF17D-204 UK and WHO vaccines and the 
parent A and B YF17D-204 UKpp strains (TABLES 5.6 and 
5.7). While biological assays (PRNT and HAl) showed the 
epitopes had lost these functions. Presumably the 
selection of the antigenic variants results in a 
conformational change in the envelope protein of the 
virus. The majority of the McAbs produced in the 
Author's laboratory elicit HAl activity (as seen in the 
last chapter). While the majority of the McAb* 
variants produced lack any HAl activity but have
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retained the haemagglutinin as determined in HA assays. 
Thus, it is possible that the loss of HAl activity is 
due to the McAbs being prepared against one or few 
antigenic domains on the envelope protein. Clearly 
epitope mapping is required to answer this question.
Buckley and Gould (1985) suggested that as McAb 
864 so effectively neutralised YF17D-204 vaccine virus, 
neutralisation of YF virus was unlikely to be merely 
effected by steric hindrance to cell receptors but more 
likely that changes in the glycoprotein conformation 
occur which impedes virus penetration into cells. The 
above PRNTs, IIF tests and HAl assays show that the 
epitope recognized by McAb 864 has altered, possibly 
causing a change in conformational structure to the E- 
protein.
While it is recognized that the E-protein of YF 
virus is responsible for the biological properties of 
neutralisation and haemagglutination, it has not 
previously been shown to be involved in the attenuation 
of YF virus. Two studies have reported detailed analysis 
of the E-protein of YF virus with McAbs. Schlesinger et 
al. (1984) identified nine epitopes while Cammack and
Gould (1986) identified five epitopes on a single major 
domain and an additional four other domains which had 
single epitopes. One of these single epitopes was 
identified as being 17D-204 sub-strain specific and was
193
recognised by McAb 864. This McAb was used to produce 
the 864* variant virus strains analysed above.
One of the variants, YF17D 864* B2, was more
neurovirulent than its parent strain B, while four out 
of the seven 864* variants selected were not 
neurovirulent for adult mice following intracerebral 
inoculation, even when an inoculum of 10,000 pfu was 
used.
It is also of interest that a wild-type epitope 
recognised by McAb 117 remains on the YF17D 864* 
variants Al, A2, and A3 that do not possess the McAb 864 
epitope and have become attenuated in mice when injected 
intracerebrally. This contrasts with the findings of 
Gould ^  (1989) who found that a variant of YF17D-
204 vaccine virus which possessed the epitopes 
recognised by the McAbs 864 and 117 was neurovirulent 
for mice. There has been a previous report describing YF 
17D-204 UK and 17D-204 SA vaccine viruses differing in 
virulence for mice (Liprandi, 1981). Moreover, Gould and 
co-workers (Gould ^  , 1985; Cammack and Gould, 1986;
Cane and Gould, 1988; Gould et , 1989) have inferred 
that the E-protein is involved in the determination of 
mouse neurovirulence.
The results above establish that alteration of 
neurovirulence of YF17D-204 vaccines for mice is linked 
to a unique epitope on the E-protein: that of the
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17D-204 sub-strain specific epitope recognised by McAb 
864 and not a YF-type specific epitope recognised by 
McAb B39.
However, we can not exclude the possibilty that 
other E-protein epitopes, including YF-type specific 
epitopes, may alter mouse neurovirulence of YF17D-204 
vaccine viruses. To date one other McAb* variant has 
been shown to have altered neurovirulence. A McAb* 
variant of Central European Tick-borne encephalitis 
virus produced by Heinz et (1990) using a
neutralising McAb that recognises the type specific 
epitope B4 was attenuated for adult mice, though only 
when inoculated subcutaneously and not intracerebrally.
The epitope recognized by McAb 864 is involved in 
a number of biological activities: neutralisation
(Buckley and Gould, 1985), haemagglutination (Gould et 
al., 1985), haemolysis (Cammack and Gould, 1985) and
passive protection (Gould et ^ . , 1986). Clearly the
epitope is also important in determining the 
neurovirulence of YF virus inoculated intracerebrally in 
mice. However, how a 17D-204 sub-strain specific epitope 
is involved in altering the neurovirulence is not clear. 
This will require a comparitive study of the role of 
other E-protein epitopes in the pathogenesis of YF 
virus. The results above support the proposal of Hahn et 
al. (1987) that the determinants of attenuation of YF
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virus may reside on the E-protein. These workers 
identified 12 amino acid diferences between the E- 
protein of the wild type Asibi virus and the YF17D-204 
vaccine virus. However, which of these amino acid(s) 
forms part of the epitope on the YF virus E-protein 
recognised by McAb 864, or is responsible for the 
alteration in virulence is not known. The determination 
of the nucleotide (and deduced amino acid) sequence of 
the E-protein genes of the 864* variants described in 
this chapter is required. Finally, it can not be 
excluded that there are nucleotide mutations within the 
envelope protein gene of the 864* variants but outside 
the epitope recognised by McAb 864 or alternatively 
mutations outside the envelope protein gene which are 
causing effects in the E-protein. However, IIF, HAl and 
PRNT data, together with the extensive neutralising 
selection pressure of the McAb 864 indicate that the 
mutation(s) are probably within the E-protein epitope 
recognised by McAb 864.
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CHAPTER 6
EXAMINATION OF THE YF VACCINE MANUFACTURED IN THE USSR
197
I. Introduction
Recently, two new centres have been approved by 
the World Health Organisation (WHO) to manufacture YF 
vaccines. These are the Federal Laboratory Service, 
Lagos, Nigeria and the Institute of Poliomyelitis and 
Viral Encephalitides, Moscow, USSR. Studies on the USSR 
vaccine indicated that it may contain viruswith 
different properties to the other YF virus vaccines 
studied. Accordingly, this chapter reports experiments 
carried out to analyse the vaccine manufactured in the 
USSR.
The Authors’ laboratory received two one dose
ampoules of the YF vaccine manufactured in the USSR
(from Dr. J. Stephenson, Public Health Laboratory 
Service, Centre for Applied Microbiological Research, 
Porton), which were part of batch or lot 57. The ampoule 
label stated it was "17D" vaccine. One of the ampoules 
was reconstituted in 300ul of distilled water and lOOul
of this sample was used to infect SW13 cells for a seed
stock. The passage history of this USSR vaccine seed 
stock is shown in FIGURE 6.1.
The USSR vaccine virus was then compared 
antigenically in IIF tests, HAl assays and PRNT’s with 
McAbs and polyclonal anti-sera, and pathogenically with
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FIGURE 6.1. PASSAGE HISTORY OF USSR VACCINE
IN AUTHORS' LABORATORY
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other YF vaccine and wild-type strains. In IIF tests, 
the USSR vaccine virus was studied with the 17D-204 sub­
strain specific McAb 854. McAb, 864 recognised only 10% 
of the USSR vaccine infected cells.
Therefore, plaque purified preparations were made of the 
USSR vaccine and were compared in antigenic and 
pathogenic studies to the parent USSR vaccine seed stock 
as described below.
II. Results
A) Antigenic reactivity of the USSR vaccine 
compared to other vaccines from each strain
i ) Indirect Immunofluorescence Tests
The USSR vaccine was compared with
representatives of the YF virus vaccine strains (YF17D-
204 UK, YF FNV IP, YF 17DD Brazil) and the other new
vaccine strain produced in Nigeria for the expression of
epitopes recognised by McAbs in IIF tests. The presence
of these epitopes were examined using McAbs which
recognise specific epitopes on the E-protein of YF
virus. Of interest were the presence of the flavivirus
group common, YF type specific, vaccine specific, 17DD
and 17D-204 sub-strain specific epitopes.
The IIF tests were performed as described in
Chapter 2. As seen in TABLE 6.1, the epitope recognised
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TABLE 6.1 COMPARISON OF THE USSR VACCINE IN IIF
TESTS WITH OTHER YF VACCINE STRAINS
YF Vaccines McAbs
H3 H5 HIO H25 H33 411 864
17-204 UK + + - + + + +
17DD BRAZIL + + + + + + -
FNV IP + + - + + + -
NIGERIA + + - + + + +
USSR + + + + + + St
+: POSITIVE IMMUNOFLUORESCENCE
-: NEGATIVE IMMUNOFLUORESCENCE
+ & 10% POSITIVE & 90% NEGATIVE IMMUNOFLUORESCENCE
OF VIRUS INFECTED CELLS
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by the flavivirus group common McAb (McAb H25), was 
present on all the viruses studied. This was also true 
for McAbs, H3 and H33 (YF type) and McAbs H5 and 411 
(vaccine specific) which recognised epitopes present on 
all the vaccine virus strains. McAb HIO recognised the 
17DD specific epitope only on the 17DD Brazil vaccine 
strain. However, McAb 864 which recognises the 17D-204 
sub-strain specific epitope was present on the YF17D-204 
UK vaccine and the new Nigerian vaccine virus infected 
cells, indicating the latter vaccine was probably a 17D- 
204 sub-strain. In comparison, McAb 864 showed only 
partial immunofluorescence with the USSR vaccine. Using 
multispot slides with cells infected with the USSR 
vaccine, McAb H25 (flavivirus group common) caused
immunofluorescence with nearly all the cells indicating 
that they were infected. Incontrast, with McAb 864 only 
10% of the cells showed fluorescence. This indicated 
that only 10% of the virus infected cells contained 
antigen expressing the 17D-204 sub-strain epitope. (As 
shown in the photographs in FIGURE 6.2)
ii) HAl assays
To study the biological activity of E-protein
epitopes of the USSR vaccine, the USSR virus was 
examined and compared to seven other YF viruses in HAl
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FIGURE 6.2 IIF TESTS ON VACCINE VIRUS
INFECTED VERO CELLS
a) USSR + McAb H25 b) USSR + McAb 864
c) UK + McAb 864 d) PBS control
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assays with the A, B and H series of McAbs, as well as 
polyclonal anti-sera (TABLE 6.2) and then also with the 
’F ’ series of McAbs (TABLE 6.3).
The HAl assays were performed as described in 
Chapter 2.
The results of McAbs, A3, B39, B44, H5, H20, H25, 
H33 are shown in TABLE 6.2, and have been described 
previously in Chapter 4. To summarise, all the McAbs 
were used to compare eight viruses which included two 
wild-type viruses ( F W  and Asibi). Also, included in 
addition to the USSR vaccine were viruses from the FNV 
strain, one from the 17DD and two from the 17D-204 sub­
strains, and P-16065 revertant from the YF17D-204 USA 
vaccine batch 6145. The HAl activity of the USSR vaccine 
with the McAbs was similar to that of the other vaccine 
strains reacting to the same extent as the YF17D-204 UK 
vaccine with both YF-type (McAbs B39, H33) and vaccine
specific (McAb H5) McAbs. Similar results were also 
obtained with the polyclonal anti-sera made to the FNV 
FC and 17D-204 USA vaccines. In TABLE 6.3, the results 
with the 'F' McAbs are summarised. Again, the USSR 
vaccine E-protein epitopes react similarly with McAbs to 
the YF17D-204 USA vaccine batch 6145 strain. Thus, in
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TABLE 6.2 COMPARISON OF THE USSR VACCINE IN 
HAl ASSAYS WITH OTHER YF VIRUS STRAINS 
USING THE A, B AND H SERIES of McAbs 
AND POLYCLONAL SERA
YF VIRUSES McAbs
Polyclonal
Sera
A3 B39 B44 H5 H20 H25 H33 17D-204
USA
FNV
FC
FVV 160* 80 160 - 320 - 80 640 640
Asibi - 40 40 - 160 - 160 640 640
FNV IP 40 20 160 160 160 320 - - 20
17DD BRAZIL 80 - 80 80 320 - 160 - 40
17D-204 UK 40 160 320 40 160 - 40 160 320
17D-204 USA 
(6145)
80 20 40 - - - - 160 640
P-16065 40 - 40 - 160 320 - 20 40
17D USSR 160 320 160 40 320 20 320 160
HAl TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION 
INHIBITING HAEMAGGLUTINATION.
HAl TITRE LESS THAN 20.
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TABLE 6.3 COMPARISON OF THE USSR VACCINE IN
HAl ASSAYS WITH OTHER YF VIRUS STRAINS
USING THE ’F SERIES OF McAbs
YF VIRUSES
F W
Asibi
FNV IP
17DD BRAZIL
I7D-204 UK
17D-204 USA 
(6145)
P-16065
17D USSR
McAbs
FIO F17 F19 F20 F23 F25 F28 F33
40
20
20
80
20 40
40 80
- 160
80
80 40
80
80 80
20 80
20 
— 80
40
20
80 80 
80 160
20
40
8040 160 20 160
20
- 160 80 20 80 320
: HAl TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION 
INHIBITING HAEMAGGLUTINATION.
■: HAl TITRE LESS THAN 20.
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HAl assays the USSR vaccine appears similar to the other 
YF 17D vaccines.
iii) PRNTs
The USSR vaccine was compared with the same group 
of YF virus strains (as in the HAl assays) using McAbs 
previously shown to elicit neutralisation activity. The 
results of using McAbs A6, B26, B39, F14, G23, H3, H6
and H25 are described previously in Chapter 4. A summary 
of the results are decribed in TABLE 6.4. While one or 
more of the McAbs neutralise the other virus strains 
(except for Asibi virus), the USSR vaccine was not 
neutralised by any of the McAbs. However, this is not a 
significant result due as other YF virus vaccines were 
also not neutralised by this group of McAbs (described 
in Chapter 4).
B ) Comparison of the USSR vaccine to other vaccine
strains in pathogenicity studies
i) In adult mice
Female mice 4 - 5  weeks old and weighing 20-25g 
(Stain TO, OLAC, UK) were inoculated with various 
concentrations of virus in a volume of 0.02 mis by the 
intracerebral route. For comparison, mice were 
inoculated with ten fold dilutions of the 17D-204 USA
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TABLE 6.4 COMPARISON OF THE USSR VACCINE IN
YF VIRUSES
F W
Asibi
FNV IP
17DD BRAZIL
17D-204 UK
17D-204 USA 
(6145)
17D-204 USA 
(4E158)
P-16065
17D USSR
PRNT's WITH OTHER YF VIRUS STRAINS
USING McAbs WHICH ELICIT NEUTRALISING
ACTIVITY
McAbs
A6 B26 B39 F14 G23
*
- — — 1.4 —
- - - 1.9 -
-  -  -  1.0 -
- - - 2.3 3.2
— 3.3 — — —
0.7
H3 H6
3.0
H25
ANTIBODY TITRES EXPRESSED AS LOG-|o REDUCTION IN 
VIRUS TITRE
DENOTES NEUTRALISATION TITRE < 0.6
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and P-16065 revertant viruses corresponding to 2x10^, 
2x10^ and 2x10^ pfu. The mice were monitored daily for 
up to 21 days. The average survival time in days and the 
percentage mortality were determined and compared with 
the data obtained by Gibson ^  (1990). As seen in
TABLE 6.5, although all viruses killed 100% of the mice 
following an inoculation of 2x10* pfu they had 
different average survival times (ASTs). The ASTs varied 
from 5.8 + 0.2 days for FNV IP to 10.3 + 0.3 days for
Asibi virus. In comparison mice infected with the USSR 
vaccine had an average survival time of 6.0 + 0.3 days. 
When an inoculum of 200 pfu was used the YF17D-204 USA 
vaccine batch had a similar AST (10.5 + 0.7 days) to 
that following inoculation of 20,000 pfu while the 
revertant vaccine, P-16065, had an extended AST of 9.8 + 
0.6 days. However, when an inoculum of 200 pfu was used 
for the USSR vaccine the AST of the infected mice could 
not be calculated due to a biphasic response with mice 
dying at 3 to 4 days or 11 to 12 days post infection. 
(FIGURE 6.3)
ii) In newborn mice
Newborn mice (1 to 4 days old), strain TO, were 
inoculated intraperitonealy with 50ul containing 200 pfu
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TABLE 6.5 COMPARISON OF THE USSR VACCINE TO
OTHER YF VIRUS STRAINS IN PATHOGENICITY
STUDIES USING ADULT MICE*
VIRUS pfu
%
MORTALITY AST + S.E.M.*
FW* 2x10* 100.0 9.5 + 0.4
Asibi* 2x10* 100.0 10.3 + 0.3
FNV IP* 2x10* 100.0 5.8 + 0.2
17DD BRAZ* 2x10* 100.0 8.3 + 0.3
17D-204 UK 1x10* 100.0 10.3 + 0.6
17D-204 USA 
(6145)
2x10*
2x10=
2x10=
100.0
100.0
100.0
10.1 + 0.5 
9.1 + 0.7 
10.5 + 0.7
P-16065 2x10*
2x103
2x10=
100.0
100.0
100.0
7.3 + 0.2 
7.1 + 0.5 
9.8 + 0.6
17D USSR 2x10%
2x10*
2x10=
100.0
100.0
71.4
6.2 + 0.2 
6.0 + 0.3 
?
* : DATA FROM[ GIBSON ET , (1990)
20ul OF VIRUS WAS 
ROUTE INTO GROUPS
INOCULATED BY 
OF 8 MICE
THE INTRACEREBRAL
^: AVERAGE 
THE MEAN
SURVIVAL TIME IN DAYS + STANDARD ERROR OF
?: AST UNABLE TO BE CALCULTED
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FIGURE 6.3 PATHOGENICITY OF THE USSR VACCINE WHEN
AN INOCULUM OF 200 pfu IS INOCULATED 
INTRACEREBRALLY
5 - 
4 - 
3 - 
2 ■ 
1
DEAD
MORTALITY = 71%
AST = ?
1 2 3 4 5 6 7 8 9
N^ . OF DAYS
10 11 12 13
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of virus. The mice were monitored for up to 15 days and 
the percentage mortality and AST + S.E.M were calculated 
for each virus. As shown in TABLE 6.6, all the vaccine 
strains used killed 100% of the mice. However, the USSR 
and the FNV IP vaccine strains had the shortest AST of
7.9 + 0.2 and 8.5 + 0.2 days respectively. The vaccine
revertant, P-16065, and the 17D-204 USA vaccine strains 
had similar AST of 10.7 + 0.4 and 11.2 + 0.3
respectively. These were statistically longer than that 
of the 17D USSR vaccine (p<0.001). Only the wild-type 
Asibi and F W  virus strains had a shorter AST than the 
USSR vaccine.
iii) Intranasal Inoculation of mice with the USSR
vaccine
Groups of nine female mice 4 - 5  weeks old and 
weighing 20-25g (Stain TO, OLAC, UK) were inoculated 
intranasally with different concentrations of virus in a 
volume of 0.02ml. Each group of mice were monitored for 
up to 26 days. Only one mouse receiving a dose of 2x10* 
pfu died on the 19^  ^day post-inoculation (Results not 
shown).
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TABLE 6.6 COMPARISON OF THE USSR VACCINE TO
OTHER YF VIRUS STRAINS IN PATHOGENICITY
STUDIES USING NEW-BORN MICE
N. DEAD %
VIRUS N°. INOCULATED MORTALITY AST + S.E.M.*
Asibi
FVV
FNV IP
17D-204 UK
17D-204 USA 
(6145)
P-16065
17D USSR
10/10
8/8
10/10
5/11
10/10
10/10
11/11
100
100
100
45
100
100
100
4.1 + 0.4
3.1 + 0.1 
8.5 + 0.2
14.6 + 1.5
11.2 + 0.3
10.7 + 0.4
7.9 + 0.2
: 50ul OF VIRUS CONTAINING 200 pfu WAS INOCULATED BY
THE INTRAPERITONEAL ROUTE
*: AVERAGE SURVIVAL TIME IN DAYS + STANDARD ERROR OF THE 
MEAN
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iv) Intracerebral Inoculation of a cynomolgus monkey
with the USSR vaccine
The monkey was inoculated by the intracerebral 
route with 3.5x10^ pfu of the USSR vaccine in a volume 
of SOOul, the monkey was monitored upto 18 days post 
inoculation for signs of any adverse affects. The monkey 
remained healthy and showed no visible signs of disease.
C) Plaque purification of the USSR Vaccine
The immunofluorescence tests on the USSR vaccine 
suggested that it consisted of a heterogeneous 
population of virions, where only 10% of virions 
expressed the 17D-204 sub-strain epitope recognised by 
McAb 864. To isolate these variant virion populations, 
the USSR vaccine was plaqued on a six well tissue 
culture plate, as described in Chapter 2. After the 
assay had been overlaid with neutral red, plaques were 
observed. Ten single isolated plaques were picked with 
the aid of a glass pasteur pippette (Wiktor & 
Kowprowski, 1980). The ten plaque purified preparations 
labelled; I through to X, were grown up in SW13 cells 
as described in the Methods section. They were all then 
plaque assayed to assertain the presence of virus (TABLE 
6.7). These plaque purified populations of virus were
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TABLE. 6.7 INFECTIVITY TITRES OF PLAQUE PURIFIED
PREPARATIONS OF THE USSR VACCINE VIRUS
PLAQUE 
>URIFIE
PREPARATION (pfu/ml)
PURI D LOG^Q INFECTIVITY
I 3.7
II 5.0
III 4.0
IV 4.0
V
VI 5.5
VII 5.8
VIII 5.0
IX 6.0
X 6.0
NO PLAQUES DETECTABLE AFTER SEVEN DAYS INCUBATION,
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then compared with the parent USSR vaccine strain in 
IIF, HAl and pathogenicity studies, as described below.
D ) Comparison of the plaque purified USSR viruses to
that of the parent USSR vaccine
i ) IIF Tests
The nine plaque purified (pp) viruses, which gave 
an infactivity titre, were compared with the parent USSR 
vaccine in IIF tests with 11 McAbs from the A, B. G, and 
H series. As above the USSR vaccine gave 100% 
immunofluorescence on infected cells with all the McAbs 
studied with the exception of McAb 864, which only 
reacted with 10% of the infected cells. Examination of 
thee USSRpp virus infected cells showed that although 
most McAbs recognised epitopes on each USSRpp virus 
there was a heterogeneous response with McAbs 411 
(vaccine specific) and 864 (17D-204 sub-strain specific) 
(TABLE 6.8). The cells infected with USSRpps I, II, VI 
and VII, gave no immunofluorescence with McAb 864, 
while cells infected with USSRpps VIII and X, did not 
fluoresce with either McAbs 864 or 411. In contrast, 
both of the epitopes recognised by McAbs 864 and 411 
were detected by immunofluorescence of cells infected 
with USSRpps III, IV, and IX.
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TABLE 6.8 COMPARISON OF THE PLAQUE PURIFIED 
USSR VIRUSES TO THAT OF THE PARENT 
VACCINE STRAIN BY IIP TESTS
USSR
McAbs I II Ill IV VI VII VIII IX X VACC]
A6 + + + + + + + + + +
B39 + + + + + + + + + +
023 + + + + + + + + + +
H3 + + + + + + + + + +
H5 + + + + + + + + + +
H6 + + + + + + + + + +
H14 + + + + + + + + + +
H25 + + + + + + + + + +
H33 + + + + + + + + + +
411 + + + + + + - + - +
864 — — + + _ _ + + &
+ & —
POSITIVE IMMUNOFLUORESCENCE 
NEGATIVE IMMUNOFLUORESCENCE 
ONLY 10% POSITIVE IMMUNOFLUORESCENCE
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ii) HAI assays
Six McAbs recognising different epitopes were used 
to examine and compare the USSR parent vaccine with 
seven of the USSRpps in HAI assays (TABLE 6.9). The 
vaccine specific McAb, H5, elicited HAI activity with 
the parent USSR vaccine and all of the USSRpps examined, 
except for USSRpp VIII. The other vaccine specific McAb, 
411, elicited high HAI activity with the parent and all 
USSRpps with the exception of USSRpps VIII and X. 
Interestingly McAb G65, a partially flavivirus group 
reactive McAb elicited high HAI activity with the USSR 
vaccine, but elicited either low or no HAI activity with 
all of the USSRpps. McAbs H3, H33 and H6 elicited either 
low or no HAI activity with both the vaccine and the 
USSRpps.
iii) Pathogenicity studies
a) In adult mice
Adult female mice were inoculated with 2x10^ pfu 
in 20ul volume by the intracerebral route. The mice were 
monitored for 21 days and the percentage mortality and 
the AST were calculated. The results are shown in TABLE 
6.10. Of the seven USSRpps tested in the pathogenicity
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TABLE 6.9 COMPARISON OF THE PLAQUE PURIFIED
USSR VIRUSES TO THAT OF THE PARENT 
VACCINE STRAIN BY HAI ASSAYS
USSR
McAbs II III VI VII VIII IX X VACCINE
411 80* 80 160 160 20 160 20 80
G65 20 — — — — 80 — 320
H3 20 20 40 20 - 20
H5 80 20 160 320 - 320 160 40
H6 20 - - - 20 40 20
H33 — — — — — — — 20
: HAI TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION 
INHIBITING HAEMAGGLUTINATION.
HAI TITRE LESS 20.
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TABLE 6.10 COMPARISON OF THE PLAQUE PURIFIED USSR
VIRUSES TO THAT OF THE USSR VACCINE IN
PATHOGENICITY STUDIES USING ADULT MICE
VIRUS* N? DEAD
%
MORTALITY AST + S.E.M.+
N°. INOCULATED
USSR
VACCINE 8/8 100 6.0 + 0.4
II 0/8 ^13 N/A
III 3/7 42 15.0 + 1.0
VI 3/8 38 13.3 + 0.3
VII 5/7 71 13.4 + 0.9
VIII 2/6 33 12.0 + 0.0*
IX 4/8 50 12.5 + 0.9
X 2/6 33 11.5 + 1.5*
*: 20ul OF VIRUS CONTAINING 1x10^ pfu WAS INOCULATED BY 
THE INTRACEREBRAL ROUTE
AVERAGE SURVIVAL TIME IN DAYS + STANDARD ERROR 
OF THE MEAN
$: NOT STATISTICALLY SIGNIFICANT AS FEW MICE DIED
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study, none killed 100% of the mice as the parent 
strain did. The USSRpp II killed no mice, while USSRpps 
X, VIII, VI, III and IX killed from 33% to 50% of mice. 
The USSRpp VII was the most neurovirulent of the seven 
plaque purified preparations in that it killed 71% of 
the mice. The AST of all the plaque purified 
preparations were similar being between 11.5 and 13.4 
days post-infection, with the exception of USSRpp III 
which had a longer AST of 15 days. However, the AST of 
the USSRpps was twice that of the parent USSR vaccine 
strain which killed 100% of mice in 6.0 + 0.4 days.
b) In newborn mice
Newborn mice (1 to 4 days old) were inoculated 
intraperitoneally with 200 pfu of virus in a volume of 
50ul. The mice were monitored for up to 21 days and the 
AST and percentage mortality were calculated. As shown 
in TABLE 6.11, the USSR parent vaccine strain was more 
virulent than any of USSRpps killing 100% of mice with 
an AST of 7.9 + 0.2 days. While USSRpps II, IX, X killed 
60%, 61% and 83% of mice respectively, USSRpps VIII,
III, VI killed 0%, 25% and 33% of mice respectively.
Although the mortality rate of the USSRpps varied they 
have a similar AST of 12.2 to 13.5 days with USSRpp III 
again having the longest AST.
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TABLE 6.11 COMPARISON OF THE PLAQUE PURIFIED USSR 
VIRUSES TO THAT OF THE USSR VACCINE 
IN PATHOGENICITY STUDIES USING NEWBORN
VIRUS
MICE
N. DEAD
%
MORTALITY
(6145)
AST + S.E.M.+
N*. INOCULATED
USSR
VACCINE 11/11 100 7.9 + 0.2
II 3/5 60 12.6 + 0.8
III 2/8 25 13.5 + 2.5*
VI 5/15 33 12.6 + 0.2
VIII 0/10 ^10 N/A
IX 8/13 61 12.2 + 0.6
X 10/12 83 12.4 + 0.3
17D-204 USA 10/10 100 11.2 + 0.3
50ul OF VIRUS CONTAINING 200 pfu WAS INOCULATED BY 
THE INTRAPERITONEAL ROUTE
$.
AVERAGE SURVIVAL TIME IN DAYS + STANDARD ERROR OF 
THE MEAN
NOT STATISTICALLY SIGNIFICANT AS FEW MICE DIED
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E ) Comparison of the original USSR vaccine passed
through mouse brain and the original vaccine 
passed in tissue culture
The brain of a 4 - 5 week old paralysed mouse, 
which had previously been inoculated with the passage 
one USSR vaccine grown in SW13 cells, was removed on the 
5^  ^ day post inoculation. The brain was homogenised 
through a 19G needle and syringe, centrifuged and the 
supernatant aliquoted into lOOul amounts and frozen at 
-70%. This preparation was then used to inoculate a 
confluent cell sheet of SW13 cells. This virus stock 
(known as Mb) was then compared with the passage one 
USSR vaccine that had been passaged through SW13 cells 
as described below.
i ) IIP Tests
Vero cells, previously infected with the USSR 
vaccine and Mb preparation as described in Chapter 2. 
were examined using a panel of 9 McAbs. As shown in 
TABLE 6.12, all the McAbs reacted with both preparations 
with the exception of McAb 864, which recognised the 
17D-204 sub-strain specific epitope in 100% of the Mb 
infected cells while this epitope was only detected in
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TABLE 6.12 COMPARISON OF USSR VACCINE PASSAGED IN
THE MOUSE BRAIN (Mb) WITH THAT PASSAGED 
FIRST IN SW13 CELLS BY IIF TESTS
McAb VIRUS STRAINS
USSR USSR
in in
SW13 CELLS MOUSE BRAIN
A6 + +
H3 + +
H5 + +
H6 + +
H14 + +
H25 + +
H33 + +
411 + +
864 4- & — +
+; POSITIVE IMMUNOFLUORESCENCE 
-: NEGATIVE IMMUNOFLUORESCENCE
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10% of the cells infected with the passage one SW13 
grown USSR vaccine.
ii) HAI assays
The USSR YF vaccine virus which had been 
propogated in mouse brain was compared to that 
propagated in SW13 cells in HAI assays as described 
previously (Chapter 2) using six McAbs recognising 
different epitopes on YF virus (TABLE 6.13). Most of the 
McAbs used (McAbs 411, H3, H6, H33) reacted to a similar 
HAI activity with both of the viruses, but McAbs G65 and 
H5 distinguished between the two viruses. McAb G65 
elicited high HAI activity with the SW13 propagated 
virus compared to that grown in mouse brain while McAb 
H5 elicited a high HAI activity with the mouse brain 
grown virus compared to the SW13 grown virus.
iii) Pathogenicity study
a) In adult mice
Adult mice were inoculated with 2x10^ pfu of virus 
as described above. As shown in TABLE 6.14, both the 
viruses killed 100% of the mice with a similar AST.
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TABLE 6.13 COMPARISON OF USSR VACCINE PASSAGED IN 
THE MOUSE BRAIN (Mb) WITH THAT PASSAGED 
FIRST IN SW13 CELLS BY HAI ASSAYS
McAb VIRUS STRAINS
411
G55
H3
H5
H6
H33
USSR
in
SW13 CELLS
*
80
320
20
40
20
USSR
in
MOUSE BRAIN 
160 
40 
40 
320 
40
: HAI TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION 
INHIBITING HAEMAGGLUTINATION.
■: HAI TITRE LESS THAN 20.
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TABLE 6.14 COMPARISON OF USSR VACCINE PASSAGED IN
THE MOUSE BRAIN WITH THAT PASSAGED 
FIRST IN SW13 CELLS IN A PATHOGENICITY 
STUDY USING ADULT MICE
%
VIRUS N. DEAD MORTALITY AST + S.E.M.+
N°. INOCULATED
USSR
in 8/8 100 6.0 + 0.4
SW13 CELLS
USSR
in 8/8 100 5.6 + 0.5
MOUSE BRAIN
: 20ul OF VIRUS CONTAINING 2x10^ pfu WAS INOCULATED BY 
THE INTRACEREBRAL ROUTE
: AVERAGE SURVIVAL TIME IN DAYS + STANDARD ERROR OF
THE MEAN
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b ) In newborn mice
Mice were inoculated and monitored as described 
previously above. As shown in TABLE 6.15, both the 
viruses killed 100% of the mice. However, the AST's of 
the infected mice were different. The mouse brain grown 
virus had an average survival time of 5.3 + 0.1 days, 
and the SW13 grown virus had an AST of 7.9 + 0.2 days. 
The difference in AST's was statistically significant
(p<0.001).
Ill. Discussion
Like any other virus popuation the YF vaccine 
viruses have a potential to undergo changes in its 
properties. Early workers (Theiler, 1951; Fox et al., 
1942; Fox and Penna, 1943) have demonstrated either 
decreases or increases in neurovirulent properties of 
the YF vaccines depending on its passage history. More 
recently, other workers have been able to differentiate 
YF vaccine viruses when inoculated into mice 
(Fitzgeorge and Bradish 1980a, b; Liprandi, 1981; 
Barrett and Gould, 1986), and by the use of McAbs 
(Schlesinger,1983; Gould et ^ . , 1985) and gentically by 
T^  ribonuclease oligonucleotide fingerprinting (Monath 
et al., 1983). The Authors laboratory obtained the USSR
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TABLE 6.15 COMPARISON OF USSR VACCINE PASSAGED IN
THE MOUSE BRAIN (Mb) WITH THAT PASSAGED
FIRST IN SW13 CELLS IN A PATHOGENICITY
STUDY USING NEWBORN MICE
%
VIRUS* N. DEAD_____ MORTALITY AST + S.E.M.+
N°. INOCULATED
USSR
in 11/11 100 7.9 + 0.2
SW13 CELLS
USSR
in 13/13 100 5.3 + 0.1
MOUSE BRAIN
: 50ul OF VIRUS CONTAINING 200 pfu WAS INOCULATED BY
THE INTRAPERITONEAL ROUTE
: AVERAGE SURVIVAL TIME IN DAYS + STANDARD ERROR OF
THE MEAN
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vaccine and examined it antigenically with McAbs and 
neurovirulence in a monkey and mice.
The USSR is one of two new centres which have been 
recently approved by the WHO (WHO, 1988) to manufacture 
the YF vaccine. The vaccine is a 17D-204 sub-strain 
virus, using the 17D-204 WHO ALV-free secondary seed as 
the inoculum. It is produced in minced chicken embryos 
that have been removed from eggs and grown in culture, 
with 200,000 doses being prepared annually (Elbert, 
personal communication).
The biological properties of the USSR vaccine 
virus were examined in this Chapter using the methods of 
HAI assays, PRNTs, IIF tests and pathogenicity studies. 
This vaccine strain was compared to different vaccine 
strains produced by different manufacturers.
As shown in HAI assays (TABLES 6.2 and 6.3) using 
both polyclonal anti-sera and McAbs, the USSR vaccine 
strain was shown to react more similar to the other 17D- 
204 vaccine virus strains manufactured in the United 
Kingdom and the United States of America than the 17DD, 
FNV-IP vaccine strains or the two wild-type YF viruses 
from Africa (Asibi and FW). However, when the USSR 
vaccine virus was analysed in PRNT’s it was not 
neutralised by any of the McAbs used in the study 
(TABLE 6.3). This result was not considered significant
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as many of the other 17D-204 vaccines studied were not 
neutralised. When, the USSR vaccine was examined in IIF 
tests, only approximately 10% of the virus infected 
cells displayed immunofluorescence with McAb 864 which 
recognises the 17D-204 sub-strain specific epitope. In 
contrast, McAb H25, which recognises a flavivirus group 
common epitope, caused 100% of the virus infected cells 
to fluoresce. This indicated that antigen and possibly 
many virions in the USSR vaccine population, lack the 
17D-204 sub-strain specific epitope. On subsequent 
plaque purification of the USSR vaccine strain and 
passaging of these USSRpps, nine different isolates were 
produced. IN IIF tests, six of these USSRpps lacked the 
17D-204 vaccine epitope, while of these six, two lacked 
the vaccine epitope (i.e. 17D-204, 17DD and FNV
specific) recognised by McAb 411. To date, of 20 
vaccines examined from different YF vaccine 
manufacturers, the USSR vaccine is the only one where 
McAb 864 has given an unusual pattern of 
immunofluorescence. Therefore, it appears that the USSR 
vaccine contains a heterogeneous population of virions. 
This is not unusual and has been reported previously. 
For example, Liprandi (1981), isolated different plaque 
variants from the YF17D-204 UK and YF17D-204 SA vaccine 
virus strains differing in plaque size and virulence.
Subsequently , the USSR parent vaccine strain was
231
compared in a pathogenicity study to other 17D-204, 17DD 
and FNV vaccine strains using both adult mice and 
newborn mice. It was found that the USSR vaccine killed 
both ages of mice with an average survival time that 
was much shorter than other 17D vaccine strains (except 
FNV IP). When the inoculum was reduced to 200 pfu in 
adult mice, a biphasic response was obtained with mice 
dying at 3 - 4  days or 11 - 12 days post inoculation. 
This indicated a mixed population of virions with 
respect to virulence. However, when the USSRpps were 
inoculated into adult and newborn mice, they were 
found to less virulent and took twice as long to die as 
the parent virus. Thus, biologically the plaque purified 
viruses appear more like other 17D vaccine strains. The 
significance of the absence of the 17D-204 sub-strain 
specific and vaccine epitopes recognised by McAbs 864 
and 411 respectively, on the USSRpps is not clear. The 
author has generated McAb^ variants (Chapter 5) to the 
864 epitope and has shown the loss of this epitope 
alters the virulence of the 17D-204 strains studied. 
However, in this study the parent USSR vaccine was very 
neurovirulent for mice and apparently only a small 
proportion of the virions in the population possess the 
17D-204 specific epitope recognised by McAb 864. Thus, 
it would appear likely that none of the plaque purified 
viruses represent the virion responsible for virulence
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with the short AST and that these virulent viruses 
represent only a small proportion of the population. The 
parent virus had no adverse affect when it was 
inoculated intracerebrally into a monkey. This would 
imply that the "mouse virulent" virus is not virulent in 
monkeys or that insufficient virions were inoculated 
into the monkey for it to have an effect. The latter 
seems unlikely as the monkey received 3.5x10® pfu.
Clearly further investigation is required to 
isolate the "mouse virulent" virion. However, the 
statistically shorter AST of the virus passaged in mouse 
brain may indicate that the virulent virus is being 
selected and enriched in mouse brain. Accordingly, 
selection of plaque purified virions from the USSR 
vaccine propagated in mouse brain may aid in the 
indentification of the virulent virus in the USSR 
vaccine. Also, another ampoule or batches of USSR 
vaccine should be examined, to see if this virulent 
population is also present in other batches of the USSR 
vaccine. Alternatively, the virulent virus may not be YF 
virus. Clearly, a careful study of the neutralisation 
kinetics of the USSR vaccine with YF type specific McAbs 
(if available) would help answer this question.
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CHAPTER 7
EXAMINATION OF THE FNV VACCINES
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I. Introduction
As discussed in chapter 1, the FNV vaccine was 
used extensively in the French speaking countries of 
Africa. Over 80 million people were vaccinated. 
Although, this vaccine was more stable to heat than 17D 
vaccine it was discontinued in 1980 due to cases of 
post-vaccinal encephalitis being reported. Three 
different strains of the FNV vaccine were examined 
below. These were FNV IP, FNV NT and FNV FC and are 
described in Chapter 2. The three vaccines were examined 
antenically in HAI assays and PRNT’s and biologically 
in pathogenicity studies in mice and monkeys. The 
results are discussed below.
II. Results
A) Comparison of reactivities of each FNV vaccine 
with other virus strains in HAI assays with McAbs
i) The A, B, G and H McAb Series
The FNV vaccines were compared to their wild-type 
parent strain (FW) using the A, B, G and H McAbs. The 
reactivities of these McAbs have been described 
previously in Chapter 4. To summarise, McAbs from these 
series were used to compare the three FNV vaccines in 
HAI assays with the wild-type YF F W  strain. As shown in
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TABLE 7.1, most McAbs (B26, B37, B44, Hll, H20, H31)
elicited HAI with all four of these YF viruses. However, 
there were some exceptions. As expected, the vaccine 
specific McAb H5 did not elicit HAI with the F W  wild- 
type virus, but elicited high HAI activity with FNV IP 
and FNV NT, but low HAI activity with FNV FC. Out of 
three YF-type specific McAbs, B39, did not elicit HAI 
activity with FNV NT, while McAb G23 did not elicit HAI 
activity with either FNV NT or FW. The last YF-type 
specific McAb, H33, elicited high HAI activity with all 
viruses with the exception of FNV IP. Finally, McAbs H8, 
and A3, did not elicit HAI with FNV IP and FNV FC 
respectively.
ii) The F McAb Series
The ’F' series of envelope protein reactive McAbs, 
which were prepared using FNV IP as the immunogen (By A. 
Jennings), were used to study and compare the F W  and 
FNV vaccines in HAI assays, as well as another African 
wild-type YF virus, Asibi. The FNV vaccines were also 
compared to other YF vaccine viruses. As shown in TABLE 
7.2, the 'F ' McAbs elicited similar HAI activity with 
each of the three FNV vaccines. However, the F W  wild- 
type YF virus reacted more similar to the wild-type 
Asibi virus than the FNV vaccines. McAb F17 did not
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TABLE 7.1 EXAMINATION OF THE FNV VACCINES IN HAI
ASSAYS WITH THEIR WILD-TYPE PARENT YF 
STRAIN F W  USING THE A, B, G and H SERIES 
OF McAbs
McAbs Viruses
F W FNV FC FNV IP FNV NT
A3 160* — 40 80
B26 80 80 40 80
B37 40 80 40 40
B39 80 160 20 -
B44 160 320 160 160
G23 - 160 80 -
G65 40 640 80 -
H5 - 20 160 80
H8 160 40 - 160
Hll 80 160 40 80
H20 320 640 160 320
H30 160 - 160 320
H31 80 40 80 40
H33 80 80
■
160
*: HAI TITRE EXPRESSED AS RECIPROCAL OF THI
INHIBITING HAEMAGGLUTINATION 
HAI TITRE LESS THAN 20
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TABLE 7.2 COMPARISON OF FNV VACCINES USING 'F 'McAbs IN 
HAI ASSAYS WITH OTHER STRAINS OF YF VIRUS
YF Viruses McAbs
FIG F17 F19 F20 F23 F25 F28 F33
FNV
FNV FC - 160* - 20 160 20 20 40
FNV IP - 80 - 20 80
FNV NT 20 160 - 20 80 20 - 20
wild-type
F W  40 - - 160 80 40 80 80
ASIBI 20 - - 80 80 20 80 160
17D
17D-204 UK - 80 40 - 80 40
17D-204 USA 80 - - 40 160 20 160 80
(6145)
P—16065 20 40 — — 20 — — —
17D USSR 40 80 - 160 80 20 80 320
17DD Brazil 20 - - - 20 - - 20
HAI TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION 
INHIBITING HAEMAGGLUTINATION 
HAI TITRE LESS THAN 20
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elicit HAI activity with the F W  virus, but elicited 
high HAI activty with all three FNV vaccines. On the 
other hand, McAb F28 did not elicit HAI activity with 
the FNV vaccines it did elicit HAI activity with the 
wild-type F W  virus. When the FNV vaccines were compared 
to the 17D vaccines the profile of HAI activity elicited
by the McAbs was more similar to that of the 17D-204
vaccines than the 17DD Brazil vaccine. The F Mcabs 
elicited very low or no HAI activity with the 17DD
Brazil vaccine viruses.
B ) Clster analysis of the HAI results using the F
McAbs series
All the HAI titres for each McAb reaction against 
each virus was converted in LOG^^ values and entered 
into the Clustan computer programme. The dendrogram, 
shown in FIGURE 7.1, gives two groups, one containing 
the wild-type YF viruses together with a few
vaccine viruses (17D-204 USA 6145, 17D USSR and 17DD
Brazil) and the other containing the three FNV
vaccine viruses (FNV FC, FNV IP, FNV NT) and the other
17D-204 vaccine viruses (17D-204 UK, P-16065) used in 
the study. This dendogram was different from that
constructed using McAbs derived from 17D virus 
immunogens (using the A, B, G and H McAbs, FIGURE 4.1) 
except that it still groups the wild-type YF viruses
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FIGURE 7.1 CLUSTER ANALYSIS OF THE HAI
RESULTS USING THE ’F ’ McAbs
SERIES
o o o o o O o o Ô
05 05 u IV) o05- tn 05 uo> IV) . œ . . o 05 ■ s
ASIBI
17D204 USA 6145
USSR
17DD BRA2
FNV FC
FNV NT
P-16065
17D204 UK
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together with the 17DD Brazil vaccine virus in the same 
group.
C ) Comparison of reactivities of the FNV vaccine 
viruses in PRNT * s with other YF viruses using YF 
type, flavivirus sub-group and group specific 
McAbs
Of all the F McAbs only McAb F14 neutralised the 
YF FNV vaccine viruses and the wild-type F W  virus (A. 
Jennings, personal communication). Therefore, McAbs 
produced in other Laboratories which used other 
flaviviuses as immunogens were examined in 
neutralisation tests. These McAbs and their properties 
are described in Chapter 2. The YF type specific McAb 
2E10 fully neutralised all the YF viruses studied (TABLE 
7.3), except for the 17D-204 WHO strain. The flavivirus 
subgroup McAb 2B5B-3 was able to distinguish between FNV 
FC and the other two FNV vaccines (FNV NT and FNV IP 
viruses) and the wild-type F W  virus, by neutralising 
the FNV FC virus to a much higher titre than the other
YF viruses. The flavivirus group reactive McAb 6B6C-1
reacted similar by neutralising the FNV FC virus
completely. McAb 1B7, was able to differentiate the FNV
NT virus from the other two FNV vaccines by neutralising 
FNV IP and FNV FC viruses but not FNV NT virus.
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TABLE 7.3 COMPARISON OF REACTIVITIES OF THE FNV
VACCINES IN PRNT's WITH OTHER YF VIRUSES
USING YF TYPE SPECIFIC, FLAVIVIRUS
SUBGROUP AND GROUP SPECIFIC McAbs
McAbs Viruses
17D204
WHO FC
FNV
IP NT
ASIBI F W B4.1
2E10 3.2* >4.0 >6.0 >4.3 >3.0 >4.0 >4.0
2B5B-3 NT >4.0 0.6 0.6 >3.0 1.5 >4.0
6B6C-1 NT >4.0 0.6 - >3.0 1.2 >4.0
1B7 NT 1.0 1.1 1.0
NT
ANTIBODY TITRES EXPRESSED AS LOG^^ REDUCTION IN 
VIRUS TITRE
DENOTES NEUTRALISATION TITRE <0.5 
NOT TESTED
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D) COMPARISON OF VIRUSES IN PATHOGENICITY STUDIES
Previous workers, using intracerebral
inoculation of adult mice, have shown that the FNV 
vaccine virus kills mice with a shorter AST than other 
vaccine viruses (Barrett and Gould, 1986; Deubel et al., 
1986). Gibson ^  (1990) studied the three different
FNV vaccine viruses in adult mice and showed that FNV IP 
and FNV NT viruses had short AST’s (5-7 days) while FNV 
FC virus had a relatively long AST (11 days). Therefore, 
the above results were extended by examining the FNV 
vaccines in newborn mice and monkeys.
i ) Newborn mice
Each virus studied was diluted to a titre of 200 
pfu in a volume of 50ul and inoculated intraperitoneally 
as described previously. The mice were monitored for 21 
days and the AST and percentage mortality were 
calculated. As seen in TABLE 7.4 all viruses killed 100% 
of the newborn mice inoculated. Mice infected with the 
parent YF wild-type strain F W  had a shorter AST (3.1 + 
0.1 days) than the Asibi wild-type strain (4.1 + 0.4
days). Mice infected with FNV FC and FNV NT viruses had 
very similar ASTs, 12.5 + 0.3, 12.2 + 0.3 respectively
similar to the AST’s of the 17D-204 USA (11.2 + 0.3) and
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TABLE 7.4 COMPARISON OF THE FNV VACCINES WITH THEIR 
WLID-TYPE PARENT STRAIN (FW) IN A 
PATHOGENICITY STUDY USING NEWBORN MICE
VIRUS
N. DEAD
N°. INOCULATED MORTALITY AST+ S.E.M.*
Asibi 10/10
F W  8/8
FNV FC 5/5
FNV IP 10/10
FNV NT 11/11
17D-204 USA 10/10 
(6145)
P-16065 10/10
100
100
100
100
100
100
100
4.1 +0.4
3.1 + 0.1 
12.4 + 0.2
8.5 + 0.2
12.2 + 0.3
11.2 + 0.3
10.7 + 0.4
200 pfu OF VIRUS IN A VOLUME OF 50ul WAS 
INOCULATED BY THE INTRAPERITONEAL ROUTE
AVERAGE SURVIVAL TIME.IN DAYS + STANDARD ERROR OF 
THE MEAN
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p-16065, the revertant 17D-204 USA vaccine batch 6145 
(10.7 + 0.4 days). Mice infected with FNV IP virus had a 
much shorter AST of 8.5 + 0.2 days which is
significantly shorter (p<0.001) than that of the other 
two FNV vaccine viruses.
ii) Comparison of FNV vaccines when inoculated
Intracerebrally into a monkey
Two of the FNV vaccinces were examined for
neurovirulence in cynmologous monkeys. Each monkey was 
inoculated with 1x10^ pfu of virus in a volume of 500ul 
by the intracerebral route and examined daily. The
monkey inoculated with the FNV FC virus died on day 
nine post infection, while the monkey inoculated with
FNV IP virus died much earlier on day six post
infection.
Ill. Discussion
The F W  strain of YF virus was attenuated by 
Mathis et (1928) by passage of the virus through
mouse brain to produce the FNV vaccine virus. The
vaccine was initially given alone by subcutaneous 
inoculation and later was given together with YF immune 
serum. However, severe reactions followed injection
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(Laigret, 1937) and the introduction of the 17D vaccine 
(attenuated by Theiler et (1937) by passage through
chick embryo tissue) restricted the use of this vaccine. 
However, workers at the Institute Pasteur in Dakar, 
Senegal improved the FNV vaccine so it would afford 
protection if it was given by linear scarification and 
no YF immune serum was required to be administered 
(Peltier 1947).
The vaccine was produced from desiccated mouse 
brain which had previously been inoculated by the 
intracerebral route with the FNV vaccine virus. The 
virus had received 250 passages by intracerebral 
inoculation of adult mice. Unfortunately, this vaccine 
was also reported to produce post-vaccinal encephalitis 
in children and the WHO recommended that it should not 
be given to chidren under the age of 14 years (WHO, 
1959).
In this Chapter three different isolates of FNV 
from three different Laboratories: FNV FC, FNV IP, FNV
NT (properties described in Chapter 2, their exact 
passage histories are unknown) were examined 
antigenically in PRNT’s and HAI assays, and biologically 
in pathogenicity tests.
The overall result of the McAb studies was that 
the FNV vaccine viruses were similar to each other and 
distinct from other YF vaccine viruses. The summary of
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the results using the A, B, G and H McAbs in TABLE 7.1 
showed that the three FNV viruses react similarly with a 
positive HAI activity with most McAbs, although the 
quality of HAI activity was different between the McAbs 
used. Accordingly, as shown in the dendrogram of the 
cluster analysis of all vaccines in Chapter 4 (FIGURE
4.1), the FNV viruses are differentiated from each 
other so that each is in a different group. On the other 
hand the dendrogram constructed using the F McAbs 
(FIGURE 7.1) does not differentiate the FNV vaccine
viruses to a great extent but groups them together away 
from the wild-type YF virus strains. Deubel ^  al. 
(1986) using a different method than Monath ^  al. 
(1983) reported the T^  oligonucleotide mapping of FW, 
Asibi, FNV and 17D-204 viruses and that the Asibi and 
F W  wild-type strains had 96.4% homology while 
comparisons of F W  and FNV gave 83.6% homology and Asibi 
and 17D gave 79.6% homology. The same type of grouping
is shown when using the F McAbs which were made against
FNV IP. The homology between the F W  and 17D-204
vaccines was 81.8% and this reflects why the A, B, G and 
G McAbs (which where made against 17D vaccines, as 
described in Chapter 3) do not group the FNV vaccines 
together in the Cluster analysis (FIGURE 4.2, Chapter 
4).
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Of the F McAbs, only one McAb (F14) neutralised 
the FNV vaccine viruses to above 1 LOG^g or more. 
Thus the three FNV vaccines were then examined in PRNT’s 
using McAbs produced in other Laboratories. As shown in 
TABLE 7.3, the YF type specific McAb 2E10 did not 
differentiate any of YF viruses studied. However, McAbs 
2B5B-3 and 6B3B-3 differentiated the FNV FC virus from 
the two other FNV viruses.
Biologically, mouse virulence studies
differentiated the FNV vaccine viruses in two ways. 
First intracerebral inoculation of adult mice showed 
that FNV IP and FNV NT viruses killed mice with a 
shorter AST than FNV FC virus infected mice. Second, 
intraperitoneal inoculation of newborn mice grouped FNV 
NT and FNV FC viruses together on the basis of AST of 
infected mice, while FNV IP virus infected mice had a 
shorter AST. Thus, as expected virulence is multi­
factorial and there are no apparent correlations to the 
results obtained with antigenic studies using McAbs.
Two of the three FNV vaccines were further 
examined for neurovirulence by inoculating each virus 
into cynmologous monkeys by the intracerebral route. As 
described previously in the Results the monkey infected 
with the FNV IP virus had a much shorter AST (killing 
the monkey on day 6 post infection) than that 
infected with the FNV FC virus (killing on day 9 post
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infection) tested. These two FNV vaccine viruses (FNV IP 
and FNV FC) were apparently more neurovirulent than the 
revertant P-16065 virus from the 17D-204 USA vaccine 
batch 6145. The cynmologous monkey inoculated with P- 
16065 virus, became paralysed on day 12 and died on day 
14 post infection (A.D.T. Barrett, personal 
communication). Therefore the increased virulence for 
monkeys of the FNV vaccine viruses requires more studies 
to investigate the reason for this increased virulence. 
Comparison of the nucleotide sequence of the genomes of 
the three FNV viruses to their parent wild-type virus 
(FW) and to the 17D-204 vaccines may give a molecular 
answer to the basis of neurovirulence. The study of 
McAb* variants of the FNV strains may also add more 
information as to why they are more neurovirulent.
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CHAPTER 8
STUDY OF THE EFFICIENCY OF PLAQUING (E.O.P) OF YF 
VIRUSES GROWN IN THE C6-36 MOSQUITO CELL LINE AND 
PLAGUED AT A RESTRICTIVE TEMPERATURE OF 39.5°C
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I. Introduction
There are three different YF virus vaccine 
strains: FNV (attenuated from the wild-type F W  virus
[Mathis et , 1928] ) and the other two are sub-strains 
derived from the original 17D vaccine (attenuated from 
the wild-type Asibi virus [Theiler and Smith, 1937]). 
The 17D-204 virus sub-strain is derived from the 204th 
passage of Asibi virus in chick embryos with the nerve 
tissue removed, while the 17DD sub-strain is derived 
from the 195th passage and subsequent passage in 
embryonated chicken eggs.
The production of temperature sensitive variants 
was discussed by Lwoff (1959) who suggested viruses 
should be passaged in cell lines incubated below 37°C. 
One biological property of some attenuated vaccine 
derivatives is temperature sensitivity (ts). For 
example, the experimental attenuated DEN-2 vaccine 
candidates are ts (Eckels et ^ . , 1976, 1980).
Therefore, the three YF vaccine strains (FNV, 17DD and 
17D-204) were examined for ts when grown in mosquito 06- 
36 cells at 28°C. Any virus found to be ts when plaqued 
at 39.5°C was examined following growth of the original 
virus in the human SW13 cell line at 37°C.
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II. Results
A) Temperature sensitivity of viruses grown in the 
C6-36 A. Albopictus mosquito cell line
i) 17D-204 vaccines
The efficiency of plaquing at 39.5°C versus 37.0°C 
of thirteen YF vaccine viruses and four plaque purified 
preparations, one each from France and South Africa, and 
two antigenically different plaque purified preparations 
from the United Kingdom (described previously in Chapter 
5 of this thesis) were studied. With the exception of 
one of the early (1941) manufactured 17D-204 vaccines 
(RF318), none of the 17D-204 vaccines grown in C6-35 
cells were ts. The RF318 vaccine had an efficiency of 
plaquing of 0.07 (TABLE 8.1).
ii) 17DD vaccines
The 17DD Brazil, Colombia and Dakar vaccines grown 
in C6-36 cells were shown to be ts. In addition the 
plaque purifications selected from 17DD Brazil and 
Colombia were also shown to be ts (TABLE 8.1). The 
efficiency of plaquing at 39.5°C versus 37.0°C was 
between 0.04 and 0.19.
However, when the original viruses were grown in 
SW13 cells none of the 17DD derived vaccines above were 
ts at 39.5°C (TABLE 8.2).
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TABLE 8.1 TEMPERATURE SENSITIVITY OF YF VIRUSES GROWN
IN THE C6-36 CELL LINE
LOG^q INFECTIVITY
VIRUSES 39.5°C 37.0°C E.O.P."
COL 5.9 6.4 0.32
DAK 5.9 5.7 1.58
FR 4.1 4.0 1.25
FRpp 5.8 5.6 1.58
FRG 4.6 4.0 3.90
HOL 3.3 3.3 1.00
IND 6.3 6.2 1.25
RF312 5.9 6.3 0.39
RF318 4.0 5.1 0.07
17D204 SA 894A 5.9 6.2 0.50
SApp 4.0 4.2 0.63
UK 5.6 6.0 0.39
UKpp+ 4.8 5.4 0.25
UKpp- 5.0 5.0 1.00
USA 4E158 5.9 6.0 0.79
USA 2848 6.1 6.3 0.63
WHO 7.0 7.4 0.39
17D NIG 6.7 6.5 1.58
USSR 6.8 6.9 0.79
BRAZ 5.0 5.5 0.19
BRAZpp 3.9 5.3 0.04
17DD COL 5.0 6.0 0.10
COLpp 4.0 5.3 0.05
DAK 5.3 6.4 0.08
FC 4.0 4.4 0.39
FNV IP 6.6 7.0 0.39
NT 5.5 5.8 0.50
ASIBI 4.2 6.7 0.003
Wild-Type ASIBI LPFC 3.2 4.5 0.05
F W 5.5 5.7 0.63
B4.1 <0.9* 6.8 <1.3x10"
fO VISIBLE PLAQUES SEEN WHEN THE VIRUS WAS
PLAQUED AT 39.5°C 
E.O.P. = pfu/ml at 39.5 C 
pfu/ml at 37.0°C
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TABLE 8.2 E.O.P OF VIRUSES GROWN IN SW13 CELLS
VIRUSES
17DD
WHICH WERE TEMPERATURE SENSITIVE WHEN
GROWN IN C636 CELLS
LOG^q pfu/ml 
of SW13 Grown 
Viruses
39.5°C 37.0°C
E.O.P of Viruses
SW13 C6-36+
Grown Grown
BRAZ
BRAZpp
COL
COLpp
DAK
5.6
3.7
6.5 
3.3
6.6
5.7
3.8 
6.0
3.4
6 .5
0.79
0.79
3.16
0.79
1.25
0.19
0.04
0.10
0.05
0.08
WILD-TYPE
ASIBI 3.0 3.3 0.50 0.003
: E.O.P. = pfu/ml at 39.5 C 
pfu/ml at 37.0°C
: RESULTS FROM TABLE 8.1
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iii) FNV vaccines
The three different FNV vaccines FNV IP, FNV FC, 
FNV NT were not ts when grown in the C6-36 cell line 
(TABLE 8.1).
iV) Wild-type viruses
The efficiency of plaquing of four wild-type viruses 
grown in C6-36 cells were examined. As seen in TABLE 8.1 
the Asibi parent virus and the large plaque purified 
variant from it were ts (efficiency of plaquing of 0.003 
and 0.05 respectively). In comparison, the F W  was not 
ts when grown in C6-36 cells. Finally, the South 
American isolate B4.1 when grown in C6-36 cells was ts 
with no plaques visible at 39.5°C, even when neat virus 
was used (i.e. E.O.P of £1.3x10"^).
However when the original Asibi parent virus was 
grown in SW13 cells it was not ts (TABLE 8.2).
B ) Analysis of the E.O.P. of the 17DD Brazil plaque 
purified preparation when passaged from SW13 to 
C6-36 and then back to SW13 cells
The original 17DD Brazil plaque purified 
preparation was first passaged in SW13 cell line using 
an MOI of 0.01, then C6-36 cells using an MOI of 0.01, 
and then back into SW13 cells using an MOI of 0.1. Then
255
each passaged virus was plaqued at 37°C and 39.5°C to 
test for ts (FIGURE 8.1). The first SW13 passage was not 
ts, while the C6-36 passage was ts, no visible plaques 
could be seen on the second SW13 passage when plaqued at 
39.5°C even when neat virus was used. However the 
infectivity titre of this virus was 1x10  ^pfu/ml when 
plaqued at 37°C. (i.e. E.O.P <7.9x10'^)
While the infectivity titre of the virus increased 
with each passage of virus the HA titre was higher in
the 06-36 cell line than in the SW13 cell line (FIGURE
8.1) and this is reflected in the Log^ ^^  pfu/HAU values 
of the 06-36 (pi) and SW13 (p2) passaged 17DD Brazilpp 
viruses.
C) Antigenic analysis with McAbs of the 17DD Brazil
plaque purified virus strain when grown in the 
06-36 and SW13 cell lines
i) HAI assays
The plaque purified preparation of the 17DD
Brazil vaccine virus grown in SW13 cells was compared to 
that grown in 06-36 cells. As shown in TABLE 8.3, with 
the exception of McAb H31 which displayed a 8-fold
difference in HAI titre, McAbs elicited similar HAI 
activity with both viruses grown in the two different
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FIGURE 8.1 PASSAGE HISTORY OF THE 17DD BRAZIL PLAQUE 
PURIFIED PREPARATION
PASSAGE Log^Q HA Log^Q
HISTORY pfu/ml titre pfu/HAU
37°C 39.5°C EOP MO I
17DD BRAZILpp 
(seed stock)
SW13 (pi) 3.8 3.7 0.79 0.01
C6-36 (pi) 5.3 3.9 0.04 0.01 64 2.2
SW13 (p2) 7.0 <0.9* <7.9x10'^ 0.1 32 4.2
: NO VISIBLE PLAQUES SEEN WHEN THE VIRUS WAS 
PLAQUED AT 39.5°C.
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TABLE 8.3 ANTIGENIC ANALYSIS OF THE 17DD BRAZILpp
VACCINE VIRUS WHEN GROWN IN SW13 AND 
C6-36 CELLS BY HAI ASSAYS
VIRUS
B26 B37 B44 G6 G49 G65 H3 H6 Hll H20 H25 H31
17DD
BRAZ 40* 80 40 40 - 20 40 80 640 80 80 320
(SW13 p2)
BRAZ 40 160 160 20 - 40 20 40 160 80 20 40
(C636)
: HAI TITRE EXPRESSED AS RECIPROCAL OF THE DILUTION
INHIBITING HAEMAGGLUTINATION 
HAI TITRE LESS THAN 20
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cell lines, 
ii) PRNT’s
When both of the virus preparations were analysed 
in PRNT’s with McAbs previously shown to elicit
neutralising activity, only one McAb would neutralise 
both viruses. This was McAb A6 which neutralised the 
preparation grown in SW13 cells (pi and p2) to an SNI of 
0.8 and 0.9 respectively, while the C6-36 preparation
was neutralised to an SNI of 1.0. However, one McAb did 
differentiate the virus preparations, McAb H6 (17D 
specific) only neutralised the C6-36 preparation to n 
SNI of 0.8 and not the SW13 grown preparations. (TABLE
8.4)
III. Discussion
Spontaneous temperature sensitive variants have 
been reported to arise in tissue culture for some 
flaviviruses. Paul in 1966, produced spontaneous 
variants of Kyasanur forest virus by repeated monkey 
epithelia cell passage, Halle and Zebovitz, (1977) 
producing a ts variant of Japanese Encephalitis virus 
(JE) in chick fibroblast cell cultures, and Eckels et 
al. (1980) used a diploid cell line of foetal rhesus
monkey lung cells (DBS-FRhL-2) to produce DEN-2 virus
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TABLE 8.4 ANTIGENIC ANALYSIS OF THE 17DD BRAZILpp
VACCINE VIRUS WHEN GROWN IN SW13 AND
C6-36 CELLS BY PRNT’s
VIRUS McAbs
A6 B26 B39 F14 G23 H3 H5 H6 H25 H33
17DD
BRAZ (SW13 pi) 0.8'
BRAZ (C636) 1.0
BRAZ (Swl3 p2) 0.9
0.8 -
NT -
: ANTIBODY TITRE EXPRESSED ASLOG^q REDUCTION IN VIRUS 
TITRE
DENOTES NEUTRALISATION TITRE £ 0.6 
NT: NOT TESTED
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ts variants. Other workers have used chemical mutagenic 
agents to produce flavivirus ts variants. Tarr and 
Lubiniek (1976) used 5-azacytidine to produce ts 
variants of DEN-2 virus. However, in the work described 
above certain YF viruses were shown to be ts when grown 
in the mosquito C6-36 cell line but not when grown in 
the human adenocarcinoma SW13 cell line. Of the 17D 
derived vaccines manufactured in different Centres it 
was significant that only one early 17D-204 vaccine was 
ts while all the 17DD vaccines plus two plaque purified 
viruses derived from them were ts when grown in C6-36 
cells. Also, two (Asibi and B4.1) out of the three wild- 
type viruses examined were ts when passaged in the C6-36 
cell line, while neither the F W  wild-type nor the FNV 
vaccine viruses derived from it were ts. Why the 17DD 
vaccines were ts when grown in the mosquito C6-36 cell 
line but not ts when grown in the vertebrate SW13 cell 
line is not known. It is known that mosquito cells lack 
sialic acid and have a different phospholipid content in 
their cell membranes to vertebrate cells (Stellar, 
1976). Thus, this may suggest that ts is due to 
differences in post-translational modifications of YF
virus proteins in mosquito versus vertebrate cells.
Since the E-protein of YF virus is glycosylated it is
possible that ts is due to these differences in 
glycosylation in the two cell types. Consequently,
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differences in antigenicity of the envelope protein may 
be seen (Barrett et , 1990). Tentative evidence
favouring this hypothesis was found with McAb H31 in HAI 
assays (TABLE 8.3). However the ts of the SW13 (p2)
passaged 17DD Brazilpp from C6-36 cells and the loss of
activity of McAb H6 in PRNT’s (TABLE 8.4) suggests that 
ts is a stable change and not a conformational change. 
Thus there is no substantial evidence that ts is due to 
the E-protein. A similar action where a McAb only 
neutralised virus grown in C6-36 cells was reported by 
Barrett ^  (1989) with McAb B14 which only
neutralised C6-36 grown vaccine viruses from the 17D-204 
WHO secondary seed lot and the 17DD manufactured in
Brazil. They postulated that this host-dependent
neutralisation was due to differences in presentation of 
epitopes on the cell surface, due to mosquito cells lack 
sialic acid and the phosholipid content of invertebrate 
cells differs from that of vertebrate cells.
The area of ts of YF virus in cell culture 
requires further study, as it is conceivable that the YF 
vaccine will eventually be manufactured in a cell line 
where YF virus replicates to a high titre. Therefore, 
the study of ts properties of the YF virus vaccine in 
certain cell lines will be important for the thermal 
stability of the vaccine. Also, differential expression 
of epitopes in different cell lines requires more study
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due to that invertebrate cells may not express epitopes 
involved in eliciting a protective immune response.
While Eckels et (1980) showed the Dengue-2 ts
variants to be attenuated, the 17DD Brazil plaque 
purified preparation grown in the C6-36 cell line though 
ts was still as pathogenic for mice as the original 
virus passaged in SW13 cells (A.D.T. Barrett, personal 
communication).
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CHAPTER 9
REACTIVITIES OF SOME McAbs IN PRNT’s WITH VIRUSES 
GROWN IN VERTEBRATE AND INVERTEBRATE CELL LINES
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I. Introduction
As described in the last Chapter, growing vaccine 
and wild-type strains of YF virus in different cell 
substrates (vertebrate or invertebrate) may affect the 
biological activity of the E-protein epitopes of YF 
virus. This is of importance as the manufacture of YF 
vaccines will ultimately be carried out in tissue 
culture. Before this can take place, a full
investigation will be required on the effects 
(immunological and biological) of growing them in 
different cell substrates. This chapter describes a 
preliminary analysis of the YF viruses grown in the 
vertebrate human adenocarcinoma cell line: SW13, and the 
invertebrate mosquito A. Albopictus cell line: C6-36
using PRNT’s. The McAbs used were of two sources, the 
first a 17D-204 sub-strain specific McAb derived using
YF17D-204 UK as the immunogen, the second using McAbs
that were flavivirus subgroup and group specific and 
derived from other flaviviruses as immunogens. Except 
for McAb 117 which is YF wild-type specific and derived 
using YF virus strain Asibi as the immunogen. The 
properties of all the McAbs are described previously in 
Chapter 2.
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II. Results
A) The YF 17D-204 sub-strain specific McAb
The 17D-204 sub-strain specific McAb 864 was used 
to examine in PRNT’s three 17D-204 viruses (Fr, SA, UK) 
and plaque purified preparations derived from them and 
three other non-plaque purified 17D-204 viruses grown in 
SW13 cells. As shown in TABLE 9.1 there were three types 
of reaction. First, where the virus was not neutralised
(P-16065), although IIF tests indicated that this virus
had the epitope recognised by McAb 864. The second where 
McAb 864 neutralised the virus to an SNI of about 1 
(e.g. Fr, SA, UK and USA) and the last where the McAb 
neutralised the viruses to a high titre (an SNI of 
approximately 4 e.g. 17D-204 WHO). The viruses which 
were neutralised to a high SNI were grown in C6-36 cells 
and the resultant virus was examined in a PRNT with McAb 
864. As shown in TABLE 9.1 the viruses which were
neutralised when grown in SW13 cells were also
neutralised when grown in C636 cells to approximately 
the same level except for the 17D-204 UKpp- which had a 
significantly lower SNI (1.5 log^^ units or 30 fold 
difference).
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TABLE 9.1 PRNT’s OF THE McAb 864 WITH YF VIRUSES
GROWN IN SW13 AND C6-36 CELLS
Viruses Cell Substrate Difference in 
neutralisation
17D-204 SW13 C6-36 titre*
Fr 0.8* NT -
Frpp 0.9 - >0.5
SA 1.3 NT -
SApp >4.4 >4.8 <-0.4
WHO >4.0 4.0 >0.0
UK 1.0 NT -
UKpp+ 3.9 >4.0 >-0.1
UKpp- 3.6 2.1 1.5
USA 0.8 NT -
P-16065 NT
: ANTIBODY TITRES EXPRESSED AS LOG^q REDUCTION IN
VIRUS TITRE
DENOTES NEUTRALISATION TITRE _< 0.4 
NT: NOT TESTED
DIFFERENCE EXPRESSED AS THE SNI (SW13) - SNI (C6-36)
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B ) Flavivirus subgroup and group specific McAbs
Six different YF viruses (three wild-type and 
three different vaccine strains) were examined with six 
McAbs in PRNT’s. All McAbs neutralised one or more of 
the viruses when they were grown in SW13 cells, with the 
exception of McAb 117. McAbs 4G2 and 6A3C-4 partially 
neutralised the 17DD Brazil vaccine virus, while the 
17D-204 USA vaccine virus was not neutralised by any of 
the McAbs used (TABLE 9.2). The FNV IP vaccine virus was 
neutralised only by McAbs 1B7 and 4G2. However, the 
wild-type viruses were neutralised by a number of McAbs; 
1B7, 4G2, 6A3C-4 and 6B3B-3 neutralised both Asibi and
B4.1. While 1B7 did not neutralise the F W  virus, McAb 
5B1D-2 neutralised the Asibi virus.
Each virus was grown in 06-36 cells and analysed 
with the same panel of McAbs. As seen in TABLE 9.3 only 
the FVV and B4.1 wild-type viruses were neutralised. F W  
was partially neutralised by McAbs 1B7 and 6B1D-2, while 
McAbs 6A3C-4 and 6B3B-3 had an increased SNI of 2 
compared to that when the virus was grown in SW13 cells. 
However, B4.1 had reduced SNI’s using virus grown in 
0636 versus that grown in SW13 cells for McAbs 6A30-4 
and 6B3B-3.
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TABLE 9.2 REACTIVITY OF FLAVIVIRUS SUBGROUP AND GROUP 
McAbs IN PRNT’S. WITH VIRUS GROWN IN SW13 
CELLS
McAbs
Viruses 117 1B7 4G2 6A3C-4 6B3B-3 6B1D
17DD BRAZ - - 0.5* 0.5 - -
17D-204 USA 
(6145)
- - - - - -
FNV IP - 1.1 1.0 - - -
ASIBI - 1.0 4.0 4.0 >4.0 1.0
FVV - - 1.3 0.7 1.1 -
B4.1 - 0.5 1.7 >3.0 >3.0 -
ANTIBODY TITRES EXPRESSED AS LOG^q REDUCTION IN 
VIRUS TITRE
DENOTES NEUTRALISATION TITRE <0.4
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TABLE 9.3 REACTIVITY OF FLAVIVIRUS SUBGROUP AND GROUP 
McAbs IN PRNT’s WITH VIRUS GROWN IN C6-36 
CELLS
Viruses
17DD BRAZ
17D-204 USA 
(6145)
FNV IP
ASIBI
F W
B4.1
McAbs
117 1B7 4G2 6A3C-4 6B3B-3 6B1D-2
0.7 1.5 2.2 2.0
2.2 2.4 1.7
0.6
ANTIBODY TITRES EXPRESSED AS LOG^^ REDUCTION IN 
VIRUS TITRE
DENOTES NEUTRALISATION TITRE <0.4
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Ill. Discussion
As shown in the last chapter, biological 
differences (ts) were shown between different strains of 
YF virus when grown in C6-36 cells, but no differences 
were seen when the various YF viruses were grown in SW13 
cells.
In this Chapter different McAbs gave different 
results when examined in a biological assay (PRNT) with 
viruses grown in SW13 and C6-36 cells. One McAb (McAb 
864) showed no difference in neutralising ability, while 
other McAbs were able to differentiate vaccine from 
wild-type strains and also differences between vaccine 
strains and between wild-type strains.
McAb 864, a 17D-204 sub-strain specific McAb, has 
been used previously by Buckley and Could (1985) to 
examine neutralisation of YF viruses grown as 20% mouse 
brain suspensions. In this chapter, each virus was grown 
from a reconstituted freeze dried preparation in SW13 
cells. As seen in TABLE 9.1 the SNI titres differ from 
what Buckley and Gould obtained, especially the UK, 
South Africa and French 17D-204 vaccine viruses. These 
differences can probably be explained by the way in 
which the virus was grown, as well as, this study using 
different batches of vaccine to that used by Buckley and
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Gould, (1985). An interesting difference was that 
between the 17D-204 USA vaccine virus and the revertant 
virus P-16065, where McAb 864 neutralised the former but 
not the latter. Also, while the plaque purified 
preparations of the 17D-204 UK and 17D-204 SA were 
neutralised to high SNI, the parent vaccine viruses were 
neutralised to a low SNI. The plaque purified and the 
17D-204 WHO secondary seed batch vaccine viruses were 
grown in C6-36 cells and their SNI titres compared to 
that of virus grown in SW13 cells. As shown in TABLE 8.1 
there were no large differences in the level of 
neutralisation. This clearly is due to McAb 864 being a 
potent neutralising antibody that recognises the 17D-204 
sub-strain epitope on viruses grown in both cell lines. 
This point was substantiated by indirect 
immunofluorescence tests (data not shown).
However, Barrett et al. (1990) examined YF virus 
strains using flavivirus subgroup and group specific 
McAbs prepared with immunogens other than YF virus in 
IIF tests. It was shown that the McAbs could distinguish 
between wild-type from 17D-204 viruses, when the 
viruses were grown in C6-36 cells but not when they were 
grown in SW13 cells. The other two vaccine strains FNV 
and 17DD were not differentiated by IIF tests to the 
wild-type viruses. A part of this study was to examine 
and compare the viruses grown in 06-36 and SW13 cells
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biologically in PRNT’s and as shown in TABLES 9.2 and
9.3 the viruses could be differentiated. While five out 
of the six McAbs used in the study neutralised wild-type 
Asibi virus when grown in SW13 cells, none of the McAbs 
examined would neutralise the virus grown in C6-36 
cells. Also, none of the McAbs neutralised the 17D-204 
USA vaccine virus grown in either cell line. Although 
McAbs 4G2 and 6A3C-4 partially neutralised the 17DD 
Brazil vaccine virus when grown in SW13 cells, none of 
the McAbs would neutralise the virus when grown in 06-36 
cells. Of interest is McAb 1B7 which only neutralised 
the FNV IP vaccine and wild-type Asibi and B4.1 viruses 
when grown in SW13 cells, but partially neutralised the 
wild-type strain FVV grown in 06-36 cells. Kjellen and 
Zeipel (1984) working on Echovirus type 4 (strain 
Pesascek) discussed the influence of host cells on the 
neutralisation ability of McAbs. They reported a minor 
fraction of the Pesascek virus strain that resisted 
neutralisation when plagued on either the 
rhabdomyosarcoma strain RD or the green monkey kidney 
strain GMK-AHl cell lines. Although, another fraction of 
infectious virus was shown to be neutralised when 
plagued on the RD cell line but resisted neutralistion 
when plagued on the GMK-AHl cell line. However,it was 
Grady and Kinch (1985) who first showed different 
neutralisation activities of a bunyavirus grown in
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invertebrate (C6-36) and vertebrate (BHK-21) cell 
lines. They showed that one McAb neutralised only the 
virus grown in vertebrate cells, while two other McAbs 
neutralised virus grown in both cell lines and a fourth 
McAb neutralised the virus grown only in invertebrate 
cells. It is of interest that three of these McAbs had 
been shown to be located on the same domain (Grady et 
al., 1983). As in this study McAbs with a flavivirus
group specificity prepared against St. Louis 
Encephalitis virus recognising the same antigenic site 
previously described by Roehrig et (1983) (E-4b)
detected similar differences. Thus, the McAb 
neutralisation differences seen by Grady and Kinch 
(1985) and in this study reported by Barrett et al. 
(1990) may represent a common phenomenon with arthropod 
borne viruses. Barrett et al. (1989, 1990) have reported 
a number of differences, both antigenically and 
biologically, when YF virus is passaged in the C6-36 
cell line when compared to YF virus being passaged in 
vertebrate cell lines. These differences may be 
explained by the differences of each cell line in 
processing the glycosylated E-protein. Stollar (1976) 
has shown the absence of sialic acid and or different 
phospholipid content in invertebrate cells compared to 
vertebrate cells. As seen in the last chapter and 
reported by Barrett et (1989, 1990) virus grown in
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C6-36 cells is biologically different to that grown in 
SW13 (vertebrate) cells. This will have important 
implications in the manufacture of YF virus vaccine or 
the production of other vaccines to important human 
flavivirus pathogens (e.g dengue) in mosquito cell 
lines.
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CHAPTER 10
GENERAL DISCUSSION
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This thesis has described the analysis of YF 
vaccine viruses produced in different countries using 
different conditions of manufacture and different seed 
viruses with McAbs directed against epitopes of the E- 
protein. Also, where appropriate, comparison has been 
made between vaccines and wild-type strains of YF virus.
The E-protein has been shown to be respnsible for 
a number of biological properties including those of 
eliciting neutralisation and haemagglutination. 
Therefore, a panel of McAbs were generated against the 
17DD Brazil and 17D-204 WHO vaccine viruses and used to 
examine the the biological function of E-protein 
epitopes of YF virus in PRNT’s and HAI’s. The majority 
of the McAbs were found to elicit HAI, but not 
neutralisation activity. This suggests that the McAbs 
are recognising the same functional domain of YF virus. 
Other workers have produced many more McAbs against 
flaviviruses that elicit neutralising activity than 
those generated in the Author’s laboratory against YF 
virus (Schlesinger et ^ . , 1983; Gould et al., 1985).
This observation and the fact that nearly every McAb 
generated in the Author’s laboratory recognises the E- 
protein (A.D.T. Barrett, personal communication) may be 
due to the immunogen used, which was tissue culture 
fluid containing virus rather than mouse brain
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suspension, polyethylene glycol precipitates or purified 
virus to generate the McAbs (Kimura-Kuroda and Yasui, 
1983; Roehrig et , 1983; Gould et , 1985).
The panels of McAbs were used to analyse the E-
protein epitopes of 34 vaccine and wild-type YF viruses 
in HAI assays and PRNT's. The results from these 
biological assays and there combined analysis
generates groupings of McAbs which define distinct 
antigenic determinants or epitopes revealing a 
serological complexity which goes far beyond that 
established with polyclonal anti-sera.
Using a computer programme to analyse the HAI 
data of 27 McAbs with the 34 YF viruses, it was found 
that the viruses were divided in a dendrogram into three 
groups. One of the groups contained the majority of the 
17D-204 vaccine viruses manufactured in different
centres around the world. Thus, although the 17D-204
viruses were not identical they were very similar. The
17DD vaccines were found to separate into a different 
second group. The last group contained two vaccines 
which were shown to be neurotropic in monkeys and mice. 
These were the discontinued FNV IP and the P-16065 
revertant viruses. Monath et (1983) also obtained a
similar grouping when using T^  RNA oligionucleotide 
fingerprint mapping he showed a high degree of homology
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between the 17D vaccines. However, the 17DD derived 
vaccines were differentiated from the 17D-204 vaccines 
by the loss of one oligonucleotide (No.37). They 
suggested that this was due to the additional 40 
passages in chick embryos for the development of the 
17DD vaccines.
Presumably the differences in biological function 
of the epitopes of the E-protein shown by McAbs used in 
this study are also due to different manufacturing 
conditions in different centres (see Chapter 1). Whether 
these differences have practical significance for the 
efficacy of YF vaccines from different manufacturers or 
reflects an academic question is not clear. However, the 
results obtained suggest that, at the very least, there 
should be some clinical studies undertaken with 
vaccinees to investigate and compare the efficacy of the 
vaccine produced in different centres.
Unfortunately, only a few of the McAbs 
recognised epitopes that elicit neutralising activity 
and the majority of these did only neutralised the 
viruses poorly. These results greatly hindered the 
generation of McAb neutralisation resistant (McAb^) 
variants to study the epitopes in detail. However, McAb* 
variants were generated using McAb 864 (17D-204 sub­
strain specific), McAb B39 (YF type specific) and McAb
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B26* (partial flavivirus group reactive). The B25* 
variants were unusual in that they had lost the ability 
to produce plaques though infectivity was demonstrated 
using the TCID^q assay. The B39* variants were shown to 
remain neurovirulent for mice, while the 864* variants 
had an altered neurovirulence for mice compared to their 
parent strains. The mouse virulence studies with the 
B26* variants yielded equivocal results on their 
alteration in mouse neurovirulence. Both the B39* and 
864* variants had lost the ability to elicit HAI 
activity with the McAbs tested.
The new 17D vaccine manufactured in the USSR was 
examined antigenically and biologically. The results 
obtained with this vaccine were somewhat worrying. While 
the 17D USSR vaccine reacted similar to other YF 17D 
vaccines in PRNT's and HAI assays, it was antigenically 
distinct being differentiated from other 17D vaccines in 
IIF studies and biologically different as it contained 
virions that were more virulent in mice than "normal" 
17D virions. In view of the virulence of the 17D USSR 
virus for mice it was surprising that the monkey which 
received the large inoculum of 3.5x10^ pfu of 17D USSR 
virus showed no clinical signs of infection following 
intracerebral challenge. However, it may be that the 
vaccine is only virulent in mice or that the virulent
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virus will only cause problems in young vaccinees, as 
has been seen previously with the FNV and P-16065 
viruses. Clearly, further investigations are required on 
the 17D vaccine manufactured in the USSR.
Studies with McAbs (series F) generated against
the FNV IP virus revealed similar biological properties 
to the McAbs raised against the 17D vaccine viruses.
However, the results of the F series of McAbs in HAI
assays revealed a different dendrogram to that derived 
from the results with the 17D generated McAbs. 
Presumably this reflects differences in antigenicity of 
the 17D and FNV vaccine viruses. Examination of 
neurovirulence of the FNV vaccine viruses in monkeys and 
mice differentiated them from each other to some extent 
and separated them from all the 17D vaccine viruses. 
However, using both animal models, FNV IP was the most 
neurovirulent of the FNV vaccines. Comparitive sequence 
data for the E-protein gene of FNV and 17D viruses will 
be required to answer the question of differences 
in antigenicity and possibly for the increased 
neurovirulence of the FNV vaccine viruses.
The properties of the YF viruses grown in
invertebrate and vertebrate cell lines was 
compared. Virus grown in the mosquito A. albopictus C6- 
36 cell line was antigenically distinct to that grown in
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human SW13 cells in that epitopes eliciting HAI and 
neutralisation differed. Furthermore, viruses of the 
17DD substrain were temperature sensitive (ts) at 39.5°C 
when grown in C6-36 cells. Presumably, this reflects the 
different passage histories of 17DD and 17D-204 
substrains of the YF vaccine 17D. It was also found that 
this ts phenotype was maintained for 17DD Brazil vaccine 
virus that was grown in C6-36 cells and then passaged 
into SW13 cells.
Thus, it would seem ts was due to a genetic change 
in the virus induced by growing the virus at 28°C in the 
C6-36 cell line. Comparison of the nucleotide sequence 
of the virus passaged in both cell lines would be 
required to answer this question. Consequently, there 
was no evidence to associate the ts phenotype with the 
E-protein of YF virus. However, the use of a potential 
ts YF virus as a vaccine requires further investigation, 
particularly of the efficacy of 17DD versus 17D-204
vaccine viruses when used in the climates of Africa and
South America. Some wild-type strains of YF virus were 
also found to be ts. Unlike the 17DD vaccine viruses 
that had never been grown in C6-36 cells, the passage 
history of wild-type strains of YF virus had involved
passage in C6-35 cells thus the ts phenotype of these
viruses can not be easily interpreted.
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This thesis has given an insight into the 
properties of YF virus vaccine viruses compared with 
those of wild-type YF viruses. Comparative studies on 
the efficacious nature of the YF vaccines manufactured 
in different centres is unlikely to take place as 
manufacturers will be reluctant to have their vaccine 
investigated in detail in case it is found unsuitable 
for vaccine purposes. Nonetheless there are still areas 
that can be investigated to continue research on the YF 
vaccine viruses. The first is comparative epitope 
mapping of the E-protein of vaccine and wild-type 
strains of YF virus with the McAbs used in this thesis 
and investigation of the relative location of epitopes 
and functional domains on different viruses. The second 
area is sequence data to support the biological results 
obtained in this thesis. Especially, the determination 
and comparison of the nucleotide (and deduced amino 
acid) sequence of the E-protein gene of the F W  and FNV 
viruses and a number of the YF virus vaccines 
manufactured in different centres. Similarly, sequence 
data is required to examine the amino acid substitutions 
in the McAb* variants to identify the amino acids that 
constitute particular epitopes of the E-protein. 
Consequently, the changes in biological function of the 
E-protein epitopes could be physically mapped on to the
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three dimensional structure of the E-protein
of YF or another flavivirus when it is determined. The 
third area is an investigation of induction of cytotoxic 
and helper T cell activity by different YF vaccine 
viruses, particularly the E-protein epitopes that elicit 
T cell activity and there conservation on different YF 
vaccine viruses, including those manufactured in 
different centres. Finally, as mosquito control is 
unlikely to succeed in eliminating YF infection in 
humans and YF vaccination will always be required, a 
more cost effective cell culture vaccine will need to be 
developed. Therefore, further analysis of the biological 
properties of the YF virus vaccines grown in different 
cell lines is needed. This new cell cultured produced 
vaccine would need to be biological stable, cheap and 
sufficiently attenuated to be gien to children just 
after birth like other vaccines. Such a YF vaccine would 
prevent infection and spread in humans and the risk of 
urban YF which has increased due to the re-introduction 
of Aedes Aegypti into Central America.
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APPENDIX
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LOG^^  HAI TITRES OF THE A, B, G AND H McAbs WITH 
VIRUSES USED IN THE GLUSTAN COMPUTER PROGRAMME
VIRUSES
17D204 17DD
Wild Type vaccine vaccine
No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
17D 17]
A F B H F F W U U U R B D C C N
S V 4 0 r r H K K K U R A 0 0 I
I V 1 L P 0 P P S Z K L L G
B L P P P S P
I + - P
McAb
A3 1.0 2.2 1.3 1.9 1.9 2.2 0 1.6 1.9 1.9 2.2 1.9 1.9 2.2 1.0 l.(
A4 1.5 0 1.0 1.3 1.9 1.0 0 1.0 1.6 1.6 1.6 1.0 1.3 0 1.3 1.'
A6 1.3 0 1.0 1.6 2.2 1.9 0 1.6 1.9 1.9 2.2 1.3 1.6 1.6 1.6 2.!
B19 0 0 0 0 0 1.3 0 0 1.0 1.0 0 1.0 1.3 1.0 1.0 0
B26 1.6 1.9 0 1.0 1.3 2.2 1.6 1.0 1.0 1.3 1.0 1.6 1.6 2.5 2.2 2.;
B37 1.0 1.6 0 1.9 1.9 1.6 0 1.6 1.9 1.9 2.2 1.3 1.3 2.2 1.6 2.:
B39 1.6 1.9 1.6 1.9 2.2 1.3 1.6 2.2 1.9 1.9 2.5 0 1.0 1.9 1.6 1.'
B44 1.6 2.2 1.9 2.2 2.2 1.9 1.3 2.5 2.8 2.5 2.2 1.9 1.9 2.2 1.6 2.:
B45 1.9 1.3 1.3 1.6 1.6 2.2 0 1.3 2.2 1.9 1.6 1.3 1.0 2.5 1.9 1.'
G6 1.0 1.9 1.9 1.0 1.0 1.3 2.5 1.6 1.6 1.0 1.3 1.0 1.3 0 1.6 0
G23 2.2 0 0 1.9 1.9 2.2 1.9 1.6 2.5 2.2 1.9 0 0 2.2 2.5 2.:
G46 1.0 1.6 0 1.0 1.3 0 1.6 1.6 1.3 1.3 1.0 1.0 1.3 1.1 1.3 0
G49 1.3 0 0 1.3 1.0 0 0 1.3 1.0 1.0 1.0 0 1.0 1.0 1.0 1.;
G65 1.9 1.6 0 2.2 2.5 2.2 1.6 2.2 2.2 2.2 2.5 0 1.0 1.9 2.2 2.1
H5 0 0 0 1.6 1.3 1.3 1.9 1.6 1.9 1.6 1.6 1.9 2.2 1.6 1.9 1.;
H6 1.0 1.0 1.0 1.0 1.0 1.0 1.9 1.0 1.0 1.0 1.0 1.6 1.9 1.0 1.6 1.
H8 2.2 2.2 2.2 1.6 1.9 1.6 2.5 1.9 1.9 1.9 1.6 2.2 2.5 1.6 2.2 1.
HID 1.0 1.0 1.0 1.3 1.3 1.0 1.3 1.3 1.3 1.6 1.3 1.6 1.6 1.6 1.6 1.
Hll 2.2 1.9 2.2 1.6 1.3 1.6 1.9 1.9 2.8 1.9 1.6 1.6 1.9 1.0 1.6 2.
H14 1.9 0 0 1.6 1.3 1.9 1.9 1.6 1.6 1.6 1.6 1.6 1.9 1.9 1.6 0
H20 2.2 2.5 2.5 2.5 1.0 1.0 2.5 2.2 2.2 2.5 2.5 2.5 2.5 2.2 2.5 1.
H23 0 0 0 1.3 1.0 0 1.9 1.0 1.0 1.3 1.0 1.9 1.9 0 1.9 0
H25 0 0 0 1.0 1.3 2.2 0 1.0 1.9 2.2 1.0 0 0 2.2 0 2.
H30 2.2 2.2 0 1.3 1.0 1.3 2.2 1.6 1.3 1.6 1.3 2.5 2.2 1.0 2.5 1.
H31 1.9 1.9 2.2 1.6 1.3 1.3 1.9 1.9 1.9 1.6 1.6 1.9 1.9 1.0 1.9 1.
H32 2.5 2.5 2.5 2.2 2.2 0 2.5 2.5 2.2 1.9 2.2 2.8 3.1 2.2 2.8 1.
H33 2.2 1.9 2.2 1.6 1.3 1.6 1.9 1.6 1.5 1.6 1.3 2.2 1.9 1.6 2.2 1.
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LOG Q^ HAI TITRES OF THE A, B, G AND H McAbs WITH 
VIRUSES USED IN THE CLUSTAN COMPUTER PROGRAMME
(CONTINUED)
VIRUSES
YF17D-204
Vaccines
FNV
Vaccines
YF17D20
Vaccin
No. 17 18 19 20 21 22 23 24 25 26 27 28 29 30
F S S S U A F F F I
R A A A S U N N N N
G P 8 1 A S V V V D
P 4 0 A B C D T N F I
9 8 T C P
A 0
o
X Y
McAbs
z
A3 2.2 2.2 2.5 1.9 1.6 1.9 1.3 2.2 1.9 1.3 1.9 1.0 1.6 1.3
A4 0 0 1.3 1.3 1.0 1.0 1.9 0 0 1.6 1.3 1.9 1.0 1.6
A6 0 0 1.0 1.9 1.3 1.3 2.2 0 0 . 1.6 1.9 1.3 1.9 1.6
B19 1.3 1.3 1.3 1.0 1.0 1.0 0 0 0 1.0 1.3 1.0 1.0 1.0
B26 1.9 1.9 2.5 1.6 1.0 1.0 1.9 2.5 1.9 2.2 1.9 1.9 1.6 1.9
B37 1.9 1.9 2.2 2.2 1.0 1.3 1.9 1.6 1.6 1.6 1.6 1.9 1.6 2.2
B39 2.2 2.8 2.8 2.2 1.0 1.3 2.2 2.2 1.9 1.9 1.0 2.2 1.3 2.2
B44 1.9 2.5 2.8 2.2 1.6 1.6 1.9 2.8 1.9 2.2 2.2 2.5 2.2 1.9
B45 1.6 1.9 2.5 2.2 1.3 1.3 1.9 2.2 1.6 1.9 1.6 1.6 1.6 1.6
G6 0 0 1.0 1.0 1.0 1.0 1.0 0 1.6 1.3 1.0 0 1.0 1.0
G23 2.8 2.8 2.8 2.2 1.3 1.6 2.2 2.5 1.6 2.2 0 2.2 1.9 2.5
G46 1.6 1.0 1.0 1.0 0 0 0 0 1.6 0 0 0 0 1.0
G49 1.3 1.3 1.0 1.3 1.3 1.0 0 0 1.0 0 0 1.3 1.6 1.0
G65 2.2 2.8 1.9 1.9 0 1.0 1.9 2.5 2.5 2.8 0 2.8 1.9 2.8
H5 0 0 0 1.6 0 0 1.6 0 0 1.9 1.9 1.3 2.2 1.3
H6 1.9 2.5 1.6 1.3 1.0 1.0 1.6 2.2 2.5 1.6 1.0 1.0 1.3 1.6
H8 2.2 2.8 1.6 0 0 0 1.3 2.8 2.8 1.9 2.2 1.6 0 1.9
HIO 1.0 2.5 1.6 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Hll 0 2.2 2.2 1.3 2.5 1.0 2.2 0 0 1.3 1.9 2.2 1.6 1.9
H14 0 0 0 1.9 2.2 1.3 1.9 0 0 0 1.6 0 2.8 1.6
H20 0 0 0 1.0 2.2 0 1.6 0 0 2.2 2.5 2.8 2.2 1.6
H23 2.2 2.8 2.2 1.0 1.0 1.0 1.0 2.8 1.6 1.0 0 1.0 2.2 0
H25 1.9 1.6 1.6 1.6 2.5 1.0 2.2 1.6 1.3 2.2 0 2.8 2.5 2.2
H30 1.3 0 0 2.2 1.0 1.6 1.0 0 2.2 1.9 2.2 1.0 2.2 1.9
H31 2.2 1.3 1.0 1.6 1.0 1.3 0 0 1.6 1.6 1.6 1.6 1.9 1.6
H32 2.2 1.3 1.3 1.6 1.0 1.0 0 0 2.5 1.6 2.8 1.0 1.3 1.6
H33 1.9 1.3 1.3 1.0 1.0 1.0 1.9 0 2.2 1.9 2.2 1.9 1.0 1.9
: USA VACCINE BATCHES; A: P-16065, B: 6145, C: 2848, D: 4E158 
: AUST VACCINE BATCHES; X: 008, Y: 0331
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LOG g^ HAI TITRES OF THE A, B, G AND H McAbs WITH 
VIRUSES USED IN THE CLUSTAN COMPUTER PROGRAMME
(CONTINUED)
VIRUSES
YF17D-204 17DD
Vaccines Vaccine
No, 31 32 33 34
McAbs
RF318 DAK COL BRZf
A3 1.6 2.5 1.0 1.0
A4 1.6 1.9 1.3 1.0
A6 1.6 2.2 1.0 1.6
B19 0 0 0 0
B26 1.3 1.6 1.3 1.6
B37 1.3 2.2 2.2 2.2
B39 0 0 1.9 2.2
B44 1.9 2.5 2.2 2.2
B45 1.6 2.5 1.6 1.9
G6 0 0 1.0 1.3
G23 1.9 2.8 1.0 1.3
G46 0 0 1.0 1.0
G49 0 0 0 0
G65 0 2.2 1.0 1.6
H5 1.9 2.5 1.3 2.2
H6 1.9 2.2 1.0 1.6
H8 1.6 1.3 1.3 1.3
HIO 0 0 1.0 0
Hll 1.6 2.5 1.6 2.2
H14 0 0 0 0
H20 0 2.5 1.9 1.9
H23 0 2.5 0 1.0
H25 0 0 0 1.3
H30 2.8 2.5 0 0
H31 2.5 2.2 1.3 1.6
H32 0 0 1.9 2.5
H33 2.2 1.6 1.0 1.0
315
OF HAI TITRES USING THE F McAbs
McAbs
FIO F17 F19 F20 F23 F25 F28 F33
Viruses
wild-type
F W  1.6 0 0 2.2 1.9 1.6 1.9 1.9
Asibi 1.3 0 0 1.9 1.9 1.3 1.9 2.2
FNV
FNV FC 1.0 2.2 1.0 1.3 2.2 1.3 1.3 1.6
FNV IP 1.0 1.9 1.0 1.3 1.9 1.0 1.0 1.0
FNV NT 1.3 2.2 0 1.3 1.9 1.3 1.0 1.3
17D-204
USA 6145 1.9 0 0 1.6 2.2 1.3 2.2 1.9
USA P-16065 1.3 1.6 1.0 1.0 1.3 1.0 1.0 1.0
UK 0 1.9 1.6 1.0 1.9 1.0 1.0 1.6
17DD
Brazil 1.3 0 0 1.0 1.3 1.0 1.0 1.3
17D
USSR 1.6 1.9 1.0 2.2 1.9 1.3 1.9 2.5
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